WO2011038364A1 - Method for producing 3-hydroxypropionic acid and other products - Google Patents
Method for producing 3-hydroxypropionic acid and other products Download PDFInfo
- Publication number
- WO2011038364A1 WO2011038364A1 PCT/US2010/050436 US2010050436W WO2011038364A1 WO 2011038364 A1 WO2011038364 A1 WO 2011038364A1 US 2010050436 W US2010050436 W US 2010050436W WO 2011038364 A1 WO2011038364 A1 WO 2011038364A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- activity
- microorganism
- genetically modified
- hydroxypropionic acid
- genetic modification
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 192
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 title claims abstract description 191
- 244000005700 microbiome Species 0.000 claims abstract description 401
- 239000000126 substance Substances 0.000 claims abstract description 111
- 230000001965 increasing effect Effects 0.000 claims abstract description 95
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 claims abstract description 64
- 238000012239 gene modification Methods 0.000 claims description 307
- 230000005017 genetic modification Effects 0.000 claims description 306
- 235000013617 genetically modified food Nutrition 0.000 claims description 306
- 230000000694 effects Effects 0.000 claims description 216
- 230000002255 enzymatic effect Effects 0.000 claims description 182
- 102000004190 Enzymes Human genes 0.000 claims description 155
- 108090000790 Enzymes Proteins 0.000 claims description 155
- 238000000034 method Methods 0.000 claims description 154
- 230000037361 pathway Effects 0.000 claims description 145
- 150000007523 nucleic acids Chemical group 0.000 claims description 143
- 108090000623 proteins and genes Proteins 0.000 claims description 136
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 121
- 229920001184 polypeptide Polymers 0.000 claims description 119
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 119
- 238000006243 chemical reaction Methods 0.000 claims description 103
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 83
- 229910052799 carbon Inorganic materials 0.000 claims description 77
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 71
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 69
- 108010008386 malonyl-Coa reductase Proteins 0.000 claims description 67
- 101710198510 Enoyl-[acyl-carrier-protein] reductase [NADH] Proteins 0.000 claims description 46
- 238000000855 fermentation Methods 0.000 claims description 41
- 230000004151 fermentation Effects 0.000 claims description 41
- 230000002829 reductive effect Effects 0.000 claims description 34
- 239000002028 Biomass Substances 0.000 claims description 32
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 27
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 claims description 26
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 claims description 26
- 108010018763 Biotin carboxylase Proteins 0.000 claims description 26
- 108090000209 Carbonic anhydrases Proteins 0.000 claims description 25
- 102000003846 Carbonic anhydrases Human genes 0.000 claims description 25
- 108010039731 Fatty Acid Synthases Proteins 0.000 claims description 25
- 102000015303 Fatty Acid Synthases Human genes 0.000 claims description 25
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 23
- 239000001301 oxygen Substances 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 22
- 230000007423 decrease Effects 0.000 claims description 22
- 230000004048 modification Effects 0.000 claims description 22
- 238000012986 modification Methods 0.000 claims description 22
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 21
- 238000000926 separation method Methods 0.000 claims description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 20
- 101710088194 Dehydrogenase Proteins 0.000 claims description 19
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 19
- 238000000605 extraction Methods 0.000 claims description 19
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 18
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 18
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 17
- 238000004113 cell culture Methods 0.000 claims description 17
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 15
- 229930006000 Sucrose Natural products 0.000 claims description 15
- 239000005720 sucrose Substances 0.000 claims description 15
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 14
- -1 thienodiazaborine Chemical compound 0.000 claims description 14
- 230000001419 dependent effect Effects 0.000 claims description 13
- 239000008103 glucose Substances 0.000 claims description 13
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 12
- 239000003208 petroleum Substances 0.000 claims description 12
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 11
- 230000009467 reduction Effects 0.000 claims description 11
- 108060002020 cyanase Proteins 0.000 claims description 10
- ALRHLSYJTWAHJZ-UHFFFAOYSA-M 3-hydroxypropionate Chemical compound OCCC([O-])=O ALRHLSYJTWAHJZ-UHFFFAOYSA-M 0.000 claims description 9
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 9
- 102000005421 acetyltransferase Human genes 0.000 claims description 9
- 108020002494 acetyltransferase Proteins 0.000 claims description 9
- 235000004279 alanine Nutrition 0.000 claims description 9
- 238000012546 transfer Methods 0.000 claims description 9
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 claims description 8
- 239000012736 aqueous medium Substances 0.000 claims description 8
- 108010019608 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase Proteins 0.000 claims description 7
- 102100037149 3-oxoacyl-[acyl-carrier-protein] synthase, mitochondrial Human genes 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 7
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 claims description 7
- 102000004316 Oxidoreductases Human genes 0.000 claims description 7
- 108090000854 Oxidoreductases Proteins 0.000 claims description 7
- 108010042687 Pyruvate Oxidase Proteins 0.000 claims description 7
- 239000003054 catalyst Substances 0.000 claims description 7
- 230000018044 dehydration Effects 0.000 claims description 7
- 238000006297 dehydration reaction Methods 0.000 claims description 7
- 239000008121 dextrose Substances 0.000 claims description 7
- 238000004821 distillation Methods 0.000 claims description 7
- 108010008221 formate C-acetyltransferase Proteins 0.000 claims description 7
- 230000003834 intracellular effect Effects 0.000 claims description 7
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 6
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 6
- 229940035437 1,3-propanediol Drugs 0.000 claims description 6
- GVEZIHKRYBHEFX-MNOVXSKESA-N 13C-Cerulenin Natural products CC=CCC=CCCC(=O)[C@H]1O[C@@H]1C(N)=O GVEZIHKRYBHEFX-MNOVXSKESA-N 0.000 claims description 6
- OKTJSMMVPCPJKN-IGMARMGPSA-N Carbon-12 Chemical compound [12C] OKTJSMMVPCPJKN-IGMARMGPSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 claims description 6
- 229940000635 beta-alanine Drugs 0.000 claims description 6
- GVEZIHKRYBHEFX-UHFFFAOYSA-N caerulein A Natural products CC=CCC=CCCC(=O)C1OC1C(N)=O GVEZIHKRYBHEFX-UHFFFAOYSA-N 0.000 claims description 6
- GVEZIHKRYBHEFX-NQQPLRFYSA-N cerulenin Chemical compound C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O GVEZIHKRYBHEFX-NQQPLRFYSA-N 0.000 claims description 6
- 229950005984 cerulenin Drugs 0.000 claims description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 6
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 108010080376 3-Deoxy-7-Phosphoheptulonate Synthase Proteins 0.000 claims description 5
- 108030001569 3-hydroxypropionate dehydrogenases Proteins 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
- 101100259583 Bacillus subtilis (strain 168) tyrS2 gene Proteins 0.000 claims description 5
- 101100236334 Escherichia coli (strain K12) lysR gene Proteins 0.000 claims description 5
- 239000005715 Fructose Substances 0.000 claims description 5
- 229930091371 Fructose Natural products 0.000 claims description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 5
- 229930195712 glutamate Natural products 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 101150040895 metJ gene Proteins 0.000 claims description 5
- 101150118209 nrdR gene Proteins 0.000 claims description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 5
- 101150006320 trpR gene Proteins 0.000 claims description 5
- 101150044161 tyrR gene Proteins 0.000 claims description 5
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 claims description 4
- SYQNUQSGEWNWKV-UHFFFAOYSA-N 5R-Thiolactomycin Natural products C=CC(C)=CC1(C)SC(=O)C(C)=C1O SYQNUQSGEWNWKV-UHFFFAOYSA-N 0.000 claims description 4
- 108010092060 Acetate kinase Proteins 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 102000004357 Transferases Human genes 0.000 claims description 4
- 108090000992 Transferases Proteins 0.000 claims description 4
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 4
- 102100033598 Triosephosphate isomerase Human genes 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- BUFLLCUFNHESEH-UUOKFMHZSA-N guanosine 3',5'-bis(diphosphate) Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](OP(O)(=O)OP(O)(O)=O)[C@H]1O BUFLLCUFNHESEH-UUOKFMHZSA-N 0.000 claims description 4
- KCPMACXZAITQAX-UUOKFMHZSA-N guanosine 3'-diphosphate 5'-triphosphate Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](OP(O)(=O)OP(O)(O)=O)[C@H]1O KCPMACXZAITQAX-UUOKFMHZSA-N 0.000 claims description 4
- 150000002402 hexoses Chemical class 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 108010083856 methylglyoxal synthase Proteins 0.000 claims description 4
- 239000011368 organic material Substances 0.000 claims description 4
- 239000003973 paint Substances 0.000 claims description 4
- 150000002972 pentoses Chemical class 0.000 claims description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 4
- 101150106935 purR gene Proteins 0.000 claims description 4
- 229960003500 triclosan Drugs 0.000 claims description 4
- 239000002699 waste material Substances 0.000 claims description 4
- 102000000157 3-oxoacyl-(acyl-carrier-protein) reductase Human genes 0.000 claims description 3
- 108010055468 3-oxoacyl-(acyl-carrier-protein) reductase Proteins 0.000 claims description 3
- SYQNUQSGEWNWKV-XUIVZRPNSA-N 4-hydroxy-3,5-dimethyl-5-(2-methyl-buta-1,3-dienyl)-5h-thiophen-2-one Chemical compound C=CC(/C)=C/[C@@]1(C)SC(=O)C(C)=C1O SYQNUQSGEWNWKV-XUIVZRPNSA-N 0.000 claims description 3
- 108010006873 Threonine Dehydratase Proteins 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 3
- 229960003350 isoniazid Drugs 0.000 claims description 3
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 150000003512 tertiary amines Chemical class 0.000 claims description 3
- OJJHFKVRJCQKLN-YFKPBYRVSA-N (4s)-4-acetamido-5-oxo-5-phosphonooxypentanoic acid Chemical compound OC(=O)CC[C@H](NC(=O)C)C(=O)OP(O)(O)=O OJJHFKVRJCQKLN-YFKPBYRVSA-N 0.000 claims description 2
- 101800001241 Acetylglutamate kinase Proteins 0.000 claims description 2
- 108030006759 Acetylornithine deacetylases Proteins 0.000 claims description 2
- 101000889837 Aeropyrum pernix (strain ATCC 700893 / DSM 11879 / JCM 9820 / NBRC 100138 / K1) Protein CysO Proteins 0.000 claims description 2
- 101710191958 Amino-acid acetyltransferase Proteins 0.000 claims description 2
- 102000009042 Argininosuccinate Lyase Human genes 0.000 claims description 2
- 108010055400 Aspartate kinase Proteins 0.000 claims description 2
- 101000742087 Bacillus subtilis (strain 168) ATP-dependent threonine adenylase Proteins 0.000 claims description 2
- 108010000898 Chorismate mutase Proteins 0.000 claims description 2
- 102100037579 D-3-phosphoglycerate dehydrogenase Human genes 0.000 claims description 2
- 108010020869 Homocysteine S-Methyltransferase Proteins 0.000 claims description 2
- 108060004316 L-cysteine desulfidase Proteins 0.000 claims description 2
- 108010048581 Lysine decarboxylase Proteins 0.000 claims description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical group [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 2
- 108010038555 Phosphoglycerate dehydrogenase Proteins 0.000 claims description 2
- 108010015724 Prephenate Dehydratase Proteins 0.000 claims description 2
- 108010035004 Prephenate Dehydrogenase Proteins 0.000 claims description 2
- 102000028649 Ribonucleoside-diphosphate reductase Human genes 0.000 claims description 2
- 108010038105 Ribonucleoside-diphosphate reductase Proteins 0.000 claims description 2
- 108030004891 Ribose-phosphate diphosphokinases Proteins 0.000 claims description 2
- 229910000831 Steel Inorganic materials 0.000 claims description 2
- 101000774739 Thermus thermophilus Aspartokinase Proteins 0.000 claims description 2
- 102000005488 Thioesterase Human genes 0.000 claims description 2
- 108010022394 Threonine synthase Proteins 0.000 claims description 2
- 101710159621 Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase Proteins 0.000 claims description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 claims description 2
- 235000003869 genetically modified organism Nutrition 0.000 claims description 2
- 229910052750 molybdenum Inorganic materials 0.000 claims description 2
- 239000011733 molybdenum Substances 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 239000010959 steel Substances 0.000 claims description 2
- 108020002982 thioesterase Proteins 0.000 claims description 2
- 229910052720 vanadium Inorganic materials 0.000 claims description 2
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical group C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 claims 4
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 abstract description 56
- 230000001580 bacterial effect Effects 0.000 abstract description 4
- 239000000047 product Substances 0.000 description 151
- 229940088598 enzyme Drugs 0.000 description 150
- 210000004027 cell Anatomy 0.000 description 86
- 125000003275 alpha amino acid group Chemical group 0.000 description 82
- 241000588724 Escherichia coli Species 0.000 description 76
- 238000013459 approach Methods 0.000 description 51
- 102000039446 nucleic acids Human genes 0.000 description 39
- 108020004707 nucleic acids Proteins 0.000 description 39
- 239000002773 nucleotide Substances 0.000 description 37
- 125000003729 nucleotide group Chemical group 0.000 description 37
- 238000006467 substitution reaction Methods 0.000 description 34
- 230000000670 limiting effect Effects 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 31
- 239000000758 substrate Substances 0.000 description 30
- 239000000203 mixture Substances 0.000 description 29
- 235000001014 amino acid Nutrition 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 28
- 235000014113 dietary fatty acids Nutrition 0.000 description 28
- 229930195729 fatty acid Natural products 0.000 description 28
- 239000000194 fatty acid Substances 0.000 description 28
- 230000002068 genetic effect Effects 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 28
- 125000000539 amino acid group Chemical group 0.000 description 27
- 238000012217 deletion Methods 0.000 description 27
- 230000037430 deletion Effects 0.000 description 27
- 230000012010 growth Effects 0.000 description 26
- 241000894007 species Species 0.000 description 25
- 239000013589 supplement Substances 0.000 description 25
- 230000000813 microbial effect Effects 0.000 description 24
- 102000040430 polynucleotide Human genes 0.000 description 24
- 108091033319 polynucleotide Proteins 0.000 description 24
- 239000002157 polynucleotide Substances 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 23
- 235000010633 broth Nutrition 0.000 description 23
- 230000037353 metabolic pathway Effects 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 20
- 108700033863 EC 2.3.1.85 Proteins 0.000 description 19
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical group NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 19
- 239000006151 minimal media Substances 0.000 description 19
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 18
- 238000007792 addition Methods 0.000 description 18
- 230000004075 alteration Effects 0.000 description 18
- 150000004665 fatty acids Chemical class 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 18
- 230000004853 protein function Effects 0.000 description 18
- OAKURXIZZOAYBC-UHFFFAOYSA-N 3-oxopropanoic acid Chemical compound OC(=O)CC=O OAKURXIZZOAYBC-UHFFFAOYSA-N 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 16
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 16
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 230000006872 improvement Effects 0.000 description 15
- 230000002503 metabolic effect Effects 0.000 description 15
- 235000000346 sugar Nutrition 0.000 description 15
- 241001528539 Cupriavidus necator Species 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 14
- 235000015097 nutrients Nutrition 0.000 description 14
- 230000009469 supplementation Effects 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 238000012224 gene deletion Methods 0.000 description 13
- 238000003780 insertion Methods 0.000 description 13
- 230000037431 insertion Effects 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 12
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 12
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 12
- 230000009088 enzymatic function Effects 0.000 description 12
- BLPJOIOMVXBHNL-QJBWUGSNSA-N s-[2-[3-[[(2r)-4-[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] ethanethioate;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 BLPJOIOMVXBHNL-QJBWUGSNSA-N 0.000 description 12
- 108020004705 Codon Proteins 0.000 description 11
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 11
- 239000004473 Threonine Substances 0.000 description 11
- 150000008163 sugars Chemical class 0.000 description 11
- 102000003960 Ligases Human genes 0.000 description 10
- 108090000364 Ligases Proteins 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 238000006722 reduction reaction Methods 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 235000014469 Bacillus subtilis Nutrition 0.000 description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 9
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 9
- 239000004472 Lysine Substances 0.000 description 9
- WTFXTQVDAKGDEY-HTQZYQBOSA-L chorismate(2-) Chemical compound O[C@@H]1C=CC(C([O-])=O)=C[C@H]1OC(=C)C([O-])=O WTFXTQVDAKGDEY-HTQZYQBOSA-L 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 229920000768 polyamine Polymers 0.000 description 9
- WTFXTQVDAKGDEY-UHFFFAOYSA-N (-)-chorismic acid Natural products OC1C=CC(C(O)=O)=CC1OC(=C)C(O)=O WTFXTQVDAKGDEY-UHFFFAOYSA-N 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 8
- 229910019142 PO4 Inorganic materials 0.000 description 8
- 240000008042 Zea mays Species 0.000 description 8
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 8
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 8
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 235000005822 corn Nutrition 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 239000010452 phosphate Substances 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- 244000063299 Bacillus subtilis Species 0.000 description 7
- 102000009114 Fatty acid desaturases Human genes 0.000 description 7
- 108010087894 Fatty acid desaturases Proteins 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 101150103637 bkdB gene Proteins 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- VLYUGYAKYZETRF-UHFFFAOYSA-N dihydrolipoamide Chemical compound NC(=O)CCCCC(S)CCS VLYUGYAKYZETRF-UHFFFAOYSA-N 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000006911 enzymatic reaction Methods 0.000 description 7
- 229940093915 gynecological organic acid Drugs 0.000 description 7
- 239000002054 inoculum Substances 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 150000007524 organic acids Chemical class 0.000 description 7
- 235000005985 organic acids Nutrition 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000013587 production medium Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000194033 Enterococcus Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- 241000235648 Pichia Species 0.000 description 6
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 6
- 238000010353 genetic engineering Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 101150056881 mcr gene Proteins 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 101150026856 zwf2 gene Proteins 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 241000192731 Chloroflexus aurantiacus Species 0.000 description 5
- 241001646716 Escherichia coli K-12 Species 0.000 description 5
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 238000012824 chemical production Methods 0.000 description 5
- 230000004907 flux Effects 0.000 description 5
- 238000004817 gas chromatography Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 238000005342 ion exchange Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 241000252867 Cupriavidus metallidurans Species 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 241000588722 Escherichia Species 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- 240000005979 Hordeum vulgare Species 0.000 description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 239000005700 Putrescine Substances 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 101150015189 aceE gene Proteins 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 101150078069 cynT gene Proteins 0.000 description 4
- 238000005115 demineralization Methods 0.000 description 4
- 230000002328 demineralizing effect Effects 0.000 description 4
- 108040007096 enoyl-[acyl-carrier-protein] reductase activity proteins Proteins 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 101150114630 mtcA2 gene Proteins 0.000 description 4
- 238000002887 multiple sequence alignment Methods 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 101150028177 pdhB gene Proteins 0.000 description 4
- 101150086832 pdhC gene Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical compound [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 229940063673 spermidine Drugs 0.000 description 4
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- WPAMZTWLKIDIOP-UCORVYFPSA-N 2-keto-3-deoxy-L-galactonic acid Chemical compound OC[C@H](O)[C@@H](O)CC(=O)C(O)=O WPAMZTWLKIDIOP-UCORVYFPSA-N 0.000 description 3
- 108010030844 2-methylcitrate synthase Proteins 0.000 description 3
- 108010046716 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) Proteins 0.000 description 3
- KPULXFNPTWGJQH-UHFFFAOYSA-N 3-hydroxy-4-oxo-4-propan-2-yloxybutanoic acid Chemical compound CC(C)OC(=O)C(O)CC(O)=O KPULXFNPTWGJQH-UHFFFAOYSA-N 0.000 description 3
- 108010071258 4-hydroxy-2-oxoglutarate aldolase Proteins 0.000 description 3
- 108010017192 4-hydroxy-4-methyl-2-oxoglutarate aldolase Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100029589 Acylpyruvase FAHD1, mitochondrial Human genes 0.000 description 3
- 241000588986 Alcaligenes Species 0.000 description 3
- 102100032252 Antizyme inhibitor 2 Human genes 0.000 description 3
- 241000186063 Arthrobacter Species 0.000 description 3
- 241000194108 Bacillus licheniformis Species 0.000 description 3
- 241000186146 Brevibacterium Species 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- 101710167917 Carbonic anhydrase 2 Proteins 0.000 description 3
- 102100024633 Carbonic anhydrase 2 Human genes 0.000 description 3
- 108010071536 Citrate (Si)-synthase Proteins 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 3
- 241000186216 Corynebacterium Species 0.000 description 3
- 102000028526 Dihydrolipoamide Dehydrogenase Human genes 0.000 description 3
- 108010028127 Dihydrolipoamide Dehydrogenase Proteins 0.000 description 3
- 241000194032 Enterococcus faecalis Species 0.000 description 3
- 241000194031 Enterococcus faecium Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 3
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 3
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 3
- 108091052347 Glucose transporter family Proteins 0.000 description 3
- 101000798222 Homo sapiens Antizyme inhibitor 2 Proteins 0.000 description 3
- 108090000769 Isomerases Proteins 0.000 description 3
- 102000004195 Isomerases Human genes 0.000 description 3
- 241000588748 Klebsiella Species 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000121202 Oligotropha carboxidovorans Species 0.000 description 3
- 108010069823 Oxaloacetate decarboxylase Proteins 0.000 description 3
- 241000179039 Paenibacillus Species 0.000 description 3
- 241000178960 Paenibacillus macerans Species 0.000 description 3
- 108700023175 Phosphate acetyltransferases Proteins 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 241000589776 Pseudomonas putida Species 0.000 description 3
- 108010091086 Recombinases Proteins 0.000 description 3
- 102000018120 Recombinases Human genes 0.000 description 3
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 3
- 241000187561 Rhodococcus erythropolis Species 0.000 description 3
- 241000235070 Saccharomyces Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 241000588901 Zymomonas Species 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- 101150042732 aroC gene Proteins 0.000 description 3
- 101150018055 aroH gene Proteins 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 238000010364 biochemical engineering Methods 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- FFQKYPRQEYGKAF-UHFFFAOYSA-N carbamoyl phosphate Chemical compound NC(=O)OP(O)(O)=O FFQKYPRQEYGKAF-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 230000019522 cellular metabolic process Effects 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 101150021225 cynS gene Proteins 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000003413 degradative effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 229940032049 enterococcus faecalis Drugs 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 150000002190 fatty acyls Chemical group 0.000 description 3
- FJEKYHHLGZLYAT-FKUIBCNASA-N galp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)[C@@H](C)O)C(C)C)C1=CNC=N1 FJEKYHHLGZLYAT-FKUIBCNASA-N 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 101150108412 kgd gene Proteins 0.000 description 3
- 238000011005 laboratory method Methods 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 229940072205 lactobacillus plantarum Drugs 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000012269 metabolic engineering Methods 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 101150043391 mmsB gene Proteins 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000004108 pentose phosphate pathway Effects 0.000 description 3
- 101150111581 pflB gene Proteins 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 101150000475 pntAB gene Proteins 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000010902 straw Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 108010028984 3-isopropylmalate dehydratase Proteins 0.000 description 2
- ROWKJAVDOGWPAT-UHFFFAOYSA-N Acetoin Chemical compound CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 description 2
- 108010009924 Aconitate hydratase Proteins 0.000 description 2
- 102000009836 Aconitate hydratase Human genes 0.000 description 2
- 241001103870 Adia Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 101001074429 Bacillus subtilis (strain 168) Polyketide biosynthesis acyltransferase homolog PksD Proteins 0.000 description 2
- 101000936617 Bacillus velezensis (strain DSM 23117 / BGSC 10A6 / FZB42) Polyketide biosynthesis acyltransferase homolog BaeD Proteins 0.000 description 2
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 2
- 101100175237 Caldanaerobacter subterraneus subsp. tengcongensis (strain DSM 15242 / JCM 11007 / NBRC 100824 / MB4) gcvPB gene Proteins 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 102000006732 Citrate synthase Human genes 0.000 description 2
- 101100163308 Clostridium perfringens (strain 13 / Type A) argR1 gene Proteins 0.000 description 2
- 101100435903 Corynebacterium glutamicum (strain ATCC 13032 / DSM 20300 / BCRC 11384 / JCM 1318 / LMG 3730 / NCIMB 10025) aroG gene Proteins 0.000 description 2
- 241001528480 Cupriavidus Species 0.000 description 2
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 2
- 101100121464 Dictyostelium discoideum gcvH1 gene Proteins 0.000 description 2
- 101100175157 Dictyostelium discoideum gcvH2 gene Proteins 0.000 description 2
- 101100175166 Dictyostelium discoideum gcvH3 gene Proteins 0.000 description 2
- 101100014303 Dictyostelium discoideum gcvH4 gene Proteins 0.000 description 2
- 101100014305 Dictyostelium discoideum gcvH5 gene Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 101100434436 Escherichia coli (strain K12) adiA gene Proteins 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 229920002488 Hemicellulose Polymers 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical group OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 101100462488 Phlebiopsis gigantea p2ox gene Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 101100217185 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) aruC gene Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 240000000111 Saccharum officinarum Species 0.000 description 2
- 235000007201 Saccharum officinarum Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 2
- 101100398785 Streptococcus agalactiae serotype V (strain ATCC BAA-611 / 2603 V/R) ldhD gene Proteins 0.000 description 2
- 235000021536 Sugar beet Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 101100002724 Thermus thermophilus aroH gene Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 241000282485 Vulpes vulpes Species 0.000 description 2
- 101100386830 Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4) ddh gene Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 108010011384 acyl-CoA dehydrogenase (NADP+) Proteins 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 101150089004 argR gene Proteins 0.000 description 2
- 101150037081 aroA gene Proteins 0.000 description 2
- 101150040872 aroE gene Proteins 0.000 description 2
- 101150019536 aroF gene Proteins 0.000 description 2
- 101150076125 aroG gene Proteins 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001651 autotrophic effect Effects 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 108010055956 beta-ketoacyl-acyl carrier protein synthase I Proteins 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000006652 catabolic pathway Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000003889 chemical engineering Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 101150029709 cysM gene Proteins 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000006114 decarboxylation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- 230000004136 fatty acid synthesis Effects 0.000 description 2
- 150000002185 fatty acyl-CoAs Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 101150064198 gapN gene Proteins 0.000 description 2
- 101150110684 gcvH gene Proteins 0.000 description 2
- 101150011909 gcvP gene Proteins 0.000 description 2
- 101150022706 gcvT gene Proteins 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 101150095957 ilvA gene Proteins 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 101150026107 ldh1 gene Proteins 0.000 description 2
- 101150041530 ldha gene Proteins 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 235000013379 molasses Nutrition 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- KCRZDTROFIOPBP-UHFFFAOYSA-N phosphono 2,3-dihydroxypropanoate Chemical compound OCC(O)C(=O)OP(O)(O)=O KCRZDTROFIOPBP-UHFFFAOYSA-N 0.000 description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 2
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 2
- 229910052939 potassium sulfate Inorganic materials 0.000 description 2
- 235000011151 potassium sulphates Nutrition 0.000 description 2
- 101150060030 poxB gene Proteins 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 101150033131 sthA gene Proteins 0.000 description 2
- 239000010907 stover Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 101150106193 tal gene Proteins 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 238000010977 unit operation Methods 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 101150090985 ydfG gene Proteins 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- VOJUXHHACRXLTD-UHFFFAOYSA-N 1,4-dihydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC(O)=C21 VOJUXHHACRXLTD-UHFFFAOYSA-N 0.000 description 1
- ICFIZJQGJAJRSU-UHFFFAOYSA-N 2,3-Dimethoxy-5-methyl-6-<3,7,11,15,19,23,27,31-octamethyl-dotriacontaoctaen-(2,6,10,14,18,22,26,30)-yl>benzochinon Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ICFIZJQGJAJRSU-UHFFFAOYSA-N 0.000 description 1
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 101710142619 3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ Proteins 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 1
- 108010093803 3-ketoacyl-acyl carrier protein synthase III Proteins 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 1
- DCTLYFZHFGENCW-UUOKFMHZSA-N 5'-xanthylic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 DCTLYFZHFGENCW-UUOKFMHZSA-N 0.000 description 1
- YQIFAMYNGGOTFB-XINAWCOVSA-N 7,8-dihydroneopterin Chemical compound N1CC([C@H](O)[C@H](O)CO)=NC2=C1N=C(N)NC2=O YQIFAMYNGGOTFB-XINAWCOVSA-N 0.000 description 1
- PLSQMGZYOGSOCE-XINAWCOVSA-N 7,8-dihydroneopterin 3'-phosphate Chemical compound N1CC([C@H](O)[C@H](O)COP(O)(O)=O)=NC2=C1N=C(N)NC2=O PLSQMGZYOGSOCE-XINAWCOVSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 101100536799 Acinetobacter baylyi (strain ATCC 33305 / BD413 / ADP1) tgnE gene Proteins 0.000 description 1
- 101710146995 Acyl carrier protein Proteins 0.000 description 1
- 102000006488 Acyl-Carrier Protein S-Malonyltransferase Human genes 0.000 description 1
- 108010058912 Acyl-Carrier Protein S-Malonyltransferase Proteins 0.000 description 1
- 108010070753 Adenosylmethionine decarboxylase Proteins 0.000 description 1
- 102000005758 Adenosylmethionine decarboxylase Human genes 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 101100163490 Alkalihalobacillus halodurans (strain ATCC BAA-125 / DSM 18197 / FERM 7344 / JCM 9153 / C-125) aroA1 gene Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000609240 Ambelania acida Species 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 101000614816 Arabidopsis thaliana 3-oxoacyl-[acyl-carrier-protein] synthase II, chloroplastic Proteins 0.000 description 1
- 241000370685 Arge Species 0.000 description 1
- 241001167018 Aroa Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 101100216993 Bacillus subtilis (strain 168) aroD gene Proteins 0.000 description 1
- 101100462570 Bacillus subtilis (strain 168) bsdB gene Proteins 0.000 description 1
- 101100488070 Bacillus subtilis (strain 168) bsdC gene Proteins 0.000 description 1
- 101100508888 Bacillus subtilis (strain 168) iolJ gene Proteins 0.000 description 1
- 101100290837 Bacillus subtilis (strain 168) metAA gene Proteins 0.000 description 1
- 101100076641 Bacillus subtilis (strain 168) metE gene Proteins 0.000 description 1
- 101100130094 Bacillus subtilis (strain 168) metK gene Proteins 0.000 description 1
- 101100087825 Bacillus subtilis (strain 168) nrdE gene Proteins 0.000 description 1
- 101100154671 Bacillus subtilis (strain 168) tsaE gene Proteins 0.000 description 1
- 101100096227 Bacteroides fragilis (strain 638R) argF' gene Proteins 0.000 description 1
- 101000856746 Bos taurus Cytochrome c oxidase subunit 7A1, mitochondrial Proteins 0.000 description 1
- 101100174521 Bradyrhizobium diazoefficiens (strain JCM 10833 / BCRC 13528 / IAM 13628 / NBRC 14792 / USDA 110) fumC2 gene Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 108010084185 Cellulases Proteins 0.000 description 1
- 102000005575 Cellulases Human genes 0.000 description 1
- 101100227595 Chlamydia pneumoniae folKP gene Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 101100054574 Corynebacterium diphtheriae (strain ATCC 700971 / NCTC 13129 / Biotype gravis) acn gene Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 241000960359 Cupriavidus basilensis Species 0.000 description 1
- 241001640455 Cupriavidus campinensis Species 0.000 description 1
- 101100138542 Cupriavidus necator (strain ATCC 17699 / DSM 428 / KCTC 22496 / NCIMB 10442 / H16 / Stanier 337) phbH gene Proteins 0.000 description 1
- 101100054578 Cupriavidus necator acnM gene Proteins 0.000 description 1
- 241000382839 Cupriavidus oxalaticus Species 0.000 description 1
- 241001635226 Cupriavidus pauculus Species 0.000 description 1
- 241001050521 Cupriavidus pinatubonensis Species 0.000 description 1
- 241001470441 Cupriavidus respiraculi Species 0.000 description 1
- 241000366859 Cupriavidus taiwanensis Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 101100215150 Dictyostelium discoideum aco1 gene Proteins 0.000 description 1
- 101100126053 Dictyostelium discoideum impdh gene Proteins 0.000 description 1
- 101100190555 Dictyostelium discoideum pkgB gene Proteins 0.000 description 1
- 101100410642 Dictyostelium discoideum purC/E gene Proteins 0.000 description 1
- 101100087840 Dictyostelium discoideum rnrB-2 gene Proteins 0.000 description 1
- 108010073112 Dihydrolipoyllysine-residue acetyltransferase Proteins 0.000 description 1
- 102000009093 Dihydrolipoyllysine-residue acetyltransferase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108091006149 Electron carriers Proteins 0.000 description 1
- 101100491986 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) aromA gene Proteins 0.000 description 1
- 101100498063 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) cysB gene Proteins 0.000 description 1
- 108010061075 Enterobactin Proteins 0.000 description 1
- SERBHKJMVBATSJ-UHFFFAOYSA-N Enterobactin Natural products OC1=CC=CC(C(=O)NC2C(OCC(C(=O)OCC(C(=O)OC2)NC(=O)C=2C(=C(O)C=CC=2)O)NC(=O)C=2C(=C(O)C=CC=2)O)=O)=C1O SERBHKJMVBATSJ-UHFFFAOYSA-N 0.000 description 1
- 101100165944 Escherichia coli (strain K12) can gene Proteins 0.000 description 1
- 101100174518 Escherichia coli (strain K12) fumB gene Proteins 0.000 description 1
- 101100075914 Escherichia coli (strain K12) malY gene Proteins 0.000 description 1
- 101100322888 Escherichia coli (strain K12) metL gene Proteins 0.000 description 1
- 101100082381 Escherichia coli (strain K12) patA gene Proteins 0.000 description 1
- 101100268630 Escherichia coli (strain K12) patD gene Proteins 0.000 description 1
- 101100246464 Escherichia coli (strain K12) puuE gene Proteins 0.000 description 1
- 101100420922 Escherichia coli (strain K12) sdaB gene Proteins 0.000 description 1
- 101100099023 Escherichia coli (strain K12) tdcE gene Proteins 0.000 description 1
- 101100323111 Escherichia coli (strain K12) tynA gene Proteins 0.000 description 1
- 101100483544 Escherichia coli (strain K12) ubiF gene Proteins 0.000 description 1
- 101100539304 Escherichia coli (strain K12) ubiH gene Proteins 0.000 description 1
- 241000644323 Escherichia coli C Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150099894 GDHA gene Proteins 0.000 description 1
- 101100295959 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) arcB gene Proteins 0.000 description 1
- 101100277701 Halobacterium salinarum gdhX gene Proteins 0.000 description 1
- 101100221590 Herbaspirillum seropedicae coq7 gene Proteins 0.000 description 1
- 102000004867 Hydro-Lyases Human genes 0.000 description 1
- 108090001042 Hydro-Lyases Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 101100399603 Lactiplantibacillus plantarum (strain ATCC BAA-793 / NCIMB 8826 / WCFS1) lpdC gene Proteins 0.000 description 1
- 241000178948 Lactococcus sp. Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 101150051213 MAOA gene Proteins 0.000 description 1
- 108030004530 Malonate-semialdehyde dehydrogenases Proteins 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241001214257 Mene Species 0.000 description 1
- PBOUVYGPDSARIS-IUCAKERBSA-N Met-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C PBOUVYGPDSARIS-IUCAKERBSA-N 0.000 description 1
- 241000157876 Metallosphaera sedula Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100435931 Methanosarcina acetivorans (strain ATCC 35395 / DSM 2834 / JCM 12185 / C2A) aroK gene Proteins 0.000 description 1
- 101100023016 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) mat gene Proteins 0.000 description 1
- 101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
- 108010093369 Multienzyme Complexes Proteins 0.000 description 1
- 102000002568 Multienzyme Complexes Human genes 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 101100010672 Mycobacterium leprae (strain TN) dxs gene Proteins 0.000 description 1
- 101100063392 Mycobacterium leprae (strain TN) folP1 gene Proteins 0.000 description 1
- 101100354186 Mycoplasma capricolum subsp. capricolum (strain California kid / ATCC 27343 / NCTC 10154) ptcA gene Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 102000000818 NADP Transhydrogenases Human genes 0.000 description 1
- 108010001609 NADP Transhydrogenases Proteins 0.000 description 1
- 241000498271 Necator Species 0.000 description 1
- 101100046676 Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) tpcA gene Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000121201 Oligotropha Species 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001520808 Panicum virgatum Species 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 101100392454 Picrophilus torridus (strain ATCC 700027 / DSM 9790 / JCM 10055 / NBRC 100828) gdh2 gene Proteins 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 1
- 101100453320 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) pfkC gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010048516 S-sulfocysteine synthase Proteins 0.000 description 1
- 101100116769 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) gdhA-2 gene Proteins 0.000 description 1
- 241000235060 Scheffersomyces stipitis Species 0.000 description 1
- 101100013797 Schizosaccharomyces pombe (strain 972 / ATCC 24843) gcd1 gene Proteins 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 244000138286 Sorghum saccharatum Species 0.000 description 1
- 241001415395 Spea Species 0.000 description 1
- 108010051753 Spermidine Synthase Proteins 0.000 description 1
- 102100030413 Spermidine synthase Human genes 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 101100370749 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) trpC1 gene Proteins 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101100022072 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) lysJ gene Proteins 0.000 description 1
- 241000160715 Sulfolobus tokodaii Species 0.000 description 1
- 101100029403 Synechocystis sp. (strain PCC 6803 / Kazusa) pfkA2 gene Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 101150024271 TKT gene Proteins 0.000 description 1
- 101100492609 Talaromyces wortmannii astC gene Proteins 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 101100354953 Treponema denticola (strain ATCC 35405 / DSM 14222 / CIP 103919 / JCM 8153 / KCTC 15104) pyrBI gene Proteins 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 101150057540 aar gene Proteins 0.000 description 1
- 101150116772 aatA gene Proteins 0.000 description 1
- 101150077561 aceF gene Proteins 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 101150113917 acnA gene Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- OFBHPPMPBOJXRT-VWJPMABRSA-N adenylosuccinic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C2=NC=NC(N[C@@H](CC(O)=O)C(O)=O)=C2N=C1 OFBHPPMPBOJXRT-VWJPMABRSA-N 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- QZBYOYPROVGOGE-UHFFFAOYSA-N aminopropylcadaverine Chemical compound NCCCCCNCCCN QZBYOYPROVGOGE-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 101150072344 argA gene Proteins 0.000 description 1
- 101150008194 argB gene Proteins 0.000 description 1
- 101150070427 argC gene Proteins 0.000 description 1
- 101150089042 argC2 gene Proteins 0.000 description 1
- 101150050866 argD gene Proteins 0.000 description 1
- 101150056313 argF gene Proteins 0.000 description 1
- 101150118463 argG gene Proteins 0.000 description 1
- 101150090235 aroB gene Proteins 0.000 description 1
- 101150102858 aroD gene Proteins 0.000 description 1
- 101150083869 aroK gene Proteins 0.000 description 1
- 101150007004 aroL gene Proteins 0.000 description 1
- 101150108612 aroQ gene Proteins 0.000 description 1
- 101150005925 aspC gene Proteins 0.000 description 1
- 101150024707 astC gene Proteins 0.000 description 1
- 239000010905 bagasse Substances 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 101150111114 cysE gene Proteins 0.000 description 1
- 101150094831 cysK gene Proteins 0.000 description 1
- 101150112941 cysK1 gene Proteins 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 101150100742 dapL gene Proteins 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 101150050862 dhaB gene Proteins 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- MRGWUDKEBPXDJX-UHFFFAOYSA-N diazaborinine Chemical class B1=CC=CN=N1 MRGWUDKEBPXDJX-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 101150032129 egsA gene Proteins 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000004050 enoyl group Chemical group 0.000 description 1
- SERBHKJMVBATSJ-BZSNNMDCSA-N enterobactin Chemical compound OC1=CC=CC(C(=O)N[C@@H]2C(OC[C@@H](C(=O)OC[C@@H](C(=O)OC2)NC(=O)C=2C(=C(O)C=CC=2)O)NC(=O)C=2C(=C(O)C=CC=2)O)=O)=C1O SERBHKJMVBATSJ-BZSNNMDCSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 101150031187 fba gene Proteins 0.000 description 1
- 101150108901 fbaA gene Proteins 0.000 description 1
- 101150050376 fbaB gene Proteins 0.000 description 1
- 101150111583 fda gene Proteins 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 101150011175 folB gene Proteins 0.000 description 1
- 101150073342 folC gene Proteins 0.000 description 1
- 101150045875 folP gene Proteins 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 101150102318 fre gene Proteins 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 101150028420 fumC gene Proteins 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 101150043302 gabD gene Proteins 0.000 description 1
- 101150116670 gabT gene Proteins 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 101150033931 gldA gene Proteins 0.000 description 1
- 238000002873 global sequence alignment Methods 0.000 description 1
- 101150106096 gltA gene Proteins 0.000 description 1
- 101150042350 gltA2 gene Proteins 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 108010064177 glutamine synthetase I Proteins 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 101150097303 glyA gene Proteins 0.000 description 1
- 101150079604 glyA1 gene Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108010014977 glycine cleavage system Proteins 0.000 description 1
- 101150084612 gpmA gene Proteins 0.000 description 1
- 101150104722 gpmI gene Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 101150114741 guaA gene Proteins 0.000 description 1
- 101150093309 guaAA gene Proteins 0.000 description 1
- 101150085008 guaAB gene Proteins 0.000 description 1
- 101150035744 guaB gene Proteins 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 101150063051 hom gene Proteins 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 101150003679 hsaG gene Proteins 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- GFAZHVHNLUBROE-UHFFFAOYSA-N hydroxymethyl propionaldehyde Natural products CCC(=O)CO GFAZHVHNLUBROE-UHFFFAOYSA-N 0.000 description 1
- 101150033780 ilvB gene Proteins 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N itaconic acid Chemical compound OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940116871 l-lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 101150095558 leuC2 gene Proteins 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000002029 lignocellulosic biomass Substances 0.000 description 1
- 239000012978 lignocellulosic material Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 101150007808 lpdC gene Proteins 0.000 description 1
- 101150035025 lysC gene Proteins 0.000 description 1
- 101150094164 lysY gene Proteins 0.000 description 1
- 101150039489 lysZ gene Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 101150095079 menB gene Proteins 0.000 description 1
- 101150085064 menC gene Proteins 0.000 description 1
- 101150017274 menF gene Proteins 0.000 description 1
- 101150086633 metAA gene Proteins 0.000 description 1
- 101150003180 metB gene Proteins 0.000 description 1
- 101150117293 metC gene Proteins 0.000 description 1
- 101150108178 metE gene Proteins 0.000 description 1
- 101150095438 metK gene Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 101150024975 mhpF gene Proteins 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 241000264288 mixed libraries Species 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 239000010813 municipal solid waste Substances 0.000 description 1
- XTAZYLNFDRKIHJ-UHFFFAOYSA-N n,n-dioctyloctan-1-amine Chemical compound CCCCCCCCN(CCCCCCCC)CCCCCCCC XTAZYLNFDRKIHJ-UHFFFAOYSA-N 0.000 description 1
- 101150101723 nrdA gene Proteins 0.000 description 1
- 101150037566 nrdB gene Proteins 0.000 description 1
- 101150035869 nrdD gene Proteins 0.000 description 1
- 101150090395 nrdE gene Proteins 0.000 description 1
- 101150085762 nrdF gene Proteins 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 101150078036 odhB gene Proteins 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- KYOBSHFOBAOFBF-XVFCMESISA-N orotidine 5'-phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1C(O)=O KYOBSHFOBAOFBF-XVFCMESISA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000021962 pH elevation Effects 0.000 description 1
- 101150013947 pabB gene Proteins 0.000 description 1
- 101150070572 pabC gene Proteins 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000010893 paper waste Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 101150038284 pfkA gene Proteins 0.000 description 1
- 101150004013 pfkA1 gene Proteins 0.000 description 1
- 101150060387 pfp gene Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 101150023849 pheA gene Proteins 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 241000512250 phototrophic bacterium Species 0.000 description 1
- 239000010908 plant waste Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000001884 polyglutamylation Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 101150045242 ptsH gene Proteins 0.000 description 1
- 101150002764 purA gene Proteins 0.000 description 1
- 101150028995 purC gene Proteins 0.000 description 1
- 101150105087 purC1 gene Proteins 0.000 description 1
- 101150084005 purD gene Proteins 0.000 description 1
- 101150076045 purF gene Proteins 0.000 description 1
- 101150103875 purH gene Proteins 0.000 description 1
- 101150035806 purK gene Proteins 0.000 description 1
- 101150056177 purM gene Proteins 0.000 description 1
- 101150112726 purN gene Proteins 0.000 description 1
- 101150008241 purT gene Proteins 0.000 description 1
- 101150098691 pyrB gene Proteins 0.000 description 1
- 101150051230 pyrC gene Proteins 0.000 description 1
- 101150107042 pyrD gene Proteins 0.000 description 1
- 101150092104 pyrDB gene Proteins 0.000 description 1
- 101150116440 pyrF gene Proteins 0.000 description 1
- 101150054232 pyrG gene Proteins 0.000 description 1
- 101150006862 pyrH gene Proteins 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000000066 reactive distillation Methods 0.000 description 1
- 230000031390 regulation of fatty acid biosynthetic process Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 101150003316 rpiA gene Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 101150100082 sdaA gene Proteins 0.000 description 1
- 101150003830 serC gene Proteins 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000002910 solid waste Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 101150101115 speB gene Proteins 0.000 description 1
- 101150022778 speF gene Proteins 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 101150055132 sucB gene Proteins 0.000 description 1
- 101150031436 sucD gene Proteins 0.000 description 1
- UIUJIQZEACWQSV-UHFFFAOYSA-N succinic semialdehyde Chemical compound OC(=O)CCC=O UIUJIQZEACWQSV-UHFFFAOYSA-N 0.000 description 1
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 101150110498 talA gene Proteins 0.000 description 1
- 101150040618 talB gene Proteins 0.000 description 1
- 101150027981 tdcB gene Proteins 0.000 description 1
- 101150019205 tdcD gene Proteins 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 239000005460 tetrahydrofolate Substances 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 101150014006 thrA gene Proteins 0.000 description 1
- 101150072448 thrB gene Proteins 0.000 description 1
- 101150000850 thrC gene Proteins 0.000 description 1
- 101150014795 tktA gene Proteins 0.000 description 1
- 101150071019 tktB gene Proteins 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 101150019416 trpA gene Proteins 0.000 description 1
- 101150081616 trpB gene Proteins 0.000 description 1
- 101150111232 trpB-1 gene Proteins 0.000 description 1
- 101150016309 trpC gene Proteins 0.000 description 1
- 101150100816 trpD gene Proteins 0.000 description 1
- 101150044170 trpE gene Proteins 0.000 description 1
- 101150079930 trpGD gene Proteins 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 101150028338 tyrB gene Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 101150007324 ubiA gene Proteins 0.000 description 1
- 101150062288 ubiB gene Proteins 0.000 description 1
- 101150001045 ubiC gene Proteins 0.000 description 1
- 101150085844 ubiD gene Proteins 0.000 description 1
- 101150025212 ubiE gene Proteins 0.000 description 1
- 101150019812 ubiG gene Proteins 0.000 description 1
- 101150003433 ubiX gene Proteins 0.000 description 1
- ICFIZJQGJAJRSU-SGHXUWJISA-N ubiquinone-8 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ICFIZJQGJAJRSU-SGHXUWJISA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
- 239000010925 yard waste Substances 0.000 description 1
- 101150117464 ydiB gene Proteins 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P11/00—Preparation of sulfur-containing organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/12—Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/42—Hydroxy-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/52—Propionic acid; Butyric acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/62—Carboxylic acid esters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/04—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with a disulfide as acceptor (1.2.4)
- C12Y102/04001—Pyruvate dehydrogenase (acetyl-transferring) (1.2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/02—Thioester hydrolases (3.1.2)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Definitions
- This invention relates to metabolically engineered microorganisms, such as bacterial strains, in which there is an increased utilization of malonyl-CoA for production of a chemical product, which may include the chemical 3-hydroxypropionic acid (3-HP) and products made from 3-HP.
- the metabolically engineered microorganisms may be adapted to exhibit increased tolerance to 3-HP.
- genetic modifications may be made to provide one or more 3-HP biosynthesis pathways such as in microorganisms comprising one or more genetic modifications of a complex identified as the 3-HP toleragenic complex.
- Numerous chemicals are produced through such means, ranging from antibiotic and anti-malarial pharmaceutical products to fine chemicals to fuels such as ethanol.
- Commercial objectives for microbial fermentation include the increase of titer, production rate, and yield of a target chemical product. When the overall specific productivity in a fermentation event is elevated, this may positively affect yield in addition to production rate and other economic factors, such as capital costs.
- 3-hydroxypropionic acid (“3-HP”, CAS No. 503-66-2), which may be converted to a number of basic building blocks for polymers used in a wide range of industrial and consumer products.
- 3-HP 3-hydroxypropionic acid
- previous efforts to microbially synthesize 3-HP to achieve commercially viable titers have revealed that the microbes being used were inhibited by concentrations of 3-HP far below a determined commercially viable titer.
- the invention is directed to a method for producing an acrylic acid-based consumer product, said method comprising i) combining a carbon source and a microorganism cell culture to produce 3-hydroxypropionic acid, wherein a) said cell culture comprises an inhibitor of fatty acid synthase or said microorganism is genetically modified for reduced enzymatic activity in the organism's fatty acid synthase pathway; or b) wherein said microorganism is genetically modified for increased enzymatic activity in the organism's malonyl-CoA reductase (mcr) pathway by introduction of a heterologous nucleic acid sequence coding for a polypeptide having mono-functional malonyl-CoA reductase activity; or c) said 3- hydroxypropionic acid is produced at a specific productivity of greater than 0.05 grams per gram of microorganism cell on a dry weight basis per hour or at a volumetric productivity of greater than 0.50 grams per liter per hour; i
- the carbon source according to the invention may be predominantly glucose, sucrose, fructose, dextrose, lactose, or a combination thereof.
- the carbon source is glycerol.
- the cell culture comprises an inhibitor of fatty acid synthase or said microorganism is genetically modified for reduced enzymatic activity in the organism's fatty acid synthase pathway.
- the inhibitor of a fatty acid synthase may be selected from the group consisting of thiolactomycin, triclosan, cerulenin, thienodiazaborine, isoniazid, and analogs thereof.
- the microorganism of the invention may be genetically modified for increased enzymatic activity in the organism's malonyl-CoA reductase (mcr) pathway by introduction of a heterologous nucleic acid sequence coding for a polypeptide having mono-functional malonyl-CoA reductase activity.
- the mono-functional malonyl-CoA reductase is NADPH-independent.
- the 3-hydroxypropionic acid is produced according to the invention at a specific productivity of greater than 0.05 grams per gram of microorganism cell on a dry weight basis per hour or at a volumetric productivity of greater than 0.05 grams per liter per hour.
- the cell culture comprises a genetically modified microorganism.
- the genetically modified microorganism can be modified for a trait selected from reduced enzymatic activity in the organism's fatty acid synthase pathway, increased enzymatic activity in the organism's malonyl-CoA reductase pathway, increased tolerance to 3-hydroxypropionic acid, increased enzymatic activity in the organism's NADPH-dependent transhydrogenase pathway, increased intracellular bicarbonate levels, increased enzymatic activity in the organism's acetyl-CoA carboxylase pathway, and combinations thereof.
- the genetically modified microorganism can be modified for reduced enzymatic activity in the organism's fatty acid synthase pathway.
- the reduced enzymatic activity is a reduction in enzymatic activity in an enzyme selected from the group consisting of beta-ketoacyl-ACP reductase, 3- hydroxyacyl-CoA dehydratase, enoyl-ACP reductase, and thioesterase.
- the reduced enzymatic activity in the organism's fatty acid synthase pathway occurs via introduction of a heterologous nucleic acid sequence coding for an inducible promoter operably linked to a sequence coding for a enzyme in the fatty acid synthase pathway or homolog thereof, or a heterologous nucleic acid sequence coding for an enzyme in the fatty acid synthase pathway or homolog thereof with reduced activity.
- the enzyme in the fatty acid synthase pathway or homolog thereof is a polypeptide with temperature -sensitive beta- ketoacyl-ACP or temperature -sensitive enoyl-ACP reductase activity.
- the genetically modified microorganism is modified for increased enzymatic activity in the organism's malonyl-CoA reductase pathway.
- the increase in enymatic activity in the malonyl-CoA reductase (mcr) pathway occurs by introduction of a heterologous nucleic acid sequence coding for a polypeptide having bi-functional malonyl-CoA reductase enzymatic activity or mono-functional malonyl-CoA reductase activity.
- the heterologous nucleic acid sequence may be selected from a sequence having at least 70% homology with a sequence selected from SEQ ID NO. 780-789.
- the genetically modified microorganism is modified for increased tolerance to 3 -hydroxypropionic acid.
- the increase in tolerance to 3 -hydroxypropionic acid may occur in one or more components of the 3 -HP toleragenic complex (3HPTGC) complex, or wherein said increase in tolerance to 3- hydroxypropionic acid results from providing at least one genetic modification of each of Group A and Group B of the 3HPTGC.
- the one or more components may be selected from CynS, CynT, AroG, SpeD, SpeE, SpeF, ThrA, Asd, CysM, IroK, IlvA, and homologs thereof.
- the modification is a disruption of one or more 3HPTGC repressor genes.
- the repressor genes may be selected from tyrR, trpR, metJ, purR, lysR, nrdR, and homologs thereof.
- Increased enzymatic activity in the organism's NADPH -dependent transhydrogenase pathway may occur by introduction of a heterologous nucleic acid sequence coding for a polypeptide having at least 70% homology with a sequence selected from SEQ ID NO. 776 or 778.
- the increased intracellular bicarbonate levels occurs by introduction of a heterologous nucleic acid sequence coding for a polypeptide having cyanase and/or carbonic anhydrase activity.
- Heterologous nucleic acid sequence may be selected from a sequence having at least 70% homology with a sequence selected from SEQ ID NO. 337.
- an increased enzymatic activity in the organism's acetyl-CoA carboxylase pathway occurs by introduction of a heterologous nucleic acid sequence coding for a polypeptide having at least 70% homology with a sequence selected from SEQ ID NO. 768-775.
- the genetically modified bacteria may be further modified to decrease activity of, lactate
- dehydrogenase phophate acetyltransferase
- pyruvate oxidase or pyruvate-formate lyase, and combinations thereof.
- the method according to the invention may further comprise separating and/or purifying 3- hydroxypropionic acid from said cell culture by extraction of 3 -hydroxypropionic acid from said culture in the presence of a tertiary amine.
- 3 -hydroxypropionic acid is produced at a specific productivity of greater than 0.05 grams per gram of microorganism cell on a dry weight basis per hour or at a volumetric productivity of greater than 0.50 grams per liter per hour.
- the method of the invention may include production of a consumer product, such as diapers, carpet, paint, adhesives, and acrylic glass.
- the invention includes biologically-produced 3 -hydroxypropionic acid, where the 3 -hydroxypropionic acid is produced according to the method of the invention.
- Such 3- hydroxypropionic acid may be essentially free of chemical catalyst, including a molybdenum and/or vanadium based catalyst.
- the 3 -hydroxypropionic acid is produced according to the method of the invention may have a ratio of carbon- 14 to carbon- 12 of about 1.0 x 10 "14 or greater.
- the 3 -hydroxypropionic acid contains less than about 10% carbon derived from petroleum.
- 3 -hydroxypropionic acid according to the invention may contain a residual amount of organic material related to its method of production.
- the 3-hydroxypropionic acid contains a residual amount of organic material in an amount between 1 and 1,000 parts per million of the 3-hydroxypropionic acid.
- Acrylic acid and a polymer produced from acrylic acid, where such are produced according to the method of the invention, are also included within the invention.
- Products, including commercial and consumer products, obtained from the polymers are also encompassed.
- diapers, carpet, paint, adhesives, and acrylic glass are encompassed.
- the invention encompasses a system for bioproduction of acrylic acid according to claim 40, said system comprising: a tank for saccharification of biomass; a line for passing the product of saccharification to a fermentation tank optionally via a pre-fermentation tank; a fermentation tank suitable for microorganism cell culture; a line for discharging contents from the fermentation tank to an extraction and/or separation vessel; an extraction and/or separation vessel suitable for removal of 3-hydroxypropionic acid from cell culture waste; a line for transferring 3-hydroxypropionic acid to a dehydration vessel; and a dehydration vessel suitable for conversion of 3-hydroxypropionic acid to acrylic acid.
- the system further comprises one or more pre-fermentation tanks, distillation columns, centrifuge vessels, back extraction columns, mixing vessels, or combinations thereof.
- the system has a minimum production capacity of at least 1 ton acrylic acid per year.
- microorganism within the scope of the invention are genetically modified microorganism, wherein the microorganism is capable of producing 3-hydroxypropionate at a specific rate selected from the rates of greater than 0.05 g/gDCW-hr, 0.08g/gDCW-hr, greater than O. lg/gDCW-hr, greater than 0.13g/gDCW-hr, greater than
- 0.15g/gDCW-hr greater than 0.175g/gDCW-hr, greater than 0.2g/gDCW-hr, greater than 0.25g/gDCW-hr, greater than 0.3g/gDCW-hr, greater than 0.35g/gDCW-hr, greater than 0.4g/gDCW-hr, greater than
- the genetically modified microorganism may comprise genetic modifications to increase malonyl-coA reductase activity and acetyl-coA carboxylase activity, and genetic modifications to reduce enoyl-ACP reductase activity, lactate dehydrogenase activity and acetate kinase activity.
- the microorganism comprises genetic modifications to increase malonyl-coA reductase activity and acetyl-coA carboxylase activity, and genetic modifications to reduce enoyl-ACP reductase activity, lactate dehydrogenase activity and acetylphosphate transferase activity.
- microorganism may comprise genetic modifications to increase malonyl-coA reductase activity and acetyl-coA carboxylase activity, and genetic modifications to reduce enoyl-ACP reductase activity, lactate dehydrogenase activity, acetate kinase activity and
- the microorganism comprises genetic modifications to increase malonyl-coA reductase activity and acetyl-coA carboxylase activity, and genetic modifications to reduce enoyl-ACP reductase activity, lactate dehydrogenase activity and pyruvate formate lyase activity.
- the microorganism comprises genetic modifications to increase malonyl-coA reductase activity and acetyl-coA carboxylase activity, and genetic modifications to reduce enoyl-ACP reductase activity, lactate dehydrogenase activity and pyruvate oxidase activity.
- microorganisms comprising genetic modifications to increase malonyl-coA reductase activity and acetyl-coA carboxylase activity, and genetic modifications to reduce enoyl-ACP reductase activity, lactate dehydrogenase activity and methylglyoxal synthase activity.
- microorganisms according to the invention may comprise genetic modifications to increase malonyl-coA reductase activity and acetyl-coA carboxylase activity, and genetic modifications to increase ⁇ -ketoacyl-ACP synthase activity, and decrease lactate dehydrogenase activity and methylglyoxal synthase activity, and/or the microorganism may comprise genetic modifications to increase malonyl-coA reductase activity and acetyl-coA carboxylase activity, and genetic modifications to reduce enoyl-ACP reductase activity, guanosine 3 '-diphosphate 5 '-triphosphate synthase activity, and guanosine 3 '-diphosphate 5'- diphosphate synthase activity. Also, in some microorganisms enoyl-CoA reductase, is reduced instead of or in addition to doing such for enoyl-ACP reductase activity.
- a further genetic modification has been made that increases NADH/NADPH transhydrogenase activity.
- the transhydrogenase activity may be soluble, may be membrane bound, may have a further genetic modification that has been made that increases cyanase activity, may include a further genetic modification that increases carbonic anhydrase activity, and/or may include a further genetic modification that increases pyruvate dehydrogenase activity.
- a further genetic modification has been made that decreases guanosine 3'- diphosphate 5 '-triphosphate synthase activity, and guanosine 3 '-diphosphate 5 '-diphosphate synthase activity. Also included is when a genetic modification has been made that increases the NADH/NAD+ ratio in an aerated environment.
- a genetic modification may be made that decreases ⁇ -ketoacyl-ACP synthase activity, decreases 3-hydroxypropionate reductase activity, decreases NAD+ dependant 3-hydroxypropionate dehydrogenase activity, decreases NAD+ dependant 3-hydroxypropionate dehydrogenase activity, increases tolerance to 3-hydroxypropionic acid, increases activity of any enzyme in the 3 -HP toleragenic complex, increases pyruvate dehydrogenase activity, increases cyanase activity, increases carbonic anhydrase activity, increases aspartate kinase activity, increases threonine dehydratase activity, increases 2-dehydro-3- deoxyphosphoheptonate aldolase activity, increases cysteine synthase activity, increases ribose-phosphate diphosphokinase activity, increases ribonucleoside-diphosphate reductase activity, increases L-cysteine desulfhydrase activity, increases lysine decarbox
- the invention includes a culture system comprising a carbon source in an aqueous medium and a genetically modified microorganism according to any one of claims 48-92, wherein said genetically modified organism is present in an amount selected from greater than 0.05 gDCW/L, 0.1 gDCW/L, greater than 1 gDCW/L, greater than 5 gDCW/L, greater than 10 gDCW/L, greater than 15 gDCW/L or greater than 20 gDCW/L, such as when the volume of the aqueous medium is selected from greater than 5 mL, greater than 100 mL, greater than 0.5L, greater than 1L, greater than 2 L, greater than 10 L, greater than 250 L, greater than 1000L, greater than 10,000L, greater than 50,000 L, greater than 100,000 L or greater than 200,000 L, and such as when the volume of the aqueous medium is greater than 250 L and contained within a steel vessel.
- the carbon source for such culture systems is selected from dextrose, sucrose, a pentose, a polyol, a hexose, both a hexose and a pentose, and combinations thereof, the pH of the aqueous medium is less than 7.5, the culture system is aerated, such as at an oxygen transfer rate selected from i) greater than 5 mmole/L-hr of oxygen and less than 200 mmole/L-hr oxygen; ii) greater than 5 mmole/L-hr of oxygen and less than 100 mmole/L-hr oxygen; iii) greater than 5 mmole/L-hr of oxygen and less than 80 mmole/L-hr oxygen; and iv) greater than 5 mmole/L-hr of oxygen and less than 50 mmole/L-hr oxygen.
- the invention is an aqueous broth obtained from a culture system according to any one of claims 93-99, wherein said aqueous broth comprises i) a concentration of 3-hydroxypropionate selected from greater than 5g/L, greater than lOg/L, greater than 15 g/L, greater than 20g/L, greater than 25g/L, greater than 30g/L, greater than 35g/L, greater than 40g/L, greater than 50g/L, greater than 60g/L, greater than 70g/L, greater than 80g/L, greater than 90g/L, or greater than lOOg/L 3-hydroxypropionate; and ii) a concentration of 1,3 -propanediol selected from less than 30g/L; less than 20g/L; less than lOg/L; less than 5g/L; less than 1 g/L; or less than 0.5 g/L.
- a concentration of 3-hydroxypropionate selected from greater than 5g/L, greater than lOg
- the aqueous broth comprises an amount of biomass selected from less than 20 gDCW/L biomass, less than 15 gDCW/L biomass, less than 10 gDCW/L biomass, less than 5 gDCW/L biomass or less than 1 gDCW/L biomass.
- the aqueous broth according to the invention is such that the 3-HP/succinate ratio (g3-HP/g succinate) is greater than 3, greater than 10 greater than 30, greater than 60, greater than 100, greater than 150 or greater than 200.
- the 3- HP/fumarate ratio is greater than 3, greater than 10 greater than 30, greater than 60, greater than 100, greater than 150 or greater than 200, or the 3-HP/glycerol ratio (g3-HP/g glycerol) is greater than 3, greater than 10, greater than 30, greater than 60, greater than 100, greater than 150 or greater than 200, or the 3- HP/acetate ratio (g3-HP/g acetate) is greater than 1.5, greater than 3, greater than 10, greater than 30, greater than 60, greater than 100, greater than 150 or greater than 200, or the 3-HP/alanine ratio (g3-HP/g alanine) is greater than 3, greater than 10, greater than 30, greater than 60, greater than 100, greater than 150 or greater than 200, or the 3-HP/beta-alanine ratio (g3-HP/g beta-alanine) is greater than 1.5, greater than 3, greater than 10, greater than 30, greater than 60, greater than 100, greater than 150 or greater than 200, or the 3-HP/beta-alanine ratio (g3-HP
- FIG. 1 depicts metabolic pathways of a microorganism related to aspects of the present invention, more particularly related to 3 -HP production, with gene names of E. coli shown at certain enzymatic steps, the latter for example and not meant to be limiting.
- FIG. 2A depicts metabolic pathways of a microorganism related to aspects of the present invention, with gene names of E. coli shown at certain enzymatic steps, the latter for example and not meant to be limiting.
- FIG. 2B provides a more detailed depiction of representative enzymatic conversions and exemplary E. coli genes of the fatty acid synthetase system that was more generally depicted in FIG. 2A.
- FIG. 3 provides an exemplary multiple sequence alignment, comparing carbonic anhydrase polypeptides
- FIG. 4A provides an exemplary sequence alignment: Comparison of DNA sequences of fablts (JP1111
- FIG. 4B provides an exemplary sequence alignment: Comparison of protein sequences oifabf (JP1111
- FIGs. 5, 6 and 7 provide data and results from Example 11.
- FIG. 8 depicts metabolic pathways of a microorganism with multiple genetic modifications related to aspects of the present invention, more particularly related to 3-HP production, with gene names of E. coli shown at certain enzymatic steps, the latter for example and not meant to be limiting.
- FIG. 9A, sheets 1-7 is a multi-sheet depiction of portions of metabolic pathways, showing pathway products and enzymes, that together comprise the 3-HP toleragenic complex (3HPTGC) in E. coli.
- Sheet 1 provides a general schematic depiction of the arrangement of the remaining sheets.
- FIG. 9B sheets 1-7, provides a multi-sheet depiction of the 3HPTGC for Bacillus subtilis.
- Sheet 1 provides a general schematic depiction of the arrangement of the remaining sheets.
- FIG. 9C sheets 1-7, provides a multi-sheet depiction of the 3HPTGC for Saccharomyces cerevisiae.
- Sheet 1 provides a general schematic depiction of the arrangement of the remaining sheets.
- FIG. 9D sheets 1-7, provides a multi-sheet depiction of the 3HPTGC for Cupriavidus necator (previously, Ralstonia eutropha).
- Sheet 1 provides a general schematic depiction of the arrangement of the remaining sheets.
- FIG. 10 provides a representation of the glycine cleavage pathway.
- FIG. 11 provides, from a prior art reference, a summary of a known 3-HP production pathway from glucose to pyruvate to acetyl-CoA to malonyl-CoA to 3-HP.
- FIG. 12 provides, from a prior art reference, a summary of a known 3-HP production pathway from glucose to phosphoenolpyruvate (PEP) to oxaloacetate (directly or via pyruvate) to aspartate to ⁇ -alanine to malonate semialdehyde to 3-HP.
- PEP phosphoenolpyruvate
- oxaloacetate directly or via pyruvate
- FIG. 13 provides, from a prior art reference, a summary of known 3-HP production pathways.
- FIG. 14A and B provide a schematic diagram of natural mixed fermentation pathways in E. coli.
- FIG. 15A-0 provides graphic data of control microorganisms responses to 3-HP
- FIG. 15P provides a comparison with one genetic modification of the 3HPTGC.
- FIG. 16 depicts a known chemical reaction catalyzed by alpha-ketoglutarate encoded by the kgd gene from M. tuberculosis.
- FIG. 17 depicts a new enzymatic function, the decarboxylation of oxaloacetate to malonate semialdehyde that is to be achieved by modification of the kgd gene.
- FIG. 18 shows a proposed selection approach for kgd mutants.
- FIG. 19 shows a screening protocol related to the proposed selection approach depicted in FIG. 18.
- FIG. 20 provides a comparison regarding the IroK peptide sequence.
- FIG. 21 provides a calibration curve for 3-HP conducted with HPLC.
- FIG. 22 provides a calibration curve for 3-HP conducted for GC/MS.
- FIG. 23 provides a representative standard curve for the enaymatic assay for 3 -HP.
- FIG. 24 A, B, and C and FIG. 25 A and B show a schematic of the entire process of converting biomass to a finished product such as a diaper.
- the present invention is related to various production methods and/or genetically modified microorganisms that have utility for fermentative production of various chemical products, to methods of making such chemical products that utilize populations of these microorganisms in vessels, and to systems for chemical production that employ these microorganisms and methods.
- Among the benefits of the present invention is increased specific productivity when such microorganisms produce a chemical product during a fermentation event or cycle.
- the present invention provides production techniques and/or genetically modified microorganisms to produce a chemical product of interest, such as 3-hydroxypropionic acid (3 -HP) with one or more means for modulating conversion of malonyl-CoA to fatty acyl molecules (which thereafter may be converted to fatty acids, for example fatty acyl-ACP molecules), wherein the production pathway comprises an enzymatic conversion step that uses malonyl-CoA as a substrate.
- the means for modulating conversion of malonyl-CoA to fatty acyl molecules, such as fatty acyl-ACP molecules is effective to balance carbon flow to microbial biomass with carbon flow to chemical product, and surprisingly affords achievement of elevated specific productivity rates.
- various aspects of the present invention are directed to a microorganism cell comprises a metabolic pathway from malonyl-CoA to 3 -HP, and means for modulating conversion of malonyl-CoA to fatty acyl molecules (which thereafter may be converted to fatty acids) also are provided. Then, when the means for modulating modulate to decrease such conversion, a proportionally greater number of malonyl-CoA molecules are 1) produced and/or 2) converted via the metabolic pathway from malonyl-CoA to 3-HP.
- additional genetic modifications may be made, such as to 1) increase intracellular bicarbonate levels, such as by increasing carbonic anhydrase, 2) increase enzymatic activity of acetyl-CoA carboxylase, and NADPH-dependent transhydrogenase.
- Unexpected increases in specific productivity by a population of a genetically modified microorganism may be achieved in methods and systems in which that microorganism has a microbial production pathway from malonyl-CoA to a selected chemical product as well as a reduction in the enzymatic activity of a selected enzyme of the microorganism's fatty acid synthase system (more particularly, its fatty acid elongation enzymes).
- specific supplements to a bioreactor vessel comprising such microorganism population may also be provided to further improve the methods and systems.
- 3-hydroxypropionic acid 3-hydroxypropionic acid
- genetic modifications for production pathways are provided, and a toleragenic complex is described for which genetic modifications, and/or culture system modifications, may be made to increase microorganism tolerance to 3-HP.
- genetic modifications to increase expression and/or enzymatic activity of carbonic anhydrase and/or cyanase may provide dual- functions to advantageously improve both 3-HP production and 3-HP tolerance.
- an "expression vector” includes a single expression vector as well as a plurality of expression vectors, either the same (e.g., the same operon) or different; reference to “microorganism” includes a single microorganism as well as a plurality of microorganisms; and the like.
- DCW dry cell weight
- reduced enzymatic activity As used herein, “reduced enzymatic activity,” “reducing enzymatic activity,” and the like is meant to indicate that a microorganism cell's, or an isolated enzyme, exhibits a lower level of activity than that measured in a comparable cell of the same species or its native enzyme. That is, enzymatic conversion of the indicated substrate(s) to indicated product(s) under known standard conditions for that enzyme is at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, or at least 90 percent less than the enzymatic activity for the same biochemical conversion by a native (non-modified) enzyme under a standard specified condition. This term also can include elimination of that enzymatic activity.
- a cell having reduced enzymatic activity of an enzyme can be identified using any method known in the art.
- enzyme activity assays can be used to identify cells having reduced enzyme activity. See, for example, Enzyme Nomenclature, Academic Press, Inc., New York 2007.
- heterologous DNA refers to a nucleic acid sequence wherein at least one of the following is true: (a) the sequence of nucleic acids is foreign to (i.e., not naturally found in) a given host microorganism; (b) the sequence may be naturally found in a given host microorganism, but in an unnatural (e.g., greater than expected) amount; or (c) the sequence of nucleic acids comprises two or more subsequences that are not found in the same relationship to each other in nature. For example, regarding instance (c), a heterologous nucleic acid sequence that is recombinantly produced will have two or more sequences from unrelated genes arranged to make a new functional nucleic acid.
- heterologous is intended to include the term “exogenous” as the latter term is generally used in the art. With reference to the host microorganism's genome prior to the introduction of a heterologous nucleic acid sequence, the nucleic acid sequence that codes for the enzyme is heterologous (whether or not the heterologous nucleic acid sequence is introduced into that genome).
- the term "gene disruption,” or grammatical equivalents thereof is intended to mean a genetic modification to a microorganism that renders the encoded gene product as having a reduced polypeptide activity compared with polypeptide activity in or from a microorganism cell not so modified.
- the genetic modification can be, for example, deletion of the entire gene, deletion or other modification of a regulatory sequence required for transcription or translation, deletion of a portion of the gene which results in a truncated gene product (e.g., enzyme) or by any of various mutation strategies that reduces activity (including to no detectable activity level) the encoded gene product.
- a disruption may broadly include a deletion of all or part of the nucleic acid sequence encoding the enzyme, and also includes, but is not limited to other types of genetic modifications, e.g., introduction of stop codons, frame shift mutations, introduction or removal of portions of the gene, and introduction of a degradation signal, those genetic modifications affecting mRNA transcription levels and/or stability, and altering the promoter or repressor upstream of the gene encoding the enzyme.
- a gene disruption is taken to mean any genetic modification to the DNA, mRNA encoded from the DNA, and the corresponding amino acid sequence that results in reduced polypeptide activity.
- Many different methods can be used to make a cell having reduced polypeptide activity.
- a cell can be engineered to have a disrupted regulatory sequence or polypeptide-encoding sequence using common mutagenesis or knock-out technology. See, e.g., Methods in Yeast Genetics (1997 edition), Adams et al., Cold Spring Harbor Press (1998).
- One particularly useful method of gene disruption is complete gene deletion because it reduces or eliminates the occurrence of genetic reversions in the genetically modified
- microorganisms of the invention Accordingly, a disruption of a gene whose product is an enzyme thereby disrupts enzymatic function.
- antisense technology can be used to reduce the activity of a particular polypeptide.
- a cell can be engineered to contain a cDNA that encodes an antisense molecule that prevents a polypeptide from being translated.
- gene silencing can be used to reduce the activity of a particular polypeptide.
- antisense molecule encompasses any nucleic acid molecule or nucleic acid analog (e.g., peptide nucleic acids) that contains a sequence that corresponds to the coding strand of an endogenous polypeptide.
- An antisense molecule also can have flanking sequences (e.g., regulatory sequences).
- antisense molecules can be ribozymes or antisense oligonucleotides.
- a ribozyme can have any general structure including, without limitation, hairpin, hammerhead, or axhead structures, provided the molecule cleaves RNA.
- Bio-production as used herein, may be aerobic, microaerobic, or anaerobic.
- the language "sufficiently homologous" refers to proteins or portions thereof that have amino acid sequences that include a minimum number of identical or equivalent amino acid residues when compared to an amino acid sequence of the amino acid sequences provided in this application (including the SEQ ID Nos./sequence listings) such that the protein or portion thereof is able to achieve the respective enzymatic reaction and/or other function.
- To determine whether a particular protein or portion thereof is sufficiently homologous may be determined by an assay of enzymatic activity, such as those commonly known in the art.
- nucleic acid sequences may be varied and still encode an enzyme or other polypeptide exhibiting a desired functionality, and such variations are within the scope of the present invention.
- hybridization refers to the process in which two single-stranded polynucleotides bind non-covalently to form a stable double-stranded polynucleotide.
- the term “hybridization” may also refer to triple-stranded hybridization.
- the resulting (usually) double-stranded polynucleotide is a “hybrid” or “duplex.”
- “Hybridization conditions” will typically include salt concentrations of less than about 1M, more usually less than about 500 mM and less than about 200 mM.
- Hybridization temperatures can be as low as 5°C, but are typically greater than 22°C, more typically greater than about 30°C, and often are in excess of about 37°C.
- Hybridizations are usually performed under stringent conditions, i.e. conditions under which a probe will hybridize to its target subsequence. Stringent conditions are sequence -dependent and are different in different circumstances. Longer fragments may require higher hybridization temperatures for specific hybridization. As other factors may affect the stringency of hybridization, including base composition and length of the complementary strands, presence of organic solvents and extent of base mismatching, the combination of parameters is more important than the absolute measure of any one alone.
- stringent conditions are selected to be about 5°C lower than the T m for the specific sequence at a defined ionic strength and pH.
- Exemplary stringent conditions include salt concentration of at least 0.01 M to no more than 1 M Na ion concentration (or other salts) at a pH 7.0 to 8.3 and a temperature of at least 25°C.
- salt concentration of at least 0.01 M to no more than 1 M Na ion concentration (or other salts) at a pH 7.0 to 8.3 and a temperature of at least 25°C.
- 5 X SSPE 750 mM NaCl, 50 mM NaPhosphate, 5 mM EDTA, pH 7.4
- a temperature of 25-30°C are suitable for allele-specific probe hybridizations.
- Hybridizing specifically to or “specifically hybridizing to” or like expressions refer to the binding, duplexing, or hybridizing of a molecule substantially to or only to a particular nucleotide sequence or sequences under stringent conditions when that sequence is present in a complex mixture (e.g., total cellular) DNA or RNA.
- the term "identified enzymatic functional variant” means a polypeptide that is determined to possess an enzymatic activity and specificity of an enzyme of interest but which has an amino acid sequence different from such enzyme of interest.
- a corresponding "variant nucleic acid sequence" may be constructed that is determined to encode such an identified enzymatic functional variant.
- one or more genetic modifications may be made to provide one or more heterologous nucleic acid sequence(s) that encode one or more identified 3HPTGC enzymatic functional variant(s).
- each such nucleic acid sequence encodes a polypeptide that is not exactly the known polypeptide of an enzyme of the 3HPTGC, but which nonetheless is shown to exhibit enzymatic activity of such enzyme.
- Such nucleic acid sequence, and the polypeptide it encodes may not fall within a specified limit of homology or identity yet by its provision in a cell nonetheless provide for a desired enzymatic activity and specificity.
- the ability to obtain such variant nucleic acid sequences and identified enzymatic functional variants is supported by recent advances in the states of the art in bioinformatics and protein engineering and design, including advances in computational, predictive and high-throughput methodologies.
- Functional variants more generally include enzymatic functional variants, and the nucleic acids sequences that encode them, as well as variants of non-enzymatic polypeptides, wherein the variant exhibits the function of the original (target) sequence.
- segment of interest is meant to include both a gene and any other nucleic acid sequence segment of interest.
- One example of a method used to obtain a segment of interest is to acquire a culture of a microorganism, where that microorganism's genome includes the gene or nucleic acid sequence segment of interest.
- the genetic modification of a gene product i.e., an enzyme
- the genetic modification is of a nucleic acid sequence, such as or including the gene, that normally encodes the stated gene product, i.e., the enzyme.
- a truncated respective polypeptide has at least about 90% of the full length of a polypeptide encoded by a nucleic acid sequence encoding the respective native enzyme, and more particularly at least 95% of the full length of a polypeptide encoded by a nucleic acid sequence encoding the respective native enzyme.
- a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a reference amino acid sequence of a polypeptide is intended that the amino acid sequence of the claimed polypeptide is identical to the reference sequence except that the claimed polypeptide sequence can include up to five amino acid alterations per each 100 amino acids of the reference amino acid of the polypeptide.
- a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence up to 5% of the amino acid residues in the reference sequence can be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence can be inserted into the reference sequence.
- These alterations of the reference sequence can occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence. In other embodiments truncation may be more substantial, as described elsewhere herein.
- Species and other phylogenic identifications are according to the classification known to a person skilled in the art of microbiology.
- Bio-production media which is used in the present invention with recombinant microorganisms having a biosynthetic pathway for 3-HP, must contain suitable carbon sources or substrates for the intended metabolic pathways.
- suitable substrates may include, but are not limited to, monosaccharides such as glucose and fructose, oligosaccharides such as lactose or sucrose, polysaccharides such as starch or cellulose or mixtures thereof and unpurified mixtures from renewable feedstocks such as cheese whey permeate, cornsteep liquor, sugar beet molasses, and barley malt.
- the carbon substrate may also be one-carbon substrates such as carbon dioxide, carbon monoxide, or methanol for which metabolic conversion into key biochemical intermediates has been demonstrated.
- methylotrophic organisms are also known to utilize a number of other carbon containing compounds such as methylamine, glucosamine and a variety of amino acids for metabolic activity.
- carbon substrates and mixtures thereof are suitable in the present invention as a carbon source
- common carbon substrates used as carbon sources are glucose, fructose, and sucrose, as well as mixtures of any of these sugars.
- suitable substrates include xylose, arabinose, other cellulose -based C-5 sugars, high-fructose corn syrup, and various other sugars and sugar mixtures as are available commercially.
- Sucrose may be obtained from feedstocks such as sugar cane, sugar beets, cassava, bananas or other fruit, and sweet sorghum.
- Glucose and dextrose may be obtained through saccharification of starch based feedstocks including grains such as corn, wheat, rye, barley, and oats. Also, in some embodiments all or a portion of the carbon source may be glycerol. Alternatively, glycerol may be excluded as an added carbon source.
- the carbon source is selected from glucose, fructose, sucrose, dextrose, lactose, glycerol, and mixtures thereof.
- the amount of these components in the carbon source may be greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, greater than about 90%, or more, up to 100% or essentially 100% of the carbon source.
- methylotrophic organisms are known to utilize a number of other carbon containing compounds such as methylamine, glucosamine and a variety of amino acids for metabolic activity.
- methylotrophic yeast are known to utilize the carbon from methylamine to form trehalose or glycerol (Bellion et al., Microb. Growth CI Compd. (Int. Symp.), 7th (1993), 415-32. Editor(s): MurreU, J. Collin; Kelly, Don P. Publisher: Intercept, Andover, UK).
- various species of Candida will metabolize alanine or oleic acid (Suiter et al., Arch. Microbiol. 153:485-489 (1990)).
- the source of carbon utilized in embodiments of the present invention may encompass a wide variety of carbon-containing substrates.
- fermentable sugars may be obtained from cellulosic and lignocellulosic biomass through processes of pretreatment and saccharification, as described, for example, in U.S. Patent Publication No.
- Biomass refers to any cellulosic or lignocellulosic material and includes materials comprising cellulose, and optionally further comprising hemicellulose, lignin, starch, oligosaccharides and/or monosaccharides. Biomass may also comprise additional components, such as protein and/or lipid. Biomass may be derived from a single source, or biomass can comprise a mixture derived from more than one source; for example, biomass could comprise a mixture of corn cobs and corn stover, or a mixture of grass and leaves.
- Biomass includes, but is not limited to, bioenergy crops, agricultural residues, municipal solid waste, industrial solid waste, sludge from paper manufacture, yard waste, wood and forestry waste.
- biomass include, but are not limited to, corn grain, corn cobs, crop residues such as corn husks, corn stover, grasses, wheat, wheat straw, barley, barley straw, hay, rice straw, switchgrass, waste paper, sugar cane bagasse, sorghum, soy, components obtained from milling of grains, trees, branches, roots, leaves, wood chips, sawdust, shrubs and bushes, vegetables, fruits, flowers and animal manure. Any such biomass may be used in a bio-production method or system to provide a carbon source.
- any of a wide range of sugars including, but not limited to sucrose, glucose, xylose, cellulose or hemicellulose
- a microorganism such as in an industrial system comprising a reactor vessel in which a defined media (such as a minimal salts media including but not limited to M9 minimal media, potassium sulfate minimal media, yeast synthetic minimal media and many others or variations of these), an inoculum of a microorganism providing one or more of the 3 -HP biosynthetic pathway alternatives, and the a carbon source may be combined.
- a defined media such as a minimal salts media including but not limited to M9 minimal media, potassium sulfate minimal media, yeast synthetic minimal media and many others or variations of these
- an inoculum of a microorganism providing one or more of the 3 -HP biosynthetic pathway alternatives, and the a carbon source may be combined.
- the carbon source enters the cell and is cataboliized by well-known and common metabolic pathways to yield common metabolic intermediates, including phosphoenolpyruvate (PEP).
- PEP phosphoenolpyruvate
- Bio-based carbon can be distinguished from petroleum-based carbon according to a variety of methods, including without limitation ASTM D6866, or various other techniques.
- carbon-14 and carbon-12 ratios differ in bio-based carbon sources versus petroleum-based sources, where higher carbon-14 ratios are found in bio-based carbon sources.
- the carbon source is not petroleum-based, or is not predominantly petroleum based.
- the carbon source is greater than about 50% non- petroleum based, greater than about 60% non-petroleum based, greater than about 70% non-petroleum based, greater than about 80% non-petroleum based, greater than about 90% non-petroleum based, or more.
- the carbon source has a carbon-14 to carbon-12 ratio of about 1.0 x 10 "14 or greater.
- the carbon source may be less than about 50% glycerol, less than about 40% glycerol, less than about 30% glycerol, less than about 20% glycerol, less than about 10% glycerol, less than about 5% glycerol, less than about 1% glycerol, or less.
- the carbon source may be essentially glycerol-free. By essentially glycerol-free is meant that any glycerol that may be present in a residual amount does not contribute substantially to the production of the target chemical compound.
- microorganism selected from the listing herein, or another suitable microorganism, that also comprises one or more natural, introduced, or enhanced 3- HP bio-production pathways.
- the microorganism comprises an endogenous 3 -HP production pathway (which may, in some such embodiments, be enhanced), whereas in other embodiments the microorganism does not comprise an endogenous 3 -HP production pathway.
- Varieties of these genetically modified microorganisms may comprise genetic modifications and/or other system alterations as may be described in other patent applications of one or more of the present inventor(s) and/or subject to assignment to the owner of the present patent application.
- bacterial and yeast microorganisms describe specific modifications and evaluations to certain bacterial and yeast microorganisms.
- the scope of the invention is not meant to be limited to such species, but to be generally applicable to a wide range of suitable microorganisms.
- a microorganism used for the present invention may be selected from bacteria, cyanobacteria, filamentous fungi and yeasts.
- microbial hosts initially selected for 3-HP toleragenic bio-production should also utilize sugars including glucose at a high rate.
- Most microbes are capable of utilizing carbohydrates.
- certain environmental microbes cannot utilize carbohydrates to high efficiency, and therefore would not be suitable hosts for such embodiments that are intended for glucose or other carbohydrates as the principal added carbon source.
- the present invention easily may be applied to an ever-increasing range of suitable microorganisms. Further, given the relatively low cost of genetic sequencing, the genetic sequence of a species of interest may readily be determined to make application of aspects of the present invention more readily obtainable (based on the ease of application of genetic modifications to an organism having a known genomic sequence).
- suitable microbial hosts for the bio- production of 3-HP that comprise tolerance aspects provided herein generally may include, but are not limited to, any gram negative organisms, more particularly a member of the family Enterobacteriaceae, such as E. coli, or Oligotropha carboxidovorans, or Pseudomononas sp. ; any gram positive microorganism, for example Bacillus subtilis, Lactobaccilus sp. or Lactococcus sp.; a yeast, for example Saccharomyces cerevisiae, Pichia pastoris or Pichia stipitis; and other groups or microbial species.
- any gram negative organisms more particularly a member of the family Enterobacteriaceae, such as E. coli, or Oligotropha carboxidovorans, or Pseudomononas sp.
- any gram positive microorganism for example Bacillus subtilis, Lactobaccilus sp. or Lactococc
- suitable microbial hosts for the bio-production of 3-HP generally include, but are not limited to, members of the genera Clostridium, Zymomonas, Escherichia, Salmonella, Rhodococcus, Pseudomonas, Bacillus, Lactobacillus, Enterococcus, Alcaligenes, Klebsiella, Paenibacillus, Arthrobacter, Corynebacterium, Brevibacterium, Pichia, Candida, Hansenula and Saccharomyces.
- Hosts that may be particularly of interest include: Oligotropha
- carboxidovorans such as strain OM5
- Escherichia coli Alcaligenes eutrophus (Cupriavidus necator)
- Bacillus licheniformis Paenibacillus macerans
- Rhodococcus erythropolis Pseudomonas putida
- Lactobacillus plantarum Enterococcus faecium, Enterococcus gallinarium, Enterococcus faecalis
- Bacillus subtilis and Saccharomyces cerevisiae Bacillus subtilis and Saccharomyces cerevisiae.
- suitable microbial hosts for the bio-production of 3-HP generally include, but are not limited to, members of the genera Clostridium, Zymomonas, Escherichia, Salmonella, Rhodococcus,
- Pseudomonas Bacillus, Lactobacillus, Enterococcus, Alcaligenes, Klebsiella, Paenibacillus, Arthrobacter, Corynebacterium, Brevibacterium, Pichia, Candida, Hansenula and Saccharomyces.
- Hosts that may be particularly of interest include: Oligotropha carboxidovorans (such as strain OM5 T ), Escherichia coli, Alcaligenes eutrophus (Cupriavidus necator), Bacillus licheniformis, Paenibacillus macerans, Rhodococcus erythropolis, Pseudomonas putida, Lactobacillus plantarum, Enterococcus faecium, Enterococcus gallinarium, Enterococcus faecalis, Bacillus subtilis and Saccharomyces cerevisiae.
- Oligotropha carboxidovorans such as strain OM5 T
- Escherichia coli Alcaligenes eutrophus (Cupriavidus necator)
- Bacillus licheniformis such as strain OM5 T
- Paenibacillus macerans such as Bacillus licheniformis
- Rhodococcus erythropolis Bacill
- any of the known strains of these species may be utilized as a starting microorganism, as may any of the following species including respective strains thereof - Cupriavidus basilensis, Cupriavidus campinensis, Cupriavidus gilardi, Cupriavidus laharsis, Cupriavidus metallidurans, Cupriavidus oxalaticus, Cupriavidus pauculus, Cupriavidus pinatubonensis, Cupriavidus respiraculi, and Cupriavidus taiwanensis.
- the recombinant microorganism is a gram-negative bacterium. In some embodiments, the recombinant microorganism is selected from the genera Zymomonas, Escherichia, Pseudomonas, Alcaligenes, and Klebsiella. In some embodiments, the recombinant microorganism is selected from the species Escherichia co i, Cupriavidus necator, Oligotropha carboxidovorans, and Pseudomonas putida. In some embodiments, the recombinant microorganism is an E. coli strain.
- the recombinant microorganism is a gram-positive bacterium. In some embodiments, the recombinant microorganism is selected from the genera Clostridium, Salmonella, Rhodococcus, Bacillus, Lactobacillus, Enterococcus, Paenibacillus, Arthrobacter, Corynebacterium, and Brevibacterium.
- the recombinant microorganism is selected from the species Bacillus licheniformis, Paenibacillus macerans, Rhodococcus erythropolis, Lactobacillus plantarum, Enterococcus faecium, Enterococcus gallinarium, Enterococcus faecalis, and Bacillus subtilis.
- the recombinant microorganism is a B. subtilis strain.
- the recombinant microorganism is a yeast.
- the recombinant microorganism is selected from the genera Pichia, Candida, Hansenula and Saccharomyces.
- the recombinant microorganism is Saccharomyces cerevisiae.
- any of the above microorganisms may be used for production of chemical products other than 3 -HP.
- the ability to genetically modify the host is essential for the production of any recombinant microorganism.
- the mode of gene transfer technology may be by electroporation, conjugation, transduction or natural transformation.
- a broad range of host conjugative plasmids and drug resistance markers are available.
- the cloning vectors are tailored to the host organisms based on the nature of antibiotic resistance markers that can function in that host.
- bio-production media must contain suitable minerals, salts, cofactors, buffers and other components, known to those skilled in the art, suitable for the growth of the cultures and promotion of the enzymatic pathway necessary for 3 -HP production, or other products made under the present invention.
- Another aspect of the invention regards media and culture conditions that comprise genetically modified microorganisms of the invention and optionally supplements.
- Suitable growth media in the present invention are common commercially prepared media such as Luria Bertani (LB) broth, M9 minimal media, Sabouraud Dextrose (SD) broth, Yeast medium (YM) broth, (Ymin) yeast synthetic minimal media, and minimal media as described herein, such as M9 minimal media.
- LB Luria Bertani
- M9 minimal media M9 minimal media
- SD Sabouraud Dextrose
- YM Yeast medium
- yeast synthetic minimal media yeast synthetic minimal media
- minimal media as described herein, such as M9 minimal media such as M9 minimal media.
- Other defined or synthetic growth media may also be used, and the appropriate medium for growth of the particular microorganism will be known by one skilled in the art of microbiology or bio-production science.
- a minimal media may be developed and used that does not comprise, or that has a low level of addition of various components, for example less than 10, 5, 2 or 1 g/L of a complex nitrogen source including but not limited to yeast extract, peptone, tryptone, soy flour, corn steep liquor, or casein.
- a complex nitrogen source including but not limited to yeast extract, peptone, tryptone, soy flour, corn steep liquor, or casein.
- These minimal medias may also have limited supplementation of vitamin mixtures including biotin, vitamin B12 and derivatives of vitamin B12, thiamin, pantothenate and other vitamins.
- Minimal medias may also have limited simple inorganic nutrient sources containing less than 28, 17, or 2.5 mM phosphate, less than 25 or 4 mM sulfate, and less than 130 or 50mM total nitrogen.
- Bio-production media which is used in embodiments of the present invention with genetically modified microorganisms, must contain suitable carbon substrates for the intended metabolic pathways.
- suitable carbon substrates include carbon monoxide, carbon dioxide, and various monomeric and oligomeric sugars.
- Suitable pH ranges for the bio-production are between pH 3.0 to pH 10.0, where pH 6.0 to pH 8.0 is a typical pH range for the initial condition.
- pH 6.0 to pH 8.0 is a typical pH range for the initial condition.
- the actual culture conditions for a particular embodiment are not meant to be limited by these pH ranges.
- Bio-productions may be performed under aerobic, microaerobic, or anaerobic conditions, with or without agitation.
- the amount of 3-HP or other product(s) produced in a bio-production media generally can be determined using a number of methods known in the art, for example, high performance liquid chromatography (HPLC), gas chromatography (GC), or GC/Mass Spectroscopy (MS). Specific HPLC methods for the specific examples are provided herein.
- HPLC high performance liquid chromatography
- GC gas chromatography
- MS GC/Mass Spectroscopy
- any of the recombinant microorganisms as described and/or referred to herein may be introduced into an industrial bio-production system where the microorganisms convert a carbon source into 3-HP in a commercially viable operation.
- the bio-production system includes the introduction of such a recombinant microorganism into a bioreactor vessel, with a carbon source substrate and bio-production media suitable for growing the recombinant microorganism, and maintaining the bio-production system within a suitable temperature range (and dissolved oxygen concentration range if the reaction is aerobic or microaerobic) for a suitable time to obtain a desired conversion of a portion of the substrate molecules to 3-HP.
- Industrial bio- production systems and their operation are well-known to those skilled in the arts of chemical engineering and bioprocess engineering.
- Bio-productions may be performed under aerobic, microaerobic, or anaerobic conditions, with or without agitation.
- the operation of cultures and populations of microorganisms to achieve aerobic, microaerobic and anaerobic conditions are known in the art, and dissolved oxygen levels of a liquid culture comprising a nutrient media and such microorganism populations may be monitored to maintain or confirm a desired aerobic, microaerobic or anaerobic condition.
- syngas is used as a feedstock
- aerobic, microaerobic, or anaerobic conditions may be utilized.
- sugars are used, anaerobic, aerobic or microaerobic conditions can be implemented in various embodiments.
- any of the recombinant microorganisms as described and/or referred to herein may be introduced into an industrial bio-production system where the microorganisms convert a carbon source into 3-HP, and optionally in various embodiments also to one or more downstream compounds of 3-HP in a commercially viable operation.
- the bio-production system includes the introduction of such a recombinant microorganism into a bioreactor vessel, with a carbon source substrate and bio-production media suitable for growing the recombinant microorganism, and maintaining the bio-production system within a suitable temperature range (and dissolved oxygen concentration range if the reaction is aerobic or microaerobic) for a suitable time to obtain a desired conversion of a portion of the substrate molecules to 3-HP.
- syngas components or sugars are provided to a microorganism, such as in an industrial system comprising a reactor vessel in which a defined media (such as a minimal salts media including but not limited to M9 minimal media, potassium sulfate minimal media, yeast synthetic minimal media and many others or variations of these), an inoculum of a microorganism providing an embodiment of the biosynthetic pathway(s) taught herein, and the carbon source may be combined.
- the carbon source enters the cell and is catabolized by well-known and common metabolic pathways to yield common metabolic intermediates, including phosphoenolpyruvate (PEP).
- PEP phosphoenolpyruvate
- various embodiments of the present invention may employ a batch type of industrial bioreactor.
- a classical batch bioreactor system is considered “closed” meaning that the composition of the medium is established at the beginning of a respective bio-production event and not subject to artificial alterations and additions during the time period ending substantially with the end of the bio-production event.
- the medium is inoculated with the desired organism or organisms, and bio-production is permitted to occur without adding anything to the system.
- a "batch" type of bio-production event is batch with respect to the addition of carbon source and attempts are often made at controlling factors such as pH and oxygen concentration.
- a variation on the standard batch system is the fed-batch system.
- Fed-batch bio-production processes are also suitable in the present invention and comprise a typical batch system with the exception that the nutrients, including the substrate, are added in increments as the bio-production progresses.
- Fed-Batch systems are useful when catabolite repression is apt to inhibit the metabolism of the cells and where it is desirable to have limited amounts of substrate in the media.
- Measurement of the actual nutrient concentration in Fed-Batch systems may be measured directly, such as by sample analysis at different times, or estimated on the basis of the changes of measurable factors such as pH, dissolved oxygen and the partial pressure of waste gases such as CO 2 .
- Batch and fed-batch approaches are common and well known in the art and examples may be found in Thomas D.
- Continuous bio-production is considered an "open" system where a defined bio-production medium is added continuously to a bioreactor and an equal amount of conditioned media is removed simultaneously for processing.
- Continuous bio-production generally maintains the cultures within a controlled density range where cells are primarily in log phase growth.
- Two types of continuous bioreactor operation include a chemostat, wherein fresh media is fed to the vessel while simultaneously removing an equal rate of the vessel contents. The limitation of this approach is that cells are lost and high cell density generally is not achievable. In fact, typically one can obtain much higher cell density with a fed-batch process.
- Another continuous bioreactor utilizes perfusion culture, which is similar to the chemostat approach except that the stream that is removed from the vessel is subjected to a separation technique which recycles viable cells back to the vessel.
- This type of continuous bioreactor operation has been shown to yield significantly higher cell densities than fed-batch and can be operated continuously.
- Continuous bio-production is particularly advantageous for industrial operations because it has less down time associated with draining, cleaning and preparing the equipment for the next bio- production event. Furthermore, it is typically more economical to continuously operate downstream unit operations, such as distillation, than to run them in batch mode.
- Continuous bio-production allows for the modulation of one factor or any number of factors that affect cell growth or end product concentration.
- one method will maintain a limiting nutrient such as the carbon source or nitrogen level at a fixed rate and allow all other parameters to moderate.
- a number of factors affecting growth can be altered continuously while the cell concentration, measured by media turbidity, is kept constant.
- Methods of modulating nutrients and growth factors for continuous bio-production processes as well as techniques for maximizing the rate of product formation are well known in the art of industrial microbiology and a variety of methods are detailed by Brock, supra.
- embodiments of the present invention may be practiced using either batch, fed- batch or continuous processes and that any known mode of bio-production would be suitable. It is contemplated that cells may be immobilized on an inert scaffold as whole cell catalysts and subjected to suitable bio- production conditions for 3-HP production, or be cultured in liquid media in a vessel, such as a culture vessel. Thus, embodiments used in such processes, and in bio-production systems using these processes, include a population of genetically modified microorganisms of the present invention, a culture system comprising such population in a media comprising nutrients for the population, and methods of making 3-HP and thereafter, a downstream product of 3-HP.
- Embodiments of the invention include methods of making 3-HP in a bio-production system, some of which methods may include obtaining 3-HP after such bio-production event.
- a method of making 3-HP may comprise: providing to a culture vessel a media comprising suitable nutrients; providing to the culture vessel an inoculum of a genetically modified microorganism comprising genetic modifications described herein such that the microorganism produces 3-HP from syngas and/or a sugar molecule; and maintaining the culture vessel under suitable conditions for the genetically modified microorganism to produce 3-HP.
- the invention is directed to a system for bioproduction of acrylic acid as described herein, said system comprising: a tank for saccharification of biomass; a line for passing the product of saccharification to a fermentation tank optionally via a pre-fermentation tank; a fermentation tank suitable for microorganism cell culture; a line for discharging contents from the fermentation tank to an extraction and/or separation vessel; an extraction and/or separation vessel suitable for removal of 3-hydroxypropionic acid from cell culture waste; a line for transferring 3-hydroxypropionic acid to a dehydration vessel; and a dehydration vessel suitable for conversion of 3-hydroxypropionic acid to acrylic acid.
- the system includes one or more pre-fermentation tanks, distillation columns, centrifuge vessels, back extraction columns, mixing vessels, or combinations thereof.
- Embodiments of the present invention may result from introduction of an expression vector into a host microorganism, wherein the expression vector contains a nucleic acid sequence coding for an enzyme that is, or is not, normally found in a host microorganism.
- the ability to genetically modify a host cell is essential for the production of any genetically modified (recombinant) microorganism.
- the mode of gene transfer technology may be by electroporation, conjugation, transduction, or natural transformation.
- a broad range of host conjugative plasmids and drug resistance markers are available.
- the cloning vectors are tailored to the host organisms based on the nature of antibiotic resistance markers that can function in that host. Also, as disclosed herein, a genetically modified
- (recombinant) microorganism may comprise modifications other than via plasmid introduction, including modifications to its genomic DNA.
- polypeptides obtained by the expression of the polynucleotide molecules of the present invention may have at least approximately 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100%o identity to one or more amino acid sequences encoded by the genes and/or nucleic acid sequences described herein for the 3 -HP tolerance-related and biosynthesis pathways.
- any particular polypeptide is at least 50%, 60%, 70%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to any reference amino acid sequence of any polypeptide described herein (which may correspond with a particular nucleic acid sequence described herein), such particular polypeptide sequence can be determined conventionally using known computer programs such the Bestlit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wis. 53711).
- the parameters are set such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acid residues in the reference sequence are allowed.
- the identity between a reference sequence (query sequence, i.e., a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment may be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245 (1990)).
- the percent identity is corrected by calculating the number of residues of the query sequence that are lateral to the N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence.
- a determination of whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of this embodiment. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence are considered for this manual correction. For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity.
- the deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus.
- the 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%.
- a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query.
- nucleic acid constructs can be prepared comprising an isolated polynucleotide encoding a polypeptide having enzyme activity operably linked to one or more (several) control sequences that direct the expression of the coding sequence in a microorganism, such as E. coli, under conditions compatible with the control sequences.
- the isolated polynucleotide may be manipulated to provide for expression of the polypeptide. Manipulation of the polynucleotide's sequence prior to its insertion into a vector may be desirable or necessary depending on the expression vector.
- the techniques for modifying polynucleotide sequences utilizing recombinant DNA methods are well established in the art.
- the control sequence may be an appropriate promoter sequence, a nucleotide sequence that is recognized by a host cell for expression of a polynucleotide encoding a polypeptide of the present invention.
- the promoter sequence contains transcriptional control sequences that mediate the expression of the polypeptide.
- the promoter may be any nucleotide sequence that shows transcriptional activity in the host cell of choice including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.
- suitable promoters for directing transcription of the nucleic acid constructs, especially in an E. coli host cell are the lac promoter (Gronenborn, 1976, Mol.
- the control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription.
- the terminator sequence is operably linked to the 3' terminus of the nucleotide sequence encoding the polypeptide. Any terminator that is functional in an i. coli cell may be used in the present invention. It may also be desirable to add regulatory sequences that allow regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those that cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems include the lac, tac, and trp operator systems.
- the genetic manipulations may be described to include various genetic manipulations, including those directed to change regulation of, and therefore ultimate activity of, an enzyme or enzymatic activity of an enzyme identified in any of the respective pathways.
- Such genetic modifications may be directed to transcriptional, translational, and post-translational modifications that result in a change of enzyme activity and/or selectivity under selected and/or identified culture conditions and/or to provision of additional nucleic acid sequences such as to increase copy number and/or mutants of an enzyme related to 3-HP production.
- Random mutagenesis may be practiced to provide genetic modifications that may fall into any of these or other stated approaches.
- the genetic modifications further broadly fall into additions (including insertions), deletions (such as by a mutation) and substitutions of one or more nucleic acids in a nucleic acid of interest.
- a genetic modification results in improved enzymatic specific activity and/or turnover number of an enzyme. Without being limited, changes may be measured by one or more of the following: K M ; K cat ; and K avidity .
- a microorganism may comprise one or more gene deletions.
- the genes encoding the lactate dehydrogenase (ldhA), phosphate acetyltransferase (pta), pyruvate oxidase (poxB), and pyruvate-formate lyase (pflB) may be disrupted, including deleted.
- lactate dehydrogenase phosphate acetyltransferase
- poxB pyruvate oxidase
- pflB pyruvate-formate lyase
- Gene deletions may be accomplished by mutational gene deletion approaches, and/or starting with a mutant strain having reduced or no expression of one or more of these enzymes, and/or other methods known to those skilled in the art. Gene deletions may be effectuated by any of a number of known specific methodologies, including but not limited to the RED/ET methods using kits and other reagents sold by Gene Bridges (Gene Bridges GmbH, Dresden, Germany,
- the host organism expressing ⁇ -red recombinase is transformed with a linear DNA product coding for a selectable marker flanked by the terminal regions (generally ⁇ 50 bp, and alternatively up to about -300 bp) homologous with the target gene.
- the marker could then be removed by another recombination step performed by a plasmid vector carrying the FLP -recombinase, or another recombinase, such as Cre.
- Targeted deletion of parts of microbial chromosomal DNA or the addition of foreign genetic material to microbial chromomes may be practiced to alter a host cell's metabolism so as to reduce or eliminate production of undesired metabolic products. This may be used in combination with other genetic modifications such as described herein in this general example.
- such genetic modifications may be chosen and/or selected for to achieve a higher flux rate through certain enzymatic conversion steps within the respective 3-HP production pathway and so may affect general cellular metabolism in fundamental and/or major ways.
- amino acid "homology” includes conservative substitutions, i.e. those that substitute a given amino acid in a polypeptide by another amino acid of similar characteristics. Typically seen as conservative substitutions are the following replacements: replacements of an aliphatic amino acid such as Ala, Val, Leu and He with another aliphatic amino acid; replacement of a Ser with a Thr or vice versa;
- nucleic acid and amino acid sequences provided herein, it is appreciated that conservatively modified variants of these sequences are included, and are within the scope of the invention in its various embodiments.
- Functionally equivalent nucleic acid and amino acid sequences which may include conservatively modified variants as well as more extensively varied sequences, which are well within the skill of the person of ordinary skill in the art, and microorganisms comprising these, also are within the scope of various embodiments of the invention, as are methods and systems comprising such sequences and/or microorganisms.
- nucleic acid sequences encoding sufficiently homologous proteins or portions thereof are within the scope of the invention.
- nucleic acids sequences that encode a particular amino acid sequence employed in the invention may vary due to the degeneracy of the genetic code, and nonetheless fall within the scope of the invention.
- the following table provides a summary of similarities among amino acids, upon which conservative and less conservative substitutions may be based, and also various codon redundancies that reflect this degeneracy.
- Valine N Ali GTT, GTC, GTA, GTG
- Lysine POS B AAA, AAG
- variants and portions of particular nucleic acid sequences, and respective encoded amino acid sequences recited herein may be exhibit a desired functionality, e.g., enzymatic activity at a selected level, when such nucleic acid sequence variant and/or portion contains a 15 nucleotide sequence identical to any 15 nucleotide sequence set forth in the nucleic acid sequences recited herein including, without limitation, the sequence starting at nucleotide number 1 and ending at nucleotide number 15, the sequence starting at nucleotide number 2 and ending at nucleotide number 16, the sequence starting at nucleotide number 3 and ending at nucleotide number 17, and so forth.
- nucleic acid that contains a nucleotide sequence that is greater than 15 nucleotides (e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more nucleotides) in length and identical to any portion of the sequence set forth in nucleic acid sequences recited herein.
- the invention provides isolated nucleic acid that contains a 25 nucleotide sequence identical to any 25 nucleotide sequence set forth in any one or more (including any grouping of) nucleic acid sequences recited herein including, without limitation, the sequence starting at nucleotide number 1 and ending at nucleotide number 25, the sequence starting at nucleotide number 2 and ending at nucleotide number 26, the sequence starting at nucleotide number 3 and ending at nucleotide number 27, and so forth.
- Additional examples include, without limitation, isolated nucleic acids that contain a nucleotide sequence that is 50 or more nucleotides (e.g., 100, 150, 200, 250, 300, or more nucleotides) in length and identical to any portion of any of the sequences disclosed herein.
- isolated nucleic acids can include, without limitation, those isolated nucleic acids containing a nucleic acid sequence represented in any one section of discussion and/or examples, such as regarding 3 -HP production pathways, nucleic acid sequences encoding enzymes of the fatty acid synthase system, or 3-HP tolerance.
- the invention provides an isolated nucleic acid containing a nucleic acid sequence listed herein that contains a single insertion, a single deletion, a single substitution, multiple insertions, multiple deletions, multiple substitutions, or any combination thereof (e. g., single deletion together with multiple insertions).
- Such isolated nucleic acid molecules can share at least 60, 65, 70, 75, 80, 85, 90, 95, 97, 98, or 99 percent sequence identity with a nucleic acid sequence listed herein (i.e., in the sequence listing).
- Additional examples include, without limitation, isolated nucleic acids that contain a nucleic acid sequence that encodes an amino acid sequence that is 50 or more amino acid residues (e.g., 100, 150, 200, 250, 300, or more amino acid residues) in length and identical to any portion of an amino acid sequence listed or otherwise disclosed herein.
- isolated nucleic acids that contain a nucleic acid sequence that encodes an amino acid sequence that is 50 or more amino acid residues (e.g., 100, 150, 200, 250, 300, or more amino acid residues) in length and identical to any portion of an amino acid sequence listed or otherwise disclosed herein.
- the invention provides isolated nucleic acid that contains a nucleic acid sequence that encodes an amino acid sequence having a variation of an amino acid sequence listed or otherwise disclosed herein.
- the invention provides isolated nucleic acid containing a nucleic acid sequence encoding an amino acid sequence listed or otherwise disclosed herein that contains a single insertion, a single deletion, a single substitution, multiple insertions, multiple deletions, multiple substitutions, or any combination thereof (e.g., single deletion together with multiple insertions).
- Such isolated nucleic acid molecules can contain a nucleic acid sequence encoding an amino acid sequence that shares at least 60, 65, 70, 75, 80, 85, 90, 95, 97, 98, or 99 percent sequence identity with an amino acid sequence listed or otherwise disclosed herein.
- substitutions may be made of one polar uncharged (PU) amino acid for a polar uncharged amino acid of a listed sequence, optionally considering size/molecular weight (i.e., substituting a serine for a threonine).
- Guidance concerning which amino acid changes are likely to be phenotypically silent can be found, inter alia, in Bowie, J. U., et Al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," Science 247: 1306-1310 (1990). This reference is incorporated by reference for such teachings, which are, however, also generally known to those skilled in the art.
- Recognized conservative amino acid substitutions comprise (substitutable amino acids following each colon of a set): ala:ser; arg:lys; asn:gln or his; asp:glu; cys:ser; gln:asn; glu:asp; gly:pro; his:asn or gin; ile:leu or val; leu:ile or val; lys: arg or gin or glu; metleu or ile; phe:met or leu or tyr; senthr; thnser; trp:tyr; tyntrp or phe; vahile or leu.
- codon preferences and codon usage tables for a particular species can be used to engineer isolated nucleic acid molecules that take advantage of the codon usage preferences of that particular species.
- the isolated nucleic acid provided herein can be designed to have codons that are preferentially used by a particular organism of interest. Numerous software and sequencing services are available for such codon-optimizing of sequences.
- the invention provides polypeptides that contain the entire amino acid sequence of an amino acid sequence listed or otherwise disclosed herein.
- the invention provides polypeptides that contain a portion of an amino acid sequence listed or otherwise disclosed herein.
- the invention provides polypeptides that contain a 15 amino acid sequence identical to any 15 amino acid sequence of an amino acid sequence listed or otherwise disclosed herein including, without limitation, the sequence starting at amino acid residue number 1 and ending at amino acid residue number 15, the sequence starting at amino acid residue number 2 and ending at amino acid residue number 16, the sequence starting at amino acid residue number 3 and ending at amino acid residue number 17, and so forth. It will be appreciated that the invention also provides polypeptides that contain an amino acid sequence that is greater than 15 amino acid residues (e.
- the invention provides polypeptides that contain a 25 amino acid sequence identical to any 25 amino acid sequence of an amino acid sequence listed or otherwise disclosed herein including, without limitation, the sequence starting at amino acid residue number 1 and ending at amino acid residue number 25, the sequence starting at amino acid residue number 2 and ending at amino acid residue number 26, the sequence starting at amino acid residue number 3 and ending at amino acid residue number 27, and so forth.
- Additional examples include, without limitation, polypeptides that contain an amino acid sequence that is 50 or more amino acid residues (e.g., 100, 150, 200, 250, 300 or more amino acid residues) in length and identical to any portion of an amino acid sequence listed or otherwise disclosed herein. Further, it is appreciated that, per above, a 15 nucleotide sequence will provide a 5 amino acid sequence, so that the latter, and higher-length amino acid sequences, may be defined by the above- described nucleotide sequence lengths having identity with a sequence provided herein.
- the invention provides polypeptides that an amino acid sequence having a variation of the amino acid sequence set forth in an amino acid sequence listed or otherwise disclosed herein.
- the invention provides polypeptides containing an amino acid sequence listed or otherwise disclosed herein that contains a single insertion, a single deletion, a single substitution, multiple insertions, multiple deletions, multiple substitutions, or any combination thereof (e.g., single deletion together with multiple insertions).
- Such polypeptides can contain an amino acid sequence that shares at least 60, 65, 70, 75, 80, 85, 90, 95, 97, 98 or 99 percent sequence identity with an amino acid sequence listed or otherwise disclosed herein.
- a particular variant amino acid sequence may comprise any number of variations as well as any combination of types of variations.
- the invention includes, in various embodiments, an amino acid sequence having a variation of any of the polynucleotide and polypeptide sequences disclosed herein.
- variations are exemplified for the carbonic anhydrase (E. coli cynT) amino acid sequence set forth in SEQ ID NO:544.
- FIG. 3 provides a CLUSTAL multiple sequence alignment of the E. coli carbonic anhydrase aligned with carbonic anhydrases of eleven other species that had relatively high homology, based on low E values, in a BLASTP comparison.
- SEQ ID NO: 544 is the fifth sequence shown.
- examples of variations of the sequence set forth in SEQ ID NO:544 include, without limitation, any variation of the sequences as set forth in FIG. 3. Such variations are provided in FIG. 3 in that a comparison of the amino acid residue (or lack thereof) at a particular position of the sequence set forth in SEQ ID NO: 544 with the amino acid residue (or lack thereof) at the same aligned position of any of the other eleven amino acid sequences of FIG. 3 provides a list of specific changes for the sequence set forth in SEQ ID NO:544.
- the "E" glutamic acid at position 14 of SEQ ID NO: 544 can be substituted with a "D" aspartic acid or "N" asparagine as indicated in FIG. 3.
- the sequence set forth in SEQ ID NO:544 can contain any number of variations as well as any combination of types of variations.
- the amino acid sequences provided in FIG. 3 can be polypeptides having carbonic anhydrase activity.
- polypeptides having a variant amino acid sequence can retain enzymatic activity.
- Such polypeptides can be produced by manipulating the nucleotide sequence encoding a polypeptide using standard procedures such as site-directed mutagenesis or various PCR techniques.
- one type of modification includes the substitution of one or more amino acid residues for amino acid residues having a similar chemical and/or biochemical property.
- a polypeptide can have an amino acid sequence set forth in an amino acid sequence listed or otherwise disclosed herein comprising one or more conservative substitutions.
- substitutions that are less conservative, and/or in areas of the sequence that may be more critical, for example selecting residues that differ more significantly in their effect on maintaining: (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation; (b) the charge or hydrophobicity of the polypeptide at the target site; or (c) the bulk of the side chain.
- substitutions that in general are expected to produce the greatest changes in polypeptide function are those in which: (a) a hydrophilic residue, e.g., serine or threonine, is substituted for (or by) a hydrophobic residue, e.g., leucine, isoleucine, phenylalanine, valine or alanine; (b) a cysteine or proline is substituted for (or by) any other residue ; (c) a residue having an electropositive side chain, e.g., lysine, arginine, or histidine, is substituted for (or by) an electronegative residue, e.g., glutamic acid or aspartic acid; or (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine.
- a hydrophilic residue e.g., serine or th
- polypeptides having enzymatic activity can be assessed for polypeptides having enzymatic activity by analyzing the ability of the polypeptide to catalyze the conversion of the same substrate as the related native polypeptide to the same product as the related native polypeptide. Accordingly, polypeptides having 5, 10, 20, 30, 40, 50 or less conservative substitutions are provided by the invention.
- Polypeptides and nucleic acids encoding polypeptides can be produced by standard DNA mutagenesis techniques, for example, Ml 3 primer mutagenesis. Details of these techniques are provided in Sambrook and Russell, 2001. Nucleic acid molecules can contain changes of a coding region to fit the codon usage bias of the particular organism into which the molecule is to be introduced.
- the coding region can be altered by taking advantage of the degeneracy of the genetic code to alter the coding sequence in such a way that, while the nucleic acid sequence is substantially altered, it nevertheless encodes a polypeptide having an amino acid sequence identical or substantially similar to the native amino acid sequence.
- alanine is encoded in the open reading frame by the nucleotide codon triplet GCT. Because of the degeneracy of the genetic code, three other nucleotide codon triplets— GCA, GCC, and GCG— also code for alanine.
- nucleic acid sequence of the open reading frame can be changed at this position to any of these three codons without affecting the amino acid sequence of the encoded polypeptide or the characteristics of the polypeptide.
- nucleic acid variants can be derived from a nucleic acid sequence disclosed herein using standard DNA mutagenesis techniques as described herein, or by synthesis of nucleic acid sequences.
- the invention encompasses nucleic acid molecules that encode the same polypeptide but vary in nucleic acid sequence by virtue of the degeneracy of the genetic code.
- the invention also provides an isolated nucleic acid that is at least about 12 bases in length (e.g., at least about 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, 60, 100, 250, 500, 750, 1000, 1500, 2000, 3000, 4000, or 5000 bases in length) and hybridizes, under hybridization conditions, to the sense or antisense strand of a nucleic acid having a sequence listed or otherwise disclosed herein.
- the hybridization conditions can be moderately or highly stringent hybridization conditions.
- the microorganism comprises an endogenous 3 -HP production pathway (which may, in some such embodiments, be enhanced), whereas in other embodiments the microorganism does not comprise a 3 -HP production pathway, but is provided with one or more nucleic acid sequences encoding polypeptides having enzymatic activity or activities to complete a pathway, described herein, resulting in production of 3-HP.
- the particular sequences disclosed herein, or conservatively modified variants thereof are provided to a selected microorganism, such as selected from one or more of the species and groups of species or other taxonomic groups listed herein.
- compositions of the present invention such as genetically modified microorganisms, comprise a production pathway for a chemical product in which malonyl-CoA is a substrate, and may also comprise one or more genetic modifications to reduce the activity of enzymes encoded by one or more of the fatty acid synthetase system genes.
- the compositions may be used in the methods and systems of the present invention.
- malonyl-CoA is a metabolic intermediate that, under normal growth conditions, is converted to fatty acids and derivatives thereof, such as phospholipids, that are then used in cell membranes and for other key cellular functions.
- fatty acids and derivatives thereof such as phospholipids
- the fatty acid synthase system is a type II or dissociated fatty acid synthase system.
- the enzymes of fatty acid production pathway are encoded by distinct genes, and, common for many critical metabolic pathways, is well-regulated, including by downstream products inhibiting upstream enzymes.
- the fatty acid synthase system comprises polypeptides that have the following enzymatic activities: malonyl-CoA-acyl carrier protein (ACP) transacylase; ⁇ -ketoacyl-ACP synthase; ⁇ -ketoacyl-ACP reductase; ⁇ -hydroxyacyl-ACP dehydratase; 3- hydroxyacyl-(acp) dehydratase; and enoyl-acyl carrier protein reductase (enoyl-ACP reductase).
- ACP malonyl-CoA-acyl carrier protein
- nucleic acid sequences that encode temperature-sensitive forms of these polypeptides may be introduced in place of the native enzymes, and when such genetically modified microorganisms are cultured at elevated temperatures (at which these thermolabile polypeptides become inactivated, partially or completely, due to alterations in protein structure or complete denaturation), there is observed an increase in a product such as 3-HP.
- other types of genetic modifications may be made to otherwise modulate, such as lower, enzymatic activities of one or more of these polypeptides.
- a result of such genetic modifications is to shift malonyl-CoA utilization so that there is a reduced conversion of malonyl-CoA to fatty acids, overall biomass, and proportionally greater conversion of carbon source to a chemical product such as 3-HP.
- the specific productivity for the microbially produced chemical product is unexpectedly high.
- additional genetic modifications, such as to increase malonyl-CoA production may be made for certain embodiments.
- enoyl(acyl carrier protein) reductase (EC No. 1.3.1.9, also referred to as enoyl-ACP reductase) is a key enzyme for fatty acid biosynthesis from malonyl-CoA.
- this enzyme, Fabl is encoded by the gene fabl (See “Enoyl-Acyl Carrier Protein (fabl) Plays a Determinant Role in Completing Cycles of Fatty Acid Elongation in Escherichia coli," Richard J. Heath and Charles O. Rock, J. Biol. Chem. 270:44, pp. 26538-26543 (1995), incorporated by reference for its discussion of fabl and the fatty acid synthase system).
- the present invention may utilize a microorganism that is provided with a nucleic acid sequence (polynucleotide) that encodes a polypeptide having enoyl-ACP reductase enzymatic activity that may be modulated during a fermentation event.
- a nucleic acid sequence encoding a temperature -sensitive enoyl-ACP reductase may be provided in place of the native enoyl-ACP reductase, so that an elevated culture temperature results in reduced enzymatic activity, which then results in a shifting utilization of malonyl-CoA to production of a desired chemical product. At such elevated temperature the enzyme is considered non- permissive, as is the temperature.
- One such sequence is a mutant temperature-sensitive fabl (fabI TS ) of E. coli, SEQ ID NO:769 for DNA, SEQ ID NO:770 for protein.
- nucleic acid and amino acid sequences for enoyl-ACP reductase in species other than E. coli are readily obtained by conducting homology searches in known genomics databases, such as BLASTN and BLASTP. Approaches to obtaining homologues in other species and functional equivalent sequences are described herein. Accordingly, it is appreciated that the present invention may be practiced by one skilled in the art for many microorganism species of commercial interest.
- enoyl-ACP reductase may be employed as known to those skilled in the art, such as, but not limited to, replacing a native enoyl-ACP or enoyl-coA reductase with a nucleic acid sequence that includes an inducible promoter for this enzyme, so that an initial induction may be followed by no induction, thereby decreasing enoyl-ACP or enoyl-coA reductase enzymatic activity after a selected cell density is attained.
- compositions, methods and systems of the present invention shift utilization of malonyl-CoA in a genetic modified microorganism, which comprises at least one enzyme of the fatty acid synthase system, such as enoyl-acyl carrier protein reductase (enoyl-ACP reductase) or enoyl-coenzyme A reductase (enoyl-coA reductase), ⁇ -ketoacyl-ACP synthase or ⁇ -ketoacyl-coA synthase malonyl-CoA-ACP, and may further comprise at least one genetic modification of nucleic acid sequence encoding carbonic anhydrase to increase bicarbonate levels in the microorganism cell and/or a supplementation of its culture medium with bicarbonate and/or carbonate, and may further comprise one or more genetic modifications to increase enzymatic activity of one or more of acetyl-CoA carboxylase and NADPH-dependent
- transhydrogenase More generally, addition of carbonate and/or bicarbonate may be used to increase bicarbonate levels in a fermentation broth.
- the present invention comprises a genetically modified microorganism that comprises at least one genetic modification that provides, completes, or enhances a 3 -HP production pathway effective to convert malonyl-CoA to 3 -HP, and further comprises a genetic modification of carbonic anhydrase to increase bicarbonate levels in the microorganism cell and/or a supplementation of its culture medium with bicarbonate and/or carbonate, and may further comprise one or more genetic modifications to increase enzymatic activity of one or more of acetyl-CoA carboxylase and NADPH-dependent transhydrogenase.
- Related methods and systems utilize such genetically modified microorganism.
- the present invention comprises a genetically modified microorganism that comprises at least one genetic modification that provides, completes, or enhances a 3 -HP production pathway effective to convert malonyl-CoA to 3 -HP, and further comprises a genetic modification of at least one enzyme of the fatty acid synthase system, such as enoyl-acyl carrier protein reductase (enoyl-ACP reductase) or enoyl-coenzyme A reductase (enoyl-coA reductase), ⁇ -ketoacyl-ACP synthase or ⁇ -ketoacyl-coA synthase , malonyl-CoA-ACP, and may further comprise a genetic modification of carbonic anhydrase to increase bicarbonate levels in the microorganism cell and/or a supplementation of its culture medium with bicarbonate and/or carbonate, and may further comprise one or more genetic modifications to increase enzymatic activity of
- the present invention is directed to a method of making a chemical product comprising: providing a selected cell density of a genetically modified microorganism population in a vessel, wherein the genetically modified microorganism comprises a production pathway for production of a chemical product from malonyl-CoA; and reducing enzymatic activity of at least one enzyme of the genetically modified microorganism's fatty acid synthase pathway.
- microorganism host cell results in production of 3 -HP at elevated specific and volumetric productivity.
- reducing the enzymatic activity of an enoyl-CoA reductase in a microorganism host cell results in production of 3 -HP at elevated specific and volumetric productivity.
- Another approach to genetic modification to reduce enzymatic activity of these enzymes is to provide an inducible promoter that promotes one such enzyme, such as the enoyl-ACP reductase gene (e.g., fabl in E. coli).
- this promoter may be induced (such as with isopropyl ⁇ -D-thiogalactopyranoiside (IPTG)) during a first phase of a method herein, and after the IPTG is exhausted, removed or diluted out the second step, of reducing enoyl-ACP reductase enzymatic activity, may begin.
- IPTG isopropyl ⁇ -D-thiogalactopyranoiside
- Other approaches may be applied to control enzyme expression and activity such as are described herein and/or known to those skilled in the art.
- enoyl-CoA reductase is considered an important enzyme of the fatty acid synthase system
- genetic modifications may be made to any combination of the polynucleotides (nucleic acid sequences) encoding the polypeptides exhibiting the enzymatic activities of this system, such as are listed herein.
- FabB ⁇ -ketoacyl-acyl carrier protein synthase I
- E. coli E. coli
- FabB Inactivation of FabB results in the inhibition of fatty acid elongation and diminished cell growth as well as eliminating a futile cycle that recycles the malonate moiety of malonyl-ACP back to acetyl-CoA.
- FabF ⁇ -ketoacyl-acyl carrier protein synthase II, is required for the synthesis of saturated fatty acids and the control membrane fluidity in cells. Both enzymes are inhibited by cerulenin.
- Inhibitors such as cerulenin, thiolactomycin, and triclosan (this list not limiting) or genetic modifications directed to reduce activity of enzymes encoded by one or more of the fatty acid synthetase system genes may be employed, singly or in combination.
- compositions, methods and systems of the present invention the reduction of enzymatic activity of enoyl-ACP reductase (or, more generally, of the fatty acid synthase system) is made to occur after a sufficient cell density of a genetically modified microorganism is attained.
- This bi-phasic culture approach balances a desired quantity of catalyst, in the cell biomass which supports a particular production rate, with yield, which may be partly attributed to having less carbon be directed to cell mass after the enoyl-ACP reductase activity (and/or activity of other enzymes of the fatty acid synthase system) is/are reduced. This results in a shifting net utilization of malonyl-CoA, thus providing for greater carbon flux to a desired chemical product.
- the specific productivity is elevated and this results in overall rapid and efficient microbial fermentation methods and systems.
- the volumetric productivity also is substantially elevated.
- a genetically modified microorganism comprises a metabolic pathway that includes conversion of malonyl-CoA to a desired chemical product, 3-hydroxypropionic acid (3-HP). This is viewed as quite advantageous for commercial 3-HP production economics and is viewed as an advance having clear economic benefit. Other chemical products also are disclosed herein.
- fatty acid synthase system enzymes such as recited herein
- the polypeptide so encoded has (such as by mutation and/or promoter substitution, etc., to lower enzymatic activity), or may be modulated to have (such as by temperature sensitivity, inducible promoter, etc.) a reduced enzymatic activity
- a means for modulating involves a conversion, during a fermentation event, from a higher to a lower activity of the fatty acid synthetase system, such as by increasing temperature of a culture vessel comprising a population of genetically modified microorganism comprising a temperature -sensitive fatty acid synthetase system polypeptide (e.g., enoyl-ACP reductase), or by adding an inhibitor
- a temperature -sensitive fatty acid synthetase system polypeptide e.g., enoyl-ACP reductase
- a shift to greater utilization of malonyl-CoA to a selected chemical product may proceed.
- each respective enzymatic activity so modulated may be reduced by at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, or at least 90 percent compared with the activity of the native, non-modulated enzymatic activity (such as in a cell or isolated).
- the conversion of malonyl-CoA to fatty acyl-ACP or fatty acyl-coA molecules may be reduced by at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, or at least 90 percent compared with such conversion in a non-modulated cell or other system.
- the conversion of malonyl-CoA to fatty acid molecules may be reduced by at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, or at least 90 percent compared with such conversion in a non-modulated cell or other system.
- compositions, methods and systems of the present invention involve inclusion of a metabolic production pathway that converts malonyl-CoA to a chemical product of interest.
- 3-HP is selected as the chemical product of interest.
- Mcr has very few sequence homologs in the NCBI data base. Blast searches finds 8 different sequences when searching over the entire protein. Hence development of a pile -up sequences comparison is expected to yield limited information.
- embodiments of the present invention nonetheless may comprise any of these eight sequences, shown herein and identified as SEQ ID NOs:784 to 791, which are expected to be but are not yet confirmed to be bi-functional as to this enzymatic activity.
- Other embodiments may comprise mutated and other variant forms of any of SEQ ID NOs:784 to 791 , as well as polynucleotides (including variant forms with conservative and other substitutions), such as those introduced into a selected microorganism to provide or increase 3-HP production therein.
- Malonyl-CoA may be converted to 3-HP in a microorganism that comprises one or more of the following:
- a bi-functional malonyl-CoA reductase such as may be obtained from Chloroflexus aurantiacus and other microorganism species.
- bi-functional in this regard is meant that the malonyl-CoA reductase catalyzes both the conversion of malonyl-CoA to malonate semialdehyde, and of malonate semialdehyde to 3-HP.
- a mono-functional malonyl-CoA reductase in combination with a 3-HP dehydrogenase By mono- functional is meant that the malonyl-CoA reductase catalyzes the conversion of malonyl-CoA to malonate semialdehyde.
- Any of the above polypeptides may be NADH- or NADPH-dependent, and methods known in the art may be used to convert a particular enzyme to be either form. More particularly, as noted in WO 2002/042418,
- any method can be used to convert a polypeptide that uses NADPH as a cofactor into a polypeptide that uses NADPH as a cofactor into a polypeptide that uses NADPH as a cofactor.
- NADH as a cofactor such as those described by others (Eppink et al., J Mol. Biol., 292 (1) : 87-96 (1999), Hall and Tomsett, Microbiology, 146 (Pt 6): 1399-406 (2000), and Dohr et al., Proc. Natl. Acad. Sci., 98 (1) : 81-86
- a bi-functional malonyl-CoA reductase may be selected from the malonyl-CoA reductase of Chloroflexus aurantiacus (such as from ATCC 29365) and other sequences.
- a mono-functional malonyl-CoA reductase may be selected from the malonyl-CoA reductase of Sulfolobus tokodaii (SEQ ID NO: 826).
- SEQ ID NO: 826 Sulfolobus tokodaii
- 3 -HP dehydrogenase enzymatic activity also may be provided to convert malonate semialdehyde to 3-HP.
- a mono-functional malonyl-CoA reductase may be obtained by truncation of a bi-functional mono-functional malonyl-CoA, and combined in a strain with an enzyme that converts malonate semialdehyde to 3-HP.
- Msed_709 Metallosphaera sedula
- malonyl-CoA reductase/succinyl-CoA reductase is known in Metallosphaera sedula (Msed_709, identified as malonyl-CoA reductase/succinyl-CoA reductase).
- a genetically modified microorganism may comprise an effective 3-HP pathway to convert malonyl-CoA to 3-HP in accordance with the embodiments of the present invention.
- 3-HP pathways such as those comprising an aminotransferase (see, e.g., WO 2010/011874, published January 28, 2010), may also be provided in embodiments of a genetically modified microorganism of the present invention.
- the present invention provides for elevated specific and volumetric productivity metrics as to production of a selected chemical product, such as 3-hydroxypropionic acid (3-HP).
- a selected chemical product such as 3-hydroxypropionic acid (3-HP)
- production of a chemical product, such as 3-HP is not linked to growth.
- production of 3-HP may reach at least 1, at least 2, at least 5, at least 10, at least 20, at least 30, at least 40, and at least 50 g/liter titer, such as by using one of the methods disclosed herein.
- embodiments of the present invention may be combined with other genetic modifications and/or method or system modulations so as to obtain a microorganism (and corresponding method) effective to produce at least 10, at least 20, at least 30, at least 40, at least 45, at least 50, at least 80, at least 100, or at least 120 grams of a chemical product, such as 3-HP, per liter of final (e.g., spent) fermentation broth while achieving this with specific and/or volumetric productivity rates as disclosed herein.
- a microorganism and corresponding method effective to produce at least 10, at least 20, at least 30, at least 40, at least 45, at least 50, at least 80, at least 100, or at least 120 grams of a chemical product, such as 3-HP, per liter of final (e.g., spent) fermentation broth while achieving this with specific and/or volumetric productivity rates as disclosed herein.
- a microbial chemical production event i.e., a fermentation event using a cultured population of a microorganism
- a genetically modified microorganism as described herein, wherein the specific productivity is between 0.01 and 0.60 grams of 3-HP produced per gram of microorganism cell on a dry weight basis per hour (g 3-HP/g DCW-hr).
- the specific productivity is greater than 0.01, greater than 0.05, greater than 0.10, greater than 0.15, greater than 0.20, greater than 0.25, greater than 0.30, greater than 0.35, greater than 0.40, greater than 0.45, or greater than 0.50 g
- 3-HP/g DCW-hr Specific productivity may be assessed over a 2, 4, 6, 8, 12 or 24 hour period in a particular microbial chemical production event. More particularly, the specific productivity for 3-HP or other chemical product is between 0.05 and 0.10, 0.10 and 0.15, 0.15 and 0.20, 0.20 and 0.25, 0.25 and 0.30, 0.30 and 0.35, 0.35 and 0.40, 0.40 and 0.45, or 0.45 and 0.50 g 3-HP/g DCW-hr., 0.50 and 0.55, or 0.55 and 0.60 g 3-HP/g DCW-hr.
- Various embodiments comprise culture systems demonstrating such productivity.
- the volumetric productivity achieved may be 0.25 g 3-HP (or other chemical product) per liter per hour (g (chemical product)/L-hr), may be greater than 0.25 g 3-HP (or other chemical product)/L-hr, may be greater than 0.50 g 3-HP (or other chemical product)/L-hr, may be greater than 1.0 g 3-HP (or other chemical product)/L-hr, may be greater than 1.50 g 3-HP (or other chemical product)/L-hr, may be greater than 2.0 g 3-HP (or other chemical product)/L-hr, may be greater than 2.50 g 3-HP (or other chemical product)/L-hr, may be greater than 3.0 g 3-HP (or other chemical product)/L-hr, may be greater than 3.50 g 3-HP (or other chemical product)/L-hr, may be greater than 4.0 g 3-HP (or other chemical product)/L-hr, may be greater than 4.50 g
- specific productivity as measured over a 24-hour fermentation (culture) period may be greater than 0.01, 0.05, 0.10, 0.20, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0 or 12.0 grams of chemical product per gram DCW of microorganisms (based on the final DCW at the end of the 24-hour period).
- the specific productivity exceeds (is at least) 0.01 g chemical product/g DCW-hr, exceeds (is at least) 0.05 g chemical product/g DCW-hr, exceeds (is at least) 0.10 g chemical product/g DCW-hr, exceeds (is at least) 0.15 g chemical product/g DCW-hr, exceeds (is at least) 0.20 g chemical product/g DCW-hr, exceeds (is at least) 0.25 g chemical product/g DCW-hr, exceeds (is at least) 0.30 g chemical product/g DCW-hr, exceeds (is at least) 0.35 g chemical product/g DCW-hr, exceeds (is at least) 0.40 g chemical product/g DCW-hr, exceeds (is at least) 0.45 g chemical product/g DCW-hr, exceeds (is at least) 0.50 g chemical product/g DCW-hr, exceeds (is at least)
- specific productivity values for 3-HP, and for other chemical products described herein may exceed 0.01 g chemical product/g DCW-hr, may exceed 0.05 g chemical product/g DCW-hr, may exceed 0.10 g chemical product/g DCW-hr, may exceed 0.15 g chemical product/g DCW-hr, may exceed 0.20 g chemical product/g DCW-hr, may exceed 0.25 g chemical product/g DCW-hr, may exceed 0.30 g chemical product/g DCW-hr, may exceed 0.35 g chemical product/g DCW-hr, may exceed 0.40 g chemical product/g DCW-hr, may exceed 0.45 g chemical product/g DCW-hr, and may exceed 0.50 g or 0.60 chemical product/g DCW-hr.
- Such specific productivity may be assessed over a 2, 4, 6, 8, 12 or 24 hour period in a particular microbial chemical production event
- the improvements achieved by embodiments of the present invention may be determined by percentage increase in specific productivity, or by percentage increase in volumetric productivity, compared with an appropriate control microorganism lacking the particular genetic modification combinations taught herein (with or without the supplements taught herein, added to a vessel comprising the microorganism population).
- specific productivity and/or volumetric productivity improvements is/are at least 10, at least 20, at least 30, at least 40, at least 50, at least 100, at least 200, at least 300, at least 400, and at least 500 percent over the respective specific productivity and/or volumetric productivity of such appropriate control microorganism.
- the metrics may be applicable to any of the compositions, e.g., genetically modified microorganisms, methods, e.g., of producing 3-HP or other chemical products, and systems, e.g., fermentation systems utilizing the genetically modified microorganisms and/or methods disclosed herein.
- Any number of strategies may lead to development of a suitable modified enzyme suitable for use in a 3-HP production pathway.
- malonyl-CoA-reductase one may utilize or modify an enzyme such as encoded by the sequences in the table immediately above, to achieve a suitable level of 3-HP production capability in a microorganism strain.
- a complex comprising all or portions of a number of inter-related metabolic pathways has been identified, wherein genetic modification to increase enzymatic activities of enzymes of such complex, named the 3-HP Toleragenic Complex (“3HPTGC”), are demonstrated to increase microorganism tolerance to exposure to 3-HP.
- the 3HPTGC is described in WO 2010/011874, published January 28, 2010, which is incorporated in the present application for its teachings of the 3HPTGC and combinations of genetic modifications related to 3 HP production and tolerance based on the 3HPTGC and groups therein.
- the present invention broadly relates to alterations, using genetic modifications, and/or medium modulations (e.g, additions of enzymatic conversion products or other specific chemicals), to achieve desired results in microbe-based industrial bio-production methods, systems and compositions.
- this invention flows from the discovery of the unexpected importance of the 3HPTPC which comprises certain metabolic pathway portions comprising enzymes whose increased activity (based on increasing copy numbers of nucleic acid sequences that encode there) correlates with increased tolerance of a microorganism to 3-HP.
- Actual data and/or prophetic examples directed to alterations of the 3HPTGC are provided herein.
- one or more genetic modifications may be made to the genetically modified microorganism to increase its tolerance to 3-HP (or other chemical products).
- a genetically modified microorganism may comprise at least one genetic modification to provide, complete, or enhance one or more 3-HP production pathways, at least one genetic modification to provide enoyl-ACP reductase enzymatic activity and/or other modifications of the fatty acid synthetase system that can be controlled so as to reduce such activity at a desired cell density, and at least one genetic modification of the 3HPTGC, or one, two, or three or more groups thereof, to increase tolerance of the genetically modified microorganism to 3-HP.
- one aspect of the invention relates to a genetically modified microorganism comprising at least one genetic modification effective to increase 3-hydroxypropionic acid (“3-HP") production, wherein the increased level of 3-HP production is greater than the level of 3-HP production in the wild-type microorganism, and at least one genetic modification of a metabolic complex identified herein as the 3-HP Toleragenic Complex (“3HPTGC”).
- 3HPTGC 3-HP Toleragenic Complex
- the 3HPTGC genetic modification(s) allow the genetically modified microorganism to produce 3-HP under specific culture conditions such that 3-HP may accumulate to a relatively higher concentration without the toxic effects observed in unmodified microorganisms.
- the at least one genetic modification of a 3-HP production pathway may be to improve 3-HP accumulation and/or production of a 3-HP production pathway found in the wild-type microorganism, or may be to provide sufficient enzymatic conversions in a microorganism that normally does not synthesize 3-HP so that 3-HP is thus bio-produced. Methods of making such genetically modified microorganisms also are described and are part of this aspect of the invention.
- Another aspect of the invention relates to a genetically modified microorganism comprising at least one genetic modification from two or more of the chorismate, threonine/homocysteine, polyamine synthesis, lysine synthesis, and nucleotide synthesis portions of the 3HPTGC.
- Non-limiting examples of multiple combinations exemplify the advantages of this aspect of the invention. Additional genetic modifications pertain to other portions of the 3HPTGC.
- Capability to bio-produce 3-HP may be added to some genetically modified microorganisms by appropriate genetic modification. Methods of identifying genetic modifications to provide a microorganism achieving an increased 3-HP tolerance, and microorganisms made by such methods, relate to this aspect of the invention.
- Another aspect of the invention relates to a genetically modified microorganism that is able to produce 3-hydroxypropionic acid ("3-HP"), comprising at least one genetic modification to the 3HPTGC that increases enzymatic conversion at one or more enzymatic conversion steps of the 3HPTGC for the microorganism, and wherein the at least one genetic modification increases 3 -HP tolerance of the genetically modified microorganism above the 3 -HP tolerance of a control microorganism lacking the genetic modification.
- 3-HP 3-hydroxypropionic acid
- Another aspect of the invention relates to a genetically modified microorganism comprising various core sets of specific genetic modification(s) of the 3HPTGC.
- this aspect may additionally comprise at least one genetic modification from one or more or two or more of the chorismate, threonine/homocysteine, polyamine synthesis, lysine synthesis, and nucleotide synthesis portions of the 3HPTGC. Methods of making such genetically modified microorganisms also are described and are part of this aspect of the invention.
- the invention includes methods of use to improve a microorganism's tolerance to 3 -HP, which may be in a microorganism having 3 -HP production capability (whether the latter is naturally occurring, enhanced and/or introduced by genetic modification).
- another aspect of the invention is directed to providing one or more supplements, which are substrates (i.e., reactants) and/or products of the 3HPTGC (collectively herein "products" noting that substrates of all but the initial conversion steps are also products of the 3HPTGC), to a culture of a microorganism to increase the effective tolerance of that microorganism to 3 -HP.
- substrates i.e., reactants
- products of the 3HPTGC collectively herein “products” noting that substrates of all but the initial conversion steps are also products of the 3HPTGC
- Another aspect of the invention regards the genetic modification to introduce a genetic element that encodes a short polypeptide identified herein as IroK.
- the introduction of genetic elements encoding this short polypeptide has been demonstrated to improve 3 -HP tolerance in E. coli under microaerobic conditions.
- This genetic modification may be combined with other genetic modifications and/or supplement additions of the invention.
- SEQ ID NOs:001 to 189 are incorporated into this section
- SEQ ID NOs: 190 to 603 are provided as nucleic acid sequences (gene, DNA) and encoded amino acid sequences (proteins) of the E. coli 3HPTGC
- SEQ ID NOs:604 to 766 are provided as sequences of the nucleic acid sequences of the Saccharomyces cerevisiae 3HPTGC.
- a particular genetic modification to increase expression of carbonic anhydrase may act in a dual function manner to advantageously improve both 3-HP production and 3-HP tolerance. This is particularly the case when malonyl-CoA reductase is provided for 3-HP production.
- FIG. 1 depicts a production pathway from malonyl-CoA to 3-HP comprising a bi- functional malonyl-CoA reductase, and other enzymatic conversions and pathways described herein.
- Carbonic anhydrase is not meant to be limiting. For instance, in E.
- coli a carbonic anhydrase 2 is known, variously designated as can and yadF, and use of genetic modifications in embodiments of the present invention may use this or other genes and their encoded enzymes.
- the sequences for can are provided as SEQ ID NO: 767 (EG12319 can "carbonic anhydrase 2 monomer” (complement (142670..142008)) Escherichia coli K-12 substr. MG1655) and SEQ ID NO: 768 (EG12319-MONOMER carbonic anhydrase 2 monomer (complement(142670..142008)) Escherichia coli K-12 substr. MG1655).
- genetic modifications to increase 3-HP tolerance may be further classified by genetic modifications made along particular respective portions of the 3HPTGC.
- genetic modifications may be made to polynucleotides that encode polypeptides that catalyze enzymatic reactions along specific portions of the of the 3HPTGC and so are expected to increase production of, respectively, aromatic amino acids (tyr and phe), tryptophan (trp), ubiquinone-8, menaquinone, enterobactin, tetrahydrofolate (see respective enzymatic conversions of Group A sheet (and inputs thereto)), one or more of the polar uncharged amino acids (gly, ser, cys, homocysteine), isoleucine, methionine (see respective enzymatic conversions of
- Group B sheet (and inputs thereto)), glutamine, arginine, putrescine, spermidine, aminopropylcadaverine (see see respective enzymatic conversions of Group C sheet (and inputs thereto)), cadaverine (see respective enzymatic conversions of Group D sheet (and input thereto)), inosine-5-phosphate, xanthosine-5-phosphate, adenylo-succinate, orotidine-5' -phosphate, and any of the mono-, di-, and tri-phosphate nucleosides (i.e., adenosine, guanosine, cytosine, uridine) obtainable there from (see respective enzymatic conversions of Group
- 3-HP tolerance thereby increases as a result of such genetic modification(s). Any portion or sub-portion may be selected for genetic modification(s) to increase 3-HP tolerance in a selected microorganism species.
- E. coli K12 genomic libraries were produced by methods known to those skilled in the art.
- the five libraries respectively comprised 500, 1000, 2000, 4000, 8000 base pair ("bp") inserts of E. coli K12 genetic material.
- Each of these libraries essentially comprising the entire E. coli K12 genome, was respectively transformed into MACH1TM-T1 ® E. coli cells and cultured to mid- exponential phase corresponding to microaerobic conditions (OD 60 o ⁇ 0.2). Batch transfer times were variable and were adjusted as needed to avoid a nutrient limited selection environment (i.e., to avoid the cultures from entering stationary phase).
- 3-HP selection in the presence of 3-HP was carried out over 8 serial transfer batches with a decreasing gradient of 3-HP over 60 hours. More particularly, the 3-HP concentrations were 20g 3-HP/L for serial batches 1 and 2, 15 g 3-HP/L for serial batches 3 and 4, 10 g 3-HP/L for serial batches 5 and 6, and 5 g 3-HP/L for serial batches 7 and 8. For serial batches 7 and 8 the culture media was replaced as the culture approached stationary phase to avoid nutrient limitations.
- Microarray technology also is well-known in the art (see, e.g. «www.affymetrix.com»).
- Affymetrix E. coli Antisense Gene Chip arrays (Affymetrix, Santa Clara, CA) were handled and scanned according to the E. coli expression protocol from Affymetrix producing affymetrix. eel files.
- a strong microarray signal after a given exposure to 3 -HP indicates that the genetic sequence introduced by the plasmid comprising this genetic sequence confers 3- HP tolerance.
- the 3HPTGC is divided into an "upper section” comprising the glycolysis pathway, the tricarboxylic acid cycle, the glyoxylate pathway, and a portion of the pentose phosphate pathway, and a "lower section” comprising all or portions of the chorismate super-pathway, the carbamoyl-phosphate to carbamate pathway, the threonine/homocysteine super-pathway, the nucleotide synthesis pathway, and the polyamine synthesis pathway.
- microorganisms are genetically modified to affect one or more enzymatic activities of the 3HPTGC so that an elevated tolerance to 3-HP may be achieved, such as in industrial systems comprising microbial 3-HP biosynthetic activity. Also, genetic modifications may be made to provide and/or improve one or more 3-HP biosynthesis pathways in microorganisms comprising one or more genetic modifications for the 3-HP toleragenic complex, thus providing for increased 3-HP production. These latter recombinant microorganisms may be referred to as 3 -HP-syntha- toleragenic recombinant microorganisms ("3HPSATG" recombinant microorganisms).
- 3HPSATG 3 -HP-syntha- toleragenic recombinant microorganisms
- the 3HPTGC for E. coli is disclosed in FIG. 9A, sheets 1-7 (a guide for positioning these sheets to view the entire depicted 3HPTGC is provided in sheet 1 of FIG. 9A).
- the 3HPTGC comprises all or various indicated portions of the following: the chorismate super-pathway, the carbamoyl-phosphate to carbamate pathway, the threonine/homocysteine super-pathway; a portion of the pentose phosphate pathway; the nucleotide synthesis pathway; the glycolysis/tricarboxylic acid cycle/glyoxylate bypass super-pathway; and the polyamine synthesis pathway.
- the chorismate pathway and the threonine pathway are identified as super-pathways since they respectively encompass a number of smaller known pathways. However, the entire 3HPTGC comprises these as well as other pathways, or portions thereof, that normally are not associated with either the chorismate super-pathway or the threonine/homocysteine super- pathway.
- FIG. 9A comprising sheets 1-7, is subdivided into the lower section, which is further subdivided into Groups A-E and the upper section, identified simply as Group F.
- the lower section groups are identified as follows: Group A, or "chorismate,” comprising the indicated, major portion of the chorismate super-pathway (sheet 3); Group B, or “threonine/homocysteine,” comprising the indicated portion of the threonine/homocysteine pathway (sheet 7); Group C, or "polyamine synthesis,” comprising the indicated portion of the polyamine pathway, which includes arginine synthesis steps and also the carbamoyl-phosphate to carbamate pathway (sheet 5); Group D, or "lysine synthesis,” comprising the indicated portion of the lysine synthesis pathway (sheet 6); Group E, or "nucleotide synthesis,” comprising the indicated portions of nucleotide synthesis pathways (sheet 4).
- Group F (sheet 2) comprises the upper section of
- genes are identified at enzymatic conversion steps of the 3HPTGC in FIG. 9A, sheets 1-7. These genes are for E. coli strain K12, substrain MG1655; nucleic acid and corresponding amino acid sequences of these are available at «http://www.ncbi.nlm.nih.gov/sites/entrez», and alternatively at «www.ecocyc.org». As is known to one skilled in the art, some genes may be found on a chromosome within an operon, under the control of a single promoter, or by other interrelationships.
- nucleic acid sequence herein is referred to as a combination, such as sucCD or cynTS, by this is meant that the nucleic acid sequence comprises, respectively, both sucC and sucD, and both cynT and cynS. Additional control and other genetic elements may also be in such nucleic acid sequences, which may be collectively referred to as "genetic elements" when added in a genetic modification, and which is intended to include a genetic modification that adds a single gene.
- acna 792.11 citrate acnM 0 aconitate hydratase isopropylmalate gi
- NP_415 isomerase large acna 792.11 citrate leuC3 6.00E-20 subunit
- FIG. 9B, sheets 1-7 shows the 3HPTGC for Bacillus subtilis
- FIG. 9C, sheets 1-7 shows the 3HPTGC for the yeast Saccharomyces cerevisiae
- FIG. 9D, sheets 1-7 shows the 3HPTGC for Cupriavidus necator. Enzyme names for the latter are shown, along with an indication of the quantity of homologous sequences meeting the criterion of having an E-value less than E "10 when compared against an E. coli enzyme known to catalyze a desired 3HPTGC enzymatic conversion step.
- one or both of the above approaches may be employed to identify relevant genes and enzymes in a selected microorganism species (for which its genomic sequence is known or has been obtained), evaluate the relative improvements in 3 -HP tolerance of selected genetic modifications of such homologously matched and identified genes, and thereby produce a recombinant selected microorganism comprising improved tolerance to 3 -HP.
- alternative pathways in various microorganisms may yield products of the 3HPTGC, the increased production or presence of which are demonstrated herein to result in increased 3-
- HP tolerance For example, in yeast species there are alternative pathways to lysine, a product within Group D.
- nucleic acid sequence variants encoding identified enzymatic functional variants of any of the enzymes of the 3HPTGC or a related complex or portion thereof as set forth herein, and their use in constructs, methods, and systems claimed herein.
- Some fitness data provided in Table 3 is not represented in the figures of the 3HPTGC but nonetheless is considered to support genetic modification(s) and/or supplementation to improve 3-HP tolerance.
- the relatively elevated fitness scores for gcvH, gcvP and gcvT related to the glycine cleavage system.
- These enzymes are involved in the glycine/5, 10-methylene-tetrahydrofolate ("5,10mTHF") conversion pathway, depicted in FIG. 10.
- the three enzymatically catalyzed reactions result in decarboxylation of glycine (a 3HPTGC product, see FIG.
- the genetic modifications to any pathways and pathway portions of the 3HPTCG and any of the 3-HP bio-production pathways may be described to include various genetic manipulations, including those directed to change regulation of, and therefore ultimate activity of, an enzyme, or enzymatic activity of an enzyme identified in any of the respective pathways.
- Such genetic modifications may be directed to transcriptional, translational, and post-translational modifications that result in a change of enzyme activity and/or overall enzymatic conversion rate under selected and/or identified culture conditions, and/or to provision of additional nucleic acid sequences (as provided in some of the Examples) so as to increase copy number and/or mutants of an enzyme of the 3HPTGC.
- Random mutagenesis may be practiced to provide genetic modifications of the 3HPTGC that may fall into any of these or other stated approaches.
- the genetic modifications further broadly fall into additions (including insertions), deletions (such as by a mutation) and substitutions of one or more nucleic acids in a nucleic acid of interest.
- a genetic modification results in improved enzymatic specific activity and/or turnover number of an enzyme. Without being limited, changes may be measured by one or more of the following: K M ; K cat ; and K avidity .
- Such genetic modifications overall are directed to increase enzymatic conversion at at least one enzymatic conversion step of the 3HPTGC so as to increase 3 -HP tolerance of a microorganism so modified.
- the enzymatic conversion steps shown in FIGs. 9A-D may be catalyzed by enzymes that are readily identified by one skilled in the art, such as by searching for the enzyme name corresponding to the gene name at a particular enzymatic conversion step in FIGs. 9A-D, and then identifying enzymes, such as in other species, having the same name and function. The latter would be able to convert the respective reactant(s) to the respective product(s) for that enzymatic conversion step.
- Public database sites such as «www.metacyc.org», «www.ecocyc.org», «www.biocyc.org», and «www.ncbi.gov» have associated tools to identify such analogous enzymes.
- MIC analysis is used frequently herein as an endpoint to indicate differences in microorganism growth when placed in various 3-HP concentrations for a specified time, this is by no means considered to be the only suitable metric to determine a difference, such as an improvement, in microorganism tolerance based on aspects of the invention.
- suitable measurement approaches may include growth rate determination, lag time determination, changes in optical density of cultures at specified culture durations, number of doublings of a population in a given time period and, for microorganisms that comprise 3-HP production capability, overall 3-HP production in a culture system in which 3-HP accumulates to a level inhibitory to a control microorganism lacking genetic modifications that increase enzymatic conversion at one or more enzymatic conversion steps of the 3HPTGC. This may result in increased productivities, yields or titers.
- a useful metric to assess increases in 3-HP tolerance can be related to a microorganism's or a microorganism culture's ability to grow while exposed to 3-HP over a specified period of time. This can be determined by various quantitative and/or qualitative analyses and endpoints, particularly by comparison to an appropriate control that lacks the 3-HP tolerance -related genetic modification(s) and/or supplements as disclosed and discussed herein. Time periods for such assessments may be, but are not limited to: 12 hours; 24 hours; 48 hours; 72 hours; 96 hours; and periods exceeding 96 hours. Varying exposure concentrations of 3 -HP may be assessed to more clearly identify a 3 -HP tolerance improvement.
- FIGs. 15A-0 provide data from various control microorganism responses to different 3-HP concentrations.
- the data in these figures is shown variously as changes in maximum growth rate ( ⁇ ), changes in optical density (“OD”), and relative doubling times over a given period, here 24 hours.
- FIGs.15 A, 15D, 15G, 15 J, and 15M demonstrate changes in maximum growth rates over a 24-hour test period for the indicated species under the indicated aerobic or anaerobic test conditions.
- this representation is termed a "toleragram" herein.
- growth toleragrams are generated by measuring the specific growth rates of microorganisms subjected to growth conditions including varying amounts of 3-HP.
- FIG. 15P compares the growth toleragrams of a control microorganism culture with a microorganism in which genetic modification was made to increase expression of cynTS (in Group C of the 3HPTGC).
- the curve for a cynTS genetic modification in E. coli shows increasing maximum growth rate with increasing 3-HP concentration over a 24-hour evaluation period for each 3-HP concentration. This provides a qualitative visually observable difference.
- the greater area under the curve for the cynTS genetic modification affords a quantitative difference as well, which may be used for comparative purposes with other genetic modifications intended to improve 3-HP tolerance. Evaluation of such curves may lead to more effective identification of genetic modifications and/or supplements, and combinations thereof.
- FIGs. 15B, 15E, 15H, 15K, and 15N demonstrate a control microorganism responses to different 3-HP concentrations wherein optical density ("OD,” measured at 600 nanometers) at 24-hours is the metric used.
- OD600 is a conventional measure of cell density in a microorganism culture.
- FIG. 15B demonstrates a dramatic reduction in cell density at 24 hours starting at 30 g/L 3-HP.
- FIG. 15D shows a relatively sharper and earlier drop for E. coli under anaerobic conditions.
- FIGs. 15C, 15F, 151, 15L, and 150 demonstrate control microorganism responses to different 3-HP concentrations wherein the number of cell doublings during the 24-hour period are displayed.
- Embodiments of the present invention may result from introduction of an expression vector into a host microorganism, wherein the expression vector contains a nucleic acid sequence coding for an enzyme that is, or is not, normally found in a host microorganism.
- the nucleic acid sequence that codes for the enzyme is heterologous (whether or not the heterologous nucleic acid sequence is introduced into that genome).
- composition results of respective methods that is, genetically modified microorganisms that comprise the one or more, two or more, three or more, etc. genetic modifications referred to toward obtaining increased tolerance to 3 -HP.
- a suitable culture vessel comprising a selected microorganism
- one or more supplements that are intermediates or end products (collectively, "products" of the 3HPTGC.
- Table 5 recites a non-limiting listing of supplements that may be added in a culture vessel comprising a genetically modified microorganism comprising one or more genetic modifications to the 3HPTGC and/or 3-HP production pathways.
- one or more of lysine, methionine, and bicarbonate may be provided.
- Such supplement additions may be combined with genetic modifications, as described herein, of the selected microorganism.
- alterations of the enzymatic activities are considered of value to increase tolerance to 3-HP (such as in combination with other alterations of the 3HPTGC).
- the fitness data and subsequently obtained data from the examples related to genetic modifications and/or supplements pertaining to the 3HPTGC support a concept of a functional relationship between such alterations to increase enzymatic conversion along the pathways of the 3HPTGC and the resulting functional increase in 3-HP tolerance in a microorganism cell or culture system. This is observable for the 3HPTGC as a whole and also within and among its defined groups.
- tables 47, 48, 50, 52, 53, and 56 incorporated into this section, provide non-limiting examples supplements additions, genetic modifications, and combinations of supplements additions and genetic modifications. Additional supplementations, genetic modifications, and combinations thereof, may be made in view of these examples and the described methods of identifying genetic modifications toward achieving an elevated tolerance to 3 -HP in a microorganism of interest. Particular combinations may involve only the
- 3HPTGC lower section including combinations involving two or more, three or more, or four or more, of the five groups therein (each involving supplement additions and/or genetic modification), any of these in various embodiments also comprising one or more genetic modifications or supplement additions regarding the
- the alteration(s) directed to the 3HPTGC are effective to increase 3 -HP tolerance by at least 5 percent, at least 10 percent, at least 20 percent, at least 30 percent, or at least 50 percent above a 3-HP tolerance of a control microorganism, lacking said at least one 3HPTGC genetic modification.
- any of the genetically modified microorganisms of the invention may be provided in a culture system and utilized, such as for the production of 3-HP.
- one or more supplements that are products of the 3HPTGC enzymatic conversion steps
- Increased tolerance to 3-HP may be assessed by any method or approach known to those skilled in the art, including but not limited to those described herein.
- the genetic modification of the 3HPTGC upper portion may involve any of the enzymatic conversion steps.
- One, non-limiting example regards the tricarboxylic acid cycle. It is known that the presence and activity of the enzyme citrate synthase (E.C. 2.3.3.1 (previously 4.1.3.7)), which catalyzes the first step in that cycle, controls the rate of the overall cycle (i.e., is a rate-limiter).
- genetic modification of a microorganism such as to increase copy numbers and/or specific activity, and/or other related characteristics (such as lower effect of a feedback inhibitor or other control molecule), may include a modification of citrase synthase.
- Ways to effectuate such change for citrate synthase may utilize any number of laboratory techniques, such as are known in the art, including approaches described herein for other enzymatic conversion steps of the 3HPTGC. Further, several commonly known techniques are described in U.S. Patent Nos. 6, 110,714 and 7,247,459, both assigned to Ajinomoto Co., Inc., both of which are herewith incorporated by reference for their respective teachings about amplifying citrate synthase activity (specifically, cols. 3 and 4, and Examples 3 and 4, of U.S. Patent No. 6,110,714, and cols. 11 and 12 (specifically Examples (1) and (2)) of U.S. Patent No. 7,247,459).
- E. coli strains are provided that comprise selected gene deletions directed to increase enzymatic conversion in the 3HPTGC and accordingly increase microorganism tolerance to 3-HP.
- the following genes which are associated with repression of pathways in the indicated 3HPTGC Groups, may be deleted: Group A - tyrR, trpR; Group B - metJ; Group C - purR; Group D - lysR; Group E - nrdR.
- a disruption of gene function may also be effectuated, in which the normal encoding of a functional enzyme by a nucleic acid sequence has been altered so that the production of the functional enzyme in a microorganism cell has been reduced or eliminated.
- a disruption may broadly include a gene deletion, and also includes, but is not limited to gene modification (e.g., introduction of stop codons, frame shift mutations, introduction or removal of portions of the gene, introduction of a degradation signal), affecting mRNA transcription levels and/or stability, and altering the promoter or repressor upstream of the gene encoding the polypeptide.
- a gene disruption is taken to mean any genetic modification to the DNA, mRNA encoded from the DNA, and the amino acid sequence that results in at least a 50 percent reduction of enzyme function of the encoded gene in the microorganism cell.
- At least one genetic modification is made to increase overall enzymatic conversion for one of the following enzymes of the 3HPTGC: 2-dehydro-3-deoxyphosphoheptonate aldolase (e.g., aroF, aroG, aroH); cyanase (e.g., cynS); carbonic anhydrase (e.g., cynT); cysteine synthase B (e.g., cysM); threonine deaminase (e.g., ilvA); ornithine decarboxylase (e.g., speC, speF); adenosylmethionine decarboxylase (e.g., speD); and spermidine synthase (e.g., speE).
- 2-dehydro-3-deoxyphosphoheptonate aldolase e.g., aroF, aroG, aroH
- cyanase e.g.,
- one aspect of the invention is to genetically modify one or more of these enzymes in a manner to increase enzymatic conversion at one or more 3HPTGC enzymatic conversion steps so as to increase flux and/or otherwise modify reaction flows through the 3HPTGC so that 3-HP tolerance is increased.
- aroH and cyanase with carbonic anhydrase
- the following examples are provided. It is noted that in E. coli a second carbonic anhydrase enzyme is known. This is identified variously as Can and yadf.
- various embodiments of the invention may comprise genetic modifications of the 3HPTGC (as may be provided in a microorganism, as described herein), and/or supplements thereof, excluding any one or more designated enzymatic conversion steps, product additions, and/or specific enzymes.
- an embodiment of the invention may comprise genetic modifications of the 3HPTGC in a microorganism, however excluding those of Group A, or of Groups A and B, or of a defined one or more members of the 3HPTGC (which may be any subset of the 3HPTGC members).
- a modified 3HPTGC may comprise all members of the 3HPTGC as depicted herein except the degradative form of arginine decarboxylase (adiA, which is known to be induced in rich medium at low pH under anaerobic conditions in the presence of excess substrate), or other subsets excluding such degradative arginine decarboxylase and other selected enzyme steps.
- AdiA the degradative form of arginine decarboxylase
- Other modified 3HPTGC complexes may also be practiced in various embodiments. Based on the noted induction of adiA, the use of the degradative form of arginine decarboxylase is not be considered within the scope of the 3HPTGC for 3-HP tolerance improvement as practiced under aerobic conditions.
- various non-limiting aspects of the invention may include, but are not limited to:
- a genetically modified (recombinant) microorganism comprising a nucleic acid sequence that encodes a polypeptide with at least 85% amino acid sequence identity to any of the enzymes of any of 3-HP tolerance- related or biosynthetic pathways, wherein the polypeptide has enzymatic activity and specificity effective to perform the enzymatic reaction of the respective 3-HP tolerance-related or biosynthetic pathway enzyme, and the recombinant microorganism exhibits greater 3-HP tolerance and/or 3-HP bio-production than an appropriate control microorganism lacking such nucleic acid sequence.
- a genetically modified (recombinant) microorganism comprising a nucleic acid sequence that encodes a polypeptide with at least 90% amino acid sequence identity to any of the enzymes of any of 3-HP tolerance- related or biosynthetic pathways, wherein the polypeptide has enzymatic activity and specificity effective to perform the enzymatic reaction of the respective 3-HP tolerance-related or biosynthetic pathway enzyme, and the recombinant microorganism exhibits greater 3-HP tolerance and/or 3-HP bio-production than an appropriate control microorganism lacking such nucleic acid sequence.
- a genetically modified (recombinant) microorganism comprising a nucleic acid sequence that encodes a polypeptide with at least 95% amino acid sequence identity to any of the enzymes of any of 3-HP tolerance- related or biosynthetic pathways, wherein the polypeptide has enzymatic activity and specificity effective to perform the enzymatic reaction of the respective 3-HP tolerance-related or biosynthetic pathway enzyme, and the recombinant microorganism exhibits greater 3-HP tolerance and/or 3-HP bio-production than an appropriate control microorganism lacking such nucleic acid sequence.
- the at least one polypeptide has at least 99% or 100% sequence identity to at least one of the enzymes of a 3-HPTGC pathway and/or a 3- HP biosynthetic pathway.
- the identity values in the preceding paragraphs are determined using the parameter set described above for the FASTDB software program, or BLASTP or BLASTN, such as version 2.2.2, using default parameters. Further, for all specifically recited sequences herein it is understood that conservatively modified variants thereof are intended to be included within the invention.
- the invention contemplates a genetically modified (e.g., recombinant) microorganism comprising a heterologous nucleic acid sequence that encodes a polypeptide that is an identified enzymatic functional variant of any of the enzymes of any of 3-HP tolerance -related pathways, or pathway portions (i.e., of the 3HPTGC), or other enyme disclosed herein (e.g., of a 3-HP production pathway), wherein the polypeptide has enzymatic activity and specificity effective to perform the enzymatic reaction of the respective 3-HP tolerance -related or other enzyme, so that the recombinant
- the invention contemplates a recombinant microorganism comprising at least one genetic modification effective to increase 3-hydroxypropionic acid (“3-HP") production, wherein the increased level of 3 -HP production is greater than the level of 3 -HP production in the wild-type microorganism, and at least one genetic modification of the 3-HP Toleragenic Complex ("3HPTGC").
- the wild-type microorganism produces 3-HP.
- the wild-type microorganism does not produce 3-HP.
- the recombinant microorganism comprises at least one vector, such as at least one plasmid, wherein the at least one vector comprises at least one heterologous nucleic acid molecule.
- the at least one genetic modification of the 3HPTGC is effective to increase the 3-HP tolerance of the recombinant microorganism above the 3-HP tolerance of a control microorganism, wherein the control microorganism lacks the at least one 3HPTGC genetic modification.
- the 3-HP tolerance of the recombinant microorganism is increased above the 3-HP tolerance of a control microorganism by about 5 %, 10%, or 20%.
- the 3-HP tolerance of the recombinant microorganism is increased above the 3-HP tolerance of a control microorganism by about 30%, 40%, 50%, 60%, 80%, or 100%.
- the at least one genetic modification of the 3HPTGC encodes at least one polypeptide exhibiting at least one enzymatic conversion of at least one enzyme of the 3HPTGC, wherein the recombinant microorganism exhibits an increased 3-HP tolerance at least about 5, 10, 20, 30, 40, 50, 60, or 100 percent greater, or more, than the 3-HP tolerance of a control microorganism lacking the at least one genetic modification of the 3HPTGC, Any evaluations for such tolerance improvements may be based on a Minimum Inhibitory Concentration evaluation in a minimal media.
- the microorganism further comprises at least one additional genetic modification encoding at least one polypeptide exhibiting at least one enzymatic conversion of at least one enzyme of a second Group different from the genetic modification of a first Group of the 3HPTGC, wherein the recombinant microorganism exhibits an increased 3-HP tolerance at least about 5, 10, 20, 30, 40, 50, 60, or 100 percent greater, or more, than the 3-HP tolerance of a control microorganism lacking all said genetic modifications of the 3HPTGC.
- the at least one additional genetic modification further comprises a genetic modification from each of two or more, or three or more, of the Groups A-F.
- the genetic modifications may comprise at least one genetic modification of Group A and at least one genetic modification of Group B, at least one genetic modification of Group A and at least one genetic modification of Group C, at least one genetic modification of Group A and at least one genetic modification of Group D, at least one genetic modification of Group A and at least one genetic modification of Group E, at least one genetic modification of Group B and at least one genetic modification of Group C, at least one genetic modification of Group B and at least one genetic modification of Group D, at least one genetic modification of Group B and at least one genetic modification of Group E, at least one genetic modification of Group C and at least one genetic modification of Group D, at least one genetic modification of Group C and at least one genetic modification of Group E, or at least one genetic modification of Group D and at least one genetic modification of Group E. Any such combinations may be further practiced with Group F genetic modifications.
- the recombinant microorganism comprises one or more gene disruptions of 3HPTGC repressor genes selected from tyrR, trpR, metJ, argR, purR, lysR and nrdR.
- the at least one genetic modification of the 3HPTGC comprises means to increase expression of SEQ ID NO: 129 (Irok peptide).
- the recombinant microorganism is an E. coli strain.
- the recombinant microorganism is a Cupriavidus necator strain.
- the at least one genetic modification encodes at least one polypeptide with at least 85% amino acid sequence identity to at least one of the enzymes of a 3-HPTGC pathway, a 3-HP biosynthetic pathway, and/or SEQ ID NO: 129 (Irak).
- the culture system comprises a genetically modified microorganism as described herein and a culture media.
- Such genetically modified microorganism may comprise a single genetic modification of the 3HPTGC, or any of the combinations described herein, and may additionally comprise one or more genetic modifications of a 3-HP production pathway.
- the culture media comprises at least about 1 g/L, at least about 5 g/L, at least about lOg/L, at least about 15 g/L, or at least about 20 g/L of 3-HP.
- the culture system comprises a 3HPTGC supplement at a respective concentration such as that shown herein.
- the invention contemplates a method of making a genetically modified microorganism comprising providing at least one genetic modification to increase the enzymatic conversion of the genetically modified microorganism over the enzymatic conversion of a control microorganism, wherein the control microorganism lacks the at least one genetic modification, at an enzymatic conversion step of the 3- hydroxypropionic acid Toleragenic Complex ("3HPTGC"), wherein the genetically modified microorganism synthesizes 3-HP.
- the control microorganism synthesizes 3-HP.
- the at least one genetic modification increases the 3-HP tolerance of the genetically modified microorganism above the 3-HP tolerance of the control microorganism.
- the 3-HP tolerance of the genetically modified microorganism is at least about 5 percent, at least about 10 percent, at least about 20 percent, at least about 30 percent, at least about 40 percent, at least about 50 percent, or at least about 100 percent above the 3-HP tolerance of the control microorganism. In some embodiments, the 3-HP tolerance of the genetically modified microorganism is from about 50 to about 300 percent above the 3-HP tolerance of the control microorganism, based on a Minimum Inhibitory
- the genetically modified microorganism further comprises one or more gene disruptions of 3HPTGC repressor genes selected from tyrR, trpR, metJ, argR, purPv, lysR and nrdR.
- the control microorganism does not synthesize 3-HP.
- providing at least one genetic modification comprises providing at least one vector.
- the at least one vector comprises at least one plasmid.
- providing at least one genetic modification comprises providing at least one nucleic acid molecule.
- the at least one nucleic acid molecule is heterologous.
- the at least one nucleic acid molecule encodes SEQ ID NO: 129 (Irok).
- genetic modifications are made to increase enzymatic conversion at an enzymatic conversion step identified to have an elevated fitness score in Table 3 and/or evaluated in the Examples. Enzymes that catalyze such reactions are numerous and include cyanase and carbonic anhydrase.
- various embodiments of the invention may be directed to amino acid sequences of enzymes that catalyze the enzymatic conversion steps of the 3HPTGC for any species. More particularly, the amino acid sequences of the 3HPTGC for FIGs. 9A-D are readily obtainable from one or more of commonly used bioinformatics databases (e.g., «www.ncbi.gov»; «www.metacyc.org») by entering a respective gene for an enzymatic conversion step therein.
- bioinformatics databases e.g., «www.ncbi.gov»; «www.metacyc.org»
- Various embodiments of the present invention comprise a genetically modified microorganism comprising at least one genetic modification to introduce or increase malonyl-CoA-reductase enzymatic activity, including by introducing a polynucleotide that expresses a functional equivalent of the malonyl-CoA- reductase provided herein.
- a functional equivalent of malonyl-CoA-reductase enzymatic activity is capable of increasing enzymatic activity for conversion of malonyl-CoA to malonate semialdehyde, malonate semialdehyde to 3 -HP, or both.
- the amino acid sequence of the malonyl-CoA-reductase comprises SEQ ID NO:783.
- the malonyl-CoA-reductase comprises a variant of any of SEQ ID NOs:783 to 791 exhibiting malonyl-CoA-reductase enzymatic activity.
- the amino acid sequence of the malonyl-CoA-reductase can comprise an amino acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% sequence identity to any one of SEQ ID NOs: 783 to 791.
- At least one genetic modification comprises providing a polynucleotide that encodes an amino acid sequence comprising one of, or a functional portion of, any of SEQ ID NOs: 783 to 791. In various embodiments, at least one genetic modification comprises providing a polynucleotide that encodes an amino acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% sequence identity to any of SEQ ID NOs: 783 to 791.
- the polynucleotide is codon-optimizedfor a selected microorganism species to encode any one of SEQ ID NOs: 783 to 791.
- the polynucleotide is codon- optimized to encode an amino acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% sequence identity to any one of SEQ ID NOs: 783 to 791.
- the polynucleotide can be codon- optimized for ?, coli, for example.
- the genetically modified microorganism that so possesses malonyl-CoA- reductase genetic modification(s) additionally comprises at least one genetic modification to increase, in the genetically modified microorganism, a protein function selected from the protein functions of Table 6A (Glucose transporter function (such as by galP), pyruvate dehydrogenase Elp, dihydrolipoamide
- the genetically modified microorganism comprises at least one genetic modification to increase two, three, or four protein functions selected from the protein functions of Table 6A.
- such genetically modified microorganism additionally comprises at least one genetic modification to decrease protein functions selected from the protein functions of Table 6B, lactate dehydrogenase, pyruvate formate lyase, pyruvate oxidase, phosphate acetyltransferase, histidyl
- phosphorylatable protein of PTS
- phosphoryl transfer protein of PTS
- polypeptide chain of PTS
- such genetically modified microorganism comprises at least one genetic modification to decrease enzymatic activity of two, three, four, five, six, or seven protein functions selected from the protein functions of Table 6B. Also, in various embodiments at least one, or more than one, genetic modification is made to modify the protein functions of Table 7 in accordance with the Comments therein.
- At least one genetic modification to decrease enzymatic activity is a gene disruption. In some embodiments, at least one genetic modification to decrease enzymatic activity is a gene deletion.
- the genetically modified microorganism comprises a protein function effective for converting malonate semialdehyde to 3-HP.
- the protein function effective for converting malonate semialdehyde to 3-HP can be native to the
- the protein function effective for converting malonate semialdehyde to 3-HP is a native or mutated form of mmsB from Pseudomonas aeruginosa s, or a functional equivalent thereof.
- this protein function can be a native or mutated form of ydfG, or a functional equivalent thereof.
- Certain embodiments of the invention additionally comprise a genetic modification to increase the availability of the cofactor NADPH, which can increase the NADPH/NADP+ ratio as may be desired.
- Non- limiting examples for such genetic modification are pgi (E.C. 5,3.1.9, in a mutated form), pntAB (E.C. 1.6.1.2), overexpressed, gapA(E.C. 1.2.1.12):gapN (E.C. 1.2.1.9, from Streptococcus mutans) substitution/replacement, and disrupting or modifying a soluble transhydrogenase such as sthA (E.C. 1.6.1.2), and/or genetic modifications of one or more of zwf (E.C.
- the genetic modification increases microbial synthesis of 3-HP above a rate or titer of a control microorganism lacking said at least one genetic modification to produce 3-HP.
- the genetic modification is effective to increase enzymatic conversions to 3-HP by at least about 5 percent, at least about 10 percent, at least about 20 percent, at least about 30 percent, or at least about 50 percent above the enzymatic conversion of a control microorganism lacking the genetic modification.
- any one or a combination of enzyme functions of the following may be decreased in a particular embodiment combined with other genetic modifications described herein: ⁇ -ketoacyl-ACP synthase I, 3-oxoacyl-ACP-synthase I; Malonyl- CoA-ACP transacylase; enoyl acyl carrier protein reductase; and ⁇ -ketoacyl-acyl carrier protein synthase III.
- compositions, methods and systems of the present invention comprise providing a genetically modified microorganism that comprises both a production pathway to a selected chemical product, such as 3 -HP, and a modified polynucleotide that encodes an enzyme of the fatty acid synthase system that exhibits reduced activity, so that utilization of malonyl-CoA shifts toward the production pathway compared with a comparable (control) microorganism lacking such modifications.
- the methods involve producing the chemical product using a population of such genetically modified
- microorganism in a vessel provided with a nutrient media.
- Providing additional copies of polynucleotides that encode polypeptides exhibiting these enzymatic activities is shown to increase 3 -HP production.
- Other ways to increase these respective enzymatic activities is known in the art and may be applied to various embodiments of the present invention.
- SEQ ID NOs for these polynucleotides and polypeptides of E. coli are: acetyl-CoA carboxylase (accABCD,
- SEQ ID NOs:771-778 SEQ ID NOs:771-778
- NADPH-dependent transhydrogenase SEQ ID NOs:779-782
- pyridine nucleotide transhydrogenase pntAB in E. coli
- a first step in some multi-phase method embodiments of making a chemical product may be exemplified by providing into a vessel, such as a culture or bioreactor vessel, a nutrient media, such as a minimal media as known to those skilled in the art, and an inoculum of a genetically modified microorganism so as to provide a population of such microorganism, such as a bacterium, and more particularly a member of the family Enterobacteriaceae, such as E. coli, where the genetically modified microorganism comprises a metabolic pathway that converts malonyl-CoA to 3-HP molecules.
- a vessel such as a culture or bioreactor vessel
- a nutrient media such as a minimal media as known to those skilled in the art
- an inoculum of a genetically modified microorganism so as to provide a population of such microorganism, such as a bacterium, and more particularly a member of the family Enterobacteriaceae, such as E.
- genetic modifications may include the provision of at least one nucleic acid sequence that encodes a gene encoding the enzyme malonyl-CoA reductase in one of its bi-functional forms, or that encodes genes encoding a mono-functional malonyl-CoA reductase and an NADH- or NADPH-dependent 3-hydroxypropionate dehydrogenase (e.g., ydfG or mmsB from E. coli, or mmsB from Pseudomonas aeruginosa).
- these genetic modifications complete a metabolic pathway that converts malonyl-CoA to 3-HP.
- This inoculum is cultured in the vessel so that the cell density increases to a cell density suitable for reaching a production level of 3-HP that meets overall productivity metrics taking into consideration the next step of the method.
- a population of these genetically modified microorganisms may be cultured to a first cell density in a first, preparatory vessel, and then transferred to the noted vessel so as to provide the selected cell density. Numerous multi-vessel culturing strategies are known to those skilled in the art. Any such embodiments provide the selected cell density according to the first noted step of the method.
- a subsequent step may be exemplified by two approaches, which also may be practiced in combination in various embodiments.
- a first approach provides a genetic modification to the genetically modified microorganism such that its enoyl-ACP reductase enzymatic activity may be controlled.
- a genetic modification may be made to substitute for the native enoyl-ACP reductase a temperature-sensitive mutant enoyl-ACP reductase (e.g., fabI TS in E. coli).
- the latter may exhibit reduced enzymatic activity at temperatures above 30 C but normal enzymatic activity at 30 C, so that elevating the culture temperature to, for example to 34C, 35C, 36C, 37C or even 42C, reduces enzymatic activity of enoyl- ACP reductase.
- elevating the culture temperature to, for example to 34C, 35C, 36C, 37C or even 42C reduces enzymatic activity of enoyl- ACP reductase.
- more malonyl-CoA is converted to 3-HP or another chemical product than at 30 C, where conversion of malonyl-CoA to fatty acids is not impeded by a less effective enoyl-ACP reductase.
- an inhibitor of enoyl-ACP reductase, or another of the fatty acid synthase enzyme is added to reduce conversion of malonyl-CoA to fatty acids.
- the inhibitor cerulenin is added at a concentration that inhibits one or more enzymes of the fatty acid synthase system.
- FIG. 2A depicts relevant pathways and shows three inhibitors - thiolactomycin, triclosan, and cerulenin, next to the enzymes that they inhibit.
- Encircled E. coli gene names indicate a temperature-sensitive mutant is available for the polypeptide encoded by the gene.
- FIG. 2B provides a more detailed depiction of representative enzymatic conversions and exemplary E. coli genes of the fatty acid synthetase system that was more generally depicted in
- FIG. 2A This listing of inhibitors of microorganism fatty acid synthetase enzymes is not meant to be limiting.
- inhibitors include, but are not limited to, diazaborines such as thienodiazaborine, and, isoniazid.
- the 3-HP tolerance aspects of the present invention can be used with any microorganism that makes 3- HP, whether that organism makes 3-HP naturally or has been genetically modified by any method to produce 3- HP.
- the genetic modifications comprise introduction of one or more nucleic acid sequences into a microorganism, wherein the one or more nucleic acid sequences encode for and express one or more production pathway enzymes (or enzymatic activities of enzymes of a production pathway).
- these improvements thereby combine to increase the efficiency and efficacy of, and consequently to lower the costs for, the industrial bio-production production of 3-HP.
- Any one or more of a number of 3-HP production pathways may be used in a microorganism such as in combination with genetic modifications directed to improve 3-HP tolerance.
- genetic modifications are made to provide enzymatic activity for implementation of one or more of such 3-HP production pathways.
- 3-HP production pathways are known in the art.
- U.S. Patent No. 6,852,517 teaches a 3-HP production pathway from glycerol as carbon source, and is incorporated by reference for its teachings of that pathway.
- This reference teaches providing a genetic construct which expresses the dhaB gene from Klebsiella pneumoniae and a gene for an aldehyde dehydrogenase. These are stated to be capable of catalyzing the production of 3-HP from glycerol.
- the carbon source for a bio-production of 3-HP excludes glycerol as a major portion of the carbon source.
- WO 2002/042418 teaches several 3-HP production pathways. This PCT publication is incorporated by reference for its teachings of such pathways. Also, Figure 44 of that publication, which summarizes a 3-HP production pathway from glucose to pyruvate to acetyl-CoA to malonyl-CoA to 3-HP, is provided herein. Figure 55 of that publication, which summarizes a 3-HP production pathway from glucose to
- PEP phosphoenolpyruvate
- oxaloacetate directly or via pyruvate
- aspartate to ⁇ -alanine to malonate semialdehyde to 3-HP
- Representative enzymes for various conversions are also shown in these figures.
- FIG. 13 from U.S. Patent Publication No. US2008/0199926, published August 21, 2008 and incorporated by reference herein, summarizes the herein-described 3-HP production pathways and other known natural pathways. More generally as to developing specific metabolic pathways, of which many may be not found in nature, Hatzimanikatis et al. discuss this in "Exploring the diversity of complex metabolic networks," Bioinforrnatics 21(8): 1603- 1609 (2005). This article is incorporated by reference for its teachings of the complexity of metabolic networks.
- one production pathway of various embodiments of the present invention comprises malonyl-Co-A reductase enzymatic activity that achieves conversions of malonyl-CoA to malonate semialdehyde to 3-HP.
- introduction into a microorganism of a nucleic acid sequence encoding a polypeptide providing this enzyme (or enzymatic activity) is effective to provide increased 3-HP biosynthesis.
- FIG. 14B Another 3-HP production pathway is provided in FIG. 14B (FIG. 14A showing the natural mixed fermentation pathways) and explained in this and following paragraphs.
- This is a 3-HP production pathway that may be used with or independently of other 3-HP production pathways.
- One possible way to establish this biosynthetic pathway in a recombinant microorganism one or more nucleic acid sequences encoding an oxaloacetate alpha-decarboxylase (oad-2) enzyme (or respective or related enzyme having such activity) is introduced into a microorganism and expressed.
- oad-2 oxaloacetate alpha-decarboxylase
- enzyme evolution techniques are applied to enzymes having a desired catalytic role for a structurally similar substrate, so as to obtain an evolved (e.g., mutated) enzyme (and corresponding nucleic acid sequence(s) encoding it), that exhibits the desired catalytic reaction at a desired rate and specificity in a microorganism.
- a microorganism may comprise one or more gene deletions. For example, as summarized in Figure 14B for a particular embodiment in E.
- lactate dehydrogenase (ldhA), phosphate acetyltransferase (pta), pyruvate oxidase (poxB) and pyruvate-formate lyase (pflB) may be deleted.
- lactate dehydrogenase (ldhA)
- pta phosphate acetyltransferase
- poxB pyruvate oxidase
- pflB pyruvate-formate lyase
- Such gene deletions are summarized at the bottom of FIG. 14B for a particular embodiment, which is not meant to be limiting.
- a further deletion or other modification to reduce enzymatic activity of multifunctional 2-keto-3-deoxygluconate 6-phosphate aldolase and 2-keto-4- hydroxyglutarate aldolase and oxaloacetate decarboxylase (eda in E. coli) may be provided to various strains.
- phosphorylatable protein (ptsH (HPr) in E. coli), phosphoryl transfer protein (of PTS) (ptsl in E. coli), and the polypeptide chain of PTS (Crr in E. coli).
- Gene deletions may be accomplished by mutational gene deletion approaches, and/or starting with a mutant strain having reduced or no expression of one or more of these enzymes, and/or other methods known to those skilled in the art.
- aspects of the invention also regard provision of multiple genetic modifications to improve microorganism overall effectiveness in converting a selected carbon source into a chemical product such as 3- HP. Particular combinations are shown, such as in the Examples, to increase specific productivity, volumetric productivity, titer and yield substantially over more basic combinations of genetic modifications.
- FIG. 8 a genetically modified strain is depicted in FIG. 8.
- This strain comprises genetic modifications for 3 -HP production (such as described above in Section VII above), 3- HP tolerance (such as described below), and additional genetic modifications as disclosed herein (including a particular genetic modification regarding the fatty acid synthase system, not to be limiting, such modifications more generally disclosed elsewhere herein including in Section VI).
- enzyme functions are indicated by indicated enzymatic conversions and/or representative E. coli gene identifiers that encode proteins having such enzyme functions (except that mcr indicates non-E.
- coli malonyl-CoA reductase deletions are shown by the standard " ⁇ " before the respective gene identifier, and increased enzymatic activities are shown by underlining (noting that additional targets for modifications are as indicated in the embedded table of the figure).
- Genes in parentheses are possible substitutes for or supplements of an enzyme encoded by another gene also shown along the respective pathway step.
- the use of fabI TS represents a substitution for the native non-temperature-sensitive gene. This is not meant to be limiting; as described elsewhere there are a number of approaches to control and limit flux to fatty acyl-ACP.
- FIG. 8 depicts a number of genetic modifications in combination, however in various embodiments of the present invention other combinations of the genetic modifications of these enzymatic functions may be provided to achieve a desired level of increased rate, titer and yield as to bio- production of a chemical product.
- a deletion, of multifunctional 2-keto-3-deoxygluconate 6-phosphate aldolase and 2- keto-4-hydroxyglutarate aldolase and oxaloacetate decarboxylase may be provided to various strains.
- sucrose For example, the ability to utilize sucrose may be provided, and this would expand the range of feed stocks that can be utilized to produce 3 -HP or other chemical products.
- Common laboratory and industrial strains of E. coli, such as the strains described herein, are not capable of utilizing sucrose as the sole carbon source. Since sucrose, and sucrose-containing feed stocks such as molasses, are abundant and often used as feed stocks for the production by microbial fermentation, adding appropriate genetic modifications to permit uptake and use of sucrose may be practiced in strains having other features as provided herein.
- sucrose uptake and metabolism systems are known in the art (for example, U.S. Pat. No. 6,960,455), incorporated by reference for such teachings. These and other approaches may be provided in strains of the present invention.
- the examples provide at least two approaches.
- genetic modifications may be provided to add functionality for breakdown of more complex carbon sources, such as cellulosic biomass or products thereof, for uptake, and/or for utilization of such carbon sources.
- complex carbon sources such as cellulosic biomass or products thereof
- numerous cellulases and cellulase-based cellulose degradation systems have been studied and characterized (see, for example, and incorporated by reference herein for such teachings, Beguin, P and Aubert, J-P (1994) FEMS Microbial. Rev. 13: 25-58; Ohima, K. et al. (1997) Biotechnol. Genet. Eng. Rev. 14: 365414).
- genetic modifications also are provided to increase the pool and availability of the cofactor NADPH, and/or, consequently, the NADPH/NADP + ratio.
- this may be done by increasing activity, such as by genetic modification, of one or more of the following genes- pgi (in a mutated form), pntAB, overexpressed, gapA:gapN substitution/replacement, and disrupting or modifying a soluble transhydrogenase such as sthA, and/or genetic modifications of one or more of zwf, gnd, and edd.
- any subgroup of genetic modifications may be made to decrease cellular production of fermentation product(s) selected from the group consisting of acetate, acetoin, acetone, acrylic, malate, fatty acid ethyl esters, isoprenoids, glycerol, ethylene glycol, ethylene, propylene, butylene, isobutylene, ethyl acetate, vinyl acetate, other acetates, 1,4-butanediol, 2,3-butanediol, butanol, isobutanol, sec-butanol, butyrate, isobutyrate, 2-OH-isobutryate, 3-OH-butyrate, ethanol, isopropanol, D-lactate, L-lactate, pyruvate, itaconate, levulinate, glucarate, glutarate, caprolactam, a
- the 3-HP may be separated and purified by the approaches described in the following paragraphs, taking into account that many methods of separation and purification are known in the art and the following disclosure is not meant to be limiting.
- Osmotic shock, sonication, homogenization, and/or a repeated freeze -thaw cycle followed by filtration and/or centrifugation, among other methods, such as pH adjustment and heat treatment, may be used to produce a cell-free extract from intact cells. Any one or more of these methods also may be employed to release 3-HP from cells as an extraction step.
- a bio-production broth comprising 3-HP various methods may be practiced to remove biomass and/or separate 3-HP from the culture broth and its components.
- Methods to separate and/or concentrate the 3-HP include centrifugation, filtration, extraction, chemical conversion such as esterification, distillation (which may result in chemical conversion, such as dehydration to acrylic acid, under some reactive-distillation conditions), crystallization, chromatography, and ion-exchange, in various forms.
- cell rupture may be conducted as needed to release 3-HP from the cell mass, such as by sonication, homogenization, pH adjustment or heating.
- 3-HP may be further separated and/or purified by methods known in the art, including any combination of one or more of centrifugation, liquid-liquid separations, including extractions such as solvent extraction, reactive extraction, two-phase aqueous extraction and two- phase solvent extraction, membrane separation technologies, distillation, evaporation, ion-exchange chromatography, adsorption chromatography, reverse phase chromatography and crystallization. Any of the above methods may be applied to a portion of a bio-production broth (i.e., a fermentation broth, whether made under aerobic, anaerobic, or microaerobic conditions), such as may be removed from a bio-production event gradually or periodically, or to the broth at termination of a bio-production event. Conversion of 3 -HP to downstream products, such as described herein, may proceed after separation and purification, or, such as with distillation, thin-film evaporation, or wiped-film evaporation optionally also in part as a separation means.
- a bio-production broth i.
- a counter-current strategy or a sequential or iterative strategy, such as multi-pass extractions.
- a given aqueous solution comprising 3 -HP may be repeatedly extracted with a non-polar phase comprising an amine to achieve multiple reactive extractions.
- spent broth may transferred to a separate tank, or remain in the culture vessel, and in either case the temperature may be elevated to at least 60°C for a minimum of one hour in order to kill the microorganisms. (Alternatively, other approaches to killing the microorganisms may be practiced.)
- spent broth is meant the final liquid volume comprising the initial nutrient media, cells grown from the microorganism inoculum (and possibly including some original cells of the inoculum), 3 -HP, and optionally liquid additions made after providing the initial nutrient media, such as periodic additions to provide additional carbon source, etc.
- the spent broth may comprise organic acids other than 3-HP, such as for example acetic acid and/or lactic acid.
- a centrifugation step may then be practiced to filter out the biomass solids (e.g., microorganism cells). This may be achieved in a continuous or batch centrifuge, and solids removal may be at least about 80%, 85%, 90%, or 95% in a single pass, or cumulatively after two or more serial centrifugations.
- biomass solids e.g., microorganism cells
- An optional step is to polish the centrifuged liquid through a filter, such as microfiltration or ultrafiltration, or may comprise a filter press or other filter device to which is added a filter aid such as diatomaceous earth.
- a filter such as microfiltration or ultrafiltration
- Alternative or supplemental approaches to this and the centrifugation may include removal of cells by a flocculent, where the cells floe and are allowed to settle, and the liquid is drawn off or otherwise removed.
- a flocculent may be added to a fermentation broth after which settling of material is allowed for a time, and then separations may be applied, including but not limited to centrifugation.
- a spent broth comprising 3-HP and substantially free of solids is obtained for further processing.
- substantially free of solids is meant that greater than 98%, 99%, or 99.5% of the solids have been removed.
- this spent broth comprises various ions of salts, such as Na, CI, S0 4 , and P0 4 .
- these ions may be removed by passing this spent broth through ion exchange columns, or otherwise contacting the spent broth with appropriate ion exchange material.
- "contacting” is taken to mean a contacting for the stated purpose by any way known to persons skilled in the art, such as, for example, in a column, under appropriate conditions that are well within the ability of persons of ordinary skill in the relevant art to determine.
- these may comprise sequential contacting with anion and cation exchange materials (in any order), or with a mixed anion/cation material.
- This demineralization step should remove most such inorganic ions without removing the 3-HP. This may be achieved, for example, by lowering the pH sufficiently to protonate 3-HP and similar organic acids so that these acids are not bound to the anion exchange material, whereas anions, such as CI and SO 4 , that remain charged at such pH are removed from the solution by binding to the resin. Likewise, positively charged ions are removed by contacting with cation exchange material. Such removal of ions may be assessed by a decrease in conductivity of the solution. Such ion exchange materials may be regenerated by methods known to those skilled in the art.
- the spent broth (such as but not necessarily after the previous demineralization step) is subjected to a pH elevation, after which it is passed through an ion exchange column, or otherwise contacted with an ion exchange resin, that comprises anionic groups, such as amines, to which organic acids, ionic at this pH, associate.
- anionic groups such as amines
- Other organics that do not so associate with amines at this pH may be separated from the organic acids at this stage, such as by flushing with an elevated pH rinse. Thereafter elution with a lower pH and/or elevated salt content rinse may remove the organic acids. Eluting with a gradient of decreasing pH and/or increasing salt content rinses may allow more distinct separation of 3 -HP from other organic acids, thereafter simplifying further processing.
- a first alternative approach comprises reactive extraction (a form of liquid-liquid extraction) as exemplified in this and the following paragraphs.
- the spent broth which may be at a stage before or after the demineralization step above, is combined with a quantity of a tertiary amine such as Alamine336® (Cognis Corp., Cincinnati, OH USA) at low pH.
- a tertiary amine such as Alamine336® (Cognis Corp., Cincinnati, OH USA) at low pH.
- Co-solvents for the Alamine336 or other tertiary amine may be added and include, but are not limited to benzene, carbon tetrachloride, chloroform, cyclohexane, disobutyl ketone, ethanol, #2 fuel oil, isopropanol, kerosene, n-butanol, isobutanol, octanol, and n-decanol that increase the partition coefficient when combined with the amine.
- a period of time for phase separation transpires, after which the non-polar phase, which comprises 3 -HP associated with the Alamine336 or other tertiary amine, is separated from the aqueous phase.
- a distilling step may be used to remove the co-solvent, thereby leaving the 3-HP-tertiary amine complex in the non-polar phase.
- a stripping or recovery step may be used to separate the 3-HP from the tertiary amine.
- An inorganic salt such as ammonium sulfate, sodium chloride, or sodium carbonate, or a base such as sodium hydroxide or ammonium hydroxide, is added to the 3-HP/tertiary amine to reverse the amine protonation reaction, and a second phase is provided by addition of an aqueous solution (which may be the vehicle for provision of the inorganic salt).
- aqueous solution which may be the vehicle for provision of the inorganic salt.
- hot water may also be used without a salt or base to recover the 3HP from the amine.
- phase separation and extraction of 3-HP to the aqueous phase can serve to concentrate the 3-HP. It is noted that chromatographic separation of respective organic acids also can serve to concentrate such acids, such as 3-HP.
- suitable, non-polar amines which may include primary, secondary and quaternary amines, may be used instead of and/or in combination with a tertiary amine.
- a second alternative approach is crystallization. For example, the spent broth (such as free of biomass solids) may be contacted with a strong base such as ammonium hydroxide, which results in formation of an ammonium salt of 3-HP.
- ammonium-3-HP crystals may be concentrated, and then ammonium-3-HP crystals are formed and may be separated, such as by filtration, from the aqueous phase. Once collected, ammonium-3-HP crystals may be treated with an acid, such as sulfuric acid, so that ammonium sulfate is regenerated, so that 3-HP and ammonium sulfate result.
- an acid such as sulfuric acid
- aqueous two-phase extraction methods may be utilized to separate and/or concentrate a desired chemical product from a fermentation broth or later-obtained solution.
- polymers such as dextran and glycol polymers, such as polyethylene glycol (PEG) and polypropylene glycol (PPG)
- PEG polyethylene glycol
- PPG polypropylene glycol
- a desired chemical product may segregate to one phase while cells and other chemicals partition to the other phase, thus providing for a separation without use of organic solvents.
- solvent extraction is another alternative. This may use any of a number of and/or combinations of solvents, including alcohols, esters, ketones, and various organic solvents. Without being limiting, after phase separation a distillation step or a secondary extraction may be employed to separate 3-HP from the organic phase.
- 3-hydroxypropionic acid 3-HP
- This organic acid, 3-HP may be converted to various other products having industrial uses, such as but not limited to acrylic acid, esters of acrylic acid, and other chemicals obtained from 3-HP, referred to as "downstream products.”
- downstream products such as acrylic acid, esters of acrylic acid, and other chemicals obtained from 3-HP
- the 3-HP may be converted to acrylic acid, acrylamide, and/or other downstream chemical products, in some instances the conversion being associated with the separation and/or purification steps.
- Many conversions to such downstream products are described herein.
- the methods of the invention include steps to produce downstream products of 3-HP.
- 3-HP offers much potential in a variety of chemical conversions to commercially important intermediates, industrial end products, and consumer products.
- 3-HP may be converted to acrylic acid, acrylates (e.g., acrylic acid salts and esters), 1,3 -propanediol, malonic acid, ethyl-3-hydroxypropionate, ethyl ethoxy propionate, propiolactone, acrylamide, or acrylonitrile.
- methyl acrylate may be made from 3-HP via dehydration and esterification, the latter to add a methyl group (such as using methanol);
- acrylamide may be made from 3-HP via dehydration and amidation reactions;
- acrylonitrile may be made via a dehydration reaction and forming a nitrile moiety;
- propriolactone may be made from 3-HP via a ring-forming internal esterification reaction (eliminating a water molecule); ethyl-3-HP may be made from 3-HP via esterification with ethanol; malonic acid may be made from 3-HP via an oxidation reaction; and 1,3 -propanediol may be made from 3-HP via a reduction reaction.
- acrylic acid first converted from 3-HP by dehydration, may be esterified with appropriate compounds to form a number of commercially important acrylate -based esters, including but not limited to methyl acrylate, ethyl acrylate, methyl acrylate, 2-ethylhexyl acrylate, butyl acrylate, and lauryl acrylate.
- 3HP may be esterified to form an ester of 3HP and then dehydrated to form the acrylate ester.
- 3-HP may be oligomerized or polymerized to form poly(3-hydroxypropionate) homopolymers, or co-polymerized with one or more other monomers to form various co-polymers. Because 3- HP has only a single stereoisomer, polymerization of 3-HP is not complicated by the stereo-specificity of monomers during chain growth. This is in contrast to (S)-2-Hydroxypropanoic acid (also known as lactic acid), which has two (D, L) stereoisomers that must be considered during its polymerizations.
- 3-HP can be converted into derivatives starting (i) substantially as the protonated form of 3-hydroxypropionic acid; (ii) substantially as the deprotonated form, 3-hydroxypropionate; or (iii) as mixtures of the protonated and deprotonated forms.
- the fraction of 3-HP present as the acid versus the salt will depend on the pH, the presence of other ionic species in solution, temperature (which changes the equilibrium constant relating the acid and salt forms), and to some extent pressure.
- Many chemical conversions may be carried out from either of the 3-HP forms, and overall process economics will typically dictate the form of 3-HP for downstream conversion.
- 3-HP in an amine salt form such as in the extraction step herein disclosed using Alamine 336 as the amine
- a dehydration catalyst such as aluminum oxide
- an elevated temperature such as 170 to 180 C, or 180 to 190 C, or 190 to 200 C
- passing the collected vapor phase over a low temperature condenser operating conditions, including 3-HP concentration, organic amine, co-solvent (if any), temperature, flow rates, dehydration catalyst, and condenser temperature, are evaluated and improved for commercial purposes.
- Conversion of 3-HP to acrylic acid is expected to exceed at least 80 percent, or at least 90 percent, in a single conversion event.
- the amine may be re-used, optionally after clean-up.
- Other dehydration catalysts, as provided herein, may be evaluated.
- U.S. Patent No.7, 186,856 discloses data regarding this conversion approach, albeit as part of an extractive salt-splitting conversion that differs from the teachings herein.
- U.S. Patent No. 7, 186,856 is incorporated by reference for its methods, including extractive salt-splitting, the latter to further indicate the various ways 3 -HP may be extracted from a microbial fermentation broth.
- the methods of the present invention can also be used to produce "downstream" compounds derived from 3 -HP, such as polymerized-3-HP (poly-3-HP), acrylic acid, polyacrylic acid (polymerized acrylic acid, in various forms), methyl acrylate, acrylamide, acrylonitrile, propiolactone, ethyl 3 -HP, malonic acid, and 1,3 -propanediol.
- polymerized-3-HP poly-3-HP
- acrylic acid acrylic acid
- polyacrylic acid polymerized acrylic acid, in various forms
- methyl acrylate acrylamide
- acrylonitrile propiolactone
- ethyl 3 -HP acrylonitrile
- malonic acid 1,3 -propanediol.
- Numerous approaches may be employed for such downstream conversions, generally falling into enzymatic, catalytic (chemical conversion process using a catalyst), thermal, and combinations thereof (including some wherein a desired pressure is applied to accelerate a reaction).
- an important industrial chemical product that may be produced from 3-HP is acrylic acid.
- one of the carbon-carbon single bonds in 3-HP must undergo a dehydration reaction, converting to a carbon-carbon double bond and rejecting a water molecule.
- Dehydration of 3-HP in principle can be carried out in the liquid phase or in the gas phase. In some embodiments, the dehydration takes place in the presence of a suitable homogeneous or heterogeneous catalyst. Suitable dehydration catalysts are both acid and alkaline catalysts.
- an acrylic acid-containing phase is obtained and can be purified where appropriate by further purification steps, such as by distillation methods, extraction methods, or crystallization methods, or combinations thereof.
- Making acrylic acid from 3-HP via a dehydration reaction may be achieved by a number of commercial methodologies including via a distillation process, which may be part of the separation regime and which may include an acid and/or a metal ion as catalyst. More broadly, incorporated herein for its teachings of conversion of 3-HP, and other ⁇ -hydroxy carbonyl compounds, to acrylic acid and other related downstream compounds, is U.S. Patent Publication No. 2007/0219390 Al, published September 20, 2007, now abandoned. This publication lists numerous catalysts and provides examples of conversions, which are specifically incorporated herein. Also among the various specific methods to dehydrate 3-HP to produce acrylic acid is an older method, described in U.S. Patent No. 2,469,701 (Redmon).
- This reference teaches a method for the preparation of acrylic acid by heating 3-HP to a temperature between 130 and 190°C, in the presence of a dehydration catalyst, such as sulfuric acid or phosphoric acid, under reduced pressure.
- a dehydration catalyst such as sulfuric acid or phosphoric acid
- U.S. Patent Publication No. 2005/0222458 Al also provides a process for the preparation of acrylic acid by heating 3-HP or its derivatives. Vapor-phase dehydration of 3-HP occurs in the presence of dehydration catalysts, such as packed beds of silica, alumina, or titania.
- the dehydration catalyst may comprise one or more metal oxides, such as A1 2 0 3 , Si0 2 , or Ti0 2 .
- the dehydration catalyst is a high surface area ⁇ 1 2 (3 ⁇ 4 or a high surface area silica wherein the silica is substantially Si0 2 .
- High surface area for the purposes of the invention means a surface area of at least about 50, 75, 100 m 2 /g, or more.
- the dehydration catalyst may comprise an aluminosilicate, such as a zeolite.
- 3-HP may be dehydrated to acrylic acid via various specific methods, each often involving one or more dehydration catalysts.
- One catalyst of particular apparent value is titanium, such as in the form of titanium oxide, TiO(2).
- a titanium dioxide catalyst may be provided in a dehydration system that distills an aqueous solution comprising 3-HP, wherein the 3-HP dehydrates, such as upon volatilization, converting to acrylic acid, and the acrylic acid is collected by condensation from the vapor phase.
- an aqueous solution of 3-HP is passed through a reactor column packed with a titanium oxide catalyst maintained at a temperature between 170 and 190 C and at ambient atmospheric pressure. Vapors leaving the reactor column are passed over a low temperature condenser, where acrylic acid is collected.
- the low temperature condenser may be cooled to 30 C or less, 2 C or less, or at any suitable temperature for efficient condensation based on the flow rate and design of the system.
- the reactor column temperatures may be lower, for instance when operating at a pressure lower than ambient atmospheric pressure.
- catalysts including chemical classes
- Such catalysts may be used in any of solid, liquid or gaseous forms, may be used individually or in any combination. This listing of catalysts is not intended to be limiting, and many specific catalysts not listed may be used for specific dehydration reactions. Further without being limiting, catalyst selection may depend on the solution pH and/or the form of 3-HP in a particular conversion, so that an acidic catalyst may be used when 3-HP is in acidic form, and a basic catalyst may be used when the ammonium salt of 3-HP is being converted to acrylic acid. Also, some catalysts may be in the form of ion exchange resins.
- the dehydration of 3-HP may also take place in the absence of a dehydration catalyst.
- the reaction may be run in the vapor phase in the presence of a nominally inert packing such as glass, ceramic, a resin, porcelain, plastic, metallic or brick dust packing and still form acrylic acid in reasonable yields and purity.
- the catalyst particles can be sized and configured such that the chemistry is, in some embodiments, mass-transfer-limited or kinetically limited.
- the catalyst can take the form of powder, pellets, granules, beads, extrudates, and so on. When a catalyst support is optionally employed, the support may assume any physical form such as pellets, spheres, monolithic channels, etc.
- the supports may be co-precipitated with active metal species; or the support may be treated with the catalytic metal species and then used as is or formed into the aforementioned shapes; or the support may be formed into the aforementioned shapes and then treated with the catalytic species.
- a reactor for dehydration of 3-HP may be engineered and operated in a wide variety of ways.
- the reactor operation can be continuous, semi-continuous, or batch. It is perceived that an operation that is substantially continuous and at steady state is advantageous from operations and economics perspectives.
- the flow pattern can be substantially plug flow, substantially well-mixed, or a flow pattern between these extremes.
- a "reactor" can actually be a series or network of several reactors in various arrangements.
- acrylic acid may be made from 3-HP via a dehydration reaction, which may be achieved by a number of commercial methodologies including via a distillation process, which may be part of the separation regime and which may include an acid and/or a metal ion as catalyst. More broadly, incorporated herein for its teachings of conversion of 3-HP, and other ⁇ -hydroxy carbonyl compounds, to acrylic acid and other related downstream compounds, is U.S. Patent Publication No. 2007/0219390 Al, published September 20, 2007, now abandoned. This publication lists numerous catalysts and provides examples of conversions, which are specifically incorporated herein.
- 3-HP may be dehydrated to acrylic acid via various specific methods, each often involving one or more dehydration catalysts.
- One catalyst of particular apparent value is titanium, such as in the form of titanium oxide, T1O 2 .
- a titanium dioxide catalyst may be provided in a dehydration system that distills an aqueous solution comprising 3-HP, wherein the 3-HP dehydrates, such as upon volatilization, converting to acrylic acid, and the acrylic acid is collected by condensation from the vapor phase.
- an aqueous solution of 3-HP is passed through a reactor column packed with a titanium oxide catalyst maintained at a temperature between 170 and 190°C and at ambient atmospheric pressure. Vapors leaving the reactor column are passed over a low temperature condenser, where acrylic acid is collected.
- the low temperature condenser may be cooled to 30°C or less, 20°C or less, 2°C or less, or at any suitable temperature for efficient condensation based on the flow rate and design of the system.
- the reactor column temperatures may be lower, for instance when operating at a pressure lower than ambient atmospheric pressure. It is noted that Example 1 of U.S. Patent Publication No.
- Crystallization of the acrylic acid obtained by dehydration of 3-HP may be used as one of the final separation/purification steps.
- Various approaches to crystallization are known in the art, including crystallization of esters.
- a salt of 3-HP is converted to acrylic acid or an ester or salt thereof.
- U.S. Patent No. 7, 186,856 (Meng et al.) teaches a process for producing acrylic acid from the ammonium salt of 3 -HP, which involves a first step of heating the ammonium salt of 3 -HP in the presence of an organic amine or solvent that is immiscible with water, to form a two-phase solution and split the 3 -HP salt into its respective ionic constituents under conditions which transfer 3 -HP from the aqueous phase to the organic phase of the solution, leaving ammonia and ammonium cations in the aqueous phase.
- Methyl acrylate may be made from 3-HP via dehydration and esterification, the latter to add a methyl group (such as using methanol), acrylamide may be made from 3-HP via dehydration and amidation reactions, acrylonitrile may be made via a dehydration reaction and forming a nitrile moiety, propriolactone may be made from 3-HP via a ring-forming internal esterification reaction (eliminating a water molecule), ethyl-3-HP may be made from 3-HP via esterification with ethanol, malonic acid may be made from 3-HP via an oxidation reaction, and 1,3-propanediol may be made from 3-HP via a reduction reaction.
- a methyl group such as using methanol
- acrylamide may be made from 3-HP via dehydration and amidation reactions
- acrylonitrile may be made via a dehydration reaction and forming a nitrile moiety
- propriolactone may be made from 3-HP via a
- Malonic acid may be produced from oxidation of 3-HP as produced herein.
- U.S. Patent No. 5,817,870 discloses catalytic oxidation of 3-HP by a precious metal selected from Ru, Rh, Pd, Os, Ir or Pt. These can be pure metal catalysts or supported catalysts.
- the catalytic oxidation can be carried out using a suspension catalyst in a suspension reactor or using a fixed-bed catalyst in a fixed-bed reactor. If the catalyst, preferably a supported catalyst, is disposed in a fixed-bed reactor, the latter can be operated in a trickle-bed procedure as well as also in a liquid-phase procedure.
- the aqueous phase comprising the 3-HP starting material, as well as the oxidation products of the same and means for the adjustment of pH, and oxygen or an oxygen-containing gas can be conducted in parallel flow or counter- flow.
- the liquid phase and the gas phase are conveniently conducted in parallel flow.
- the conversion is carried out at a pH equal or greater than 6, preferably at least 7, and in particular between 7.5 and 9.
- the pH is kept constant, preferably at a pH in the range between 7.5 and 9, by adding a base, such as an alkaline or alkaline earth hydroxide solution.
- the oxidation is usefully carried out at a temperature of at least 10°C and maximally 70°C.
- the flow of oxygen is not limited. In the suspension method it is important that the liquid and the gaseous phase are brought into contact by stirring vigorously. Malonic acid can be obtained in nearly quantitative yields.
- U.S. Patent No. 5,817,870 is incorporated by reference herein for its methods to oxidize 3-HP to malonic acid.
- 1,3 -Propanediol may be produced from hydrogenation of 3-HP as produced herein.
- U.S. Patent Publication No. 2005/0283029 (Meng et al.) is incorporated by reference herein for its methods to
- catalysts include ruthenium metal, or compounds of ruthenium, supported or unsupported, alone or in combination with at least one or more additional metal(s) selected from molybdenum, tungsten, titanium, zirconium, niobium, vanadium or chromium.
- the ruthenium metal or compound thereof, and/or the additional metal(s), or compound thereof, may be utilized in supported or unsupported form. If utilized in supported form, the method of preparing the supported catalyst is not critical and can be any technique such as impregnation of the support or deposition on the support.
- Supports that may be used include, but are not limited to, alumina, titania, silica, zirconia, carbons, carbon blacks, graphites, silicates, zeolites, aluminosilicate zeolites, aluminosilicate clays, and the like.
- the hydrogenation process may be carried out in liquid phase.
- the liquid phase includes water, organic solvents that are not hydrogenatable, such as any aliphatic or aromatic hydrocarbon, alcohols, ethers, toluene, decalin, dioxane, diglyme, n-heptane, hexane, xylene, benzene, tetrahydrofuran, cyclohexane, methylcyclohexane, and the like, and mixtures of water and organic solvent(s).
- the hydrogenation process may be carried out batch wise, semi-continuously, or continuously.
- the hydrogenation process may be carried out in any suitable apparatus. Exemplary of such apparatus are stirred tank reactors, trickle-bed reactors, high pressure hydrogenation reactors, and the like.
- the hydrogenation process is generally carried out at a temperature ranging from about 20 to about 250°C, more particularly from about 100 to about 200°C. Further, the hydrogenation process is generally carried out in a pressure range of from about 20 psi to about 4000 psi.
- the hydrogen containing gas utilized in the hydrogenation process is, optionally, commercially pure hydrogen.
- the hydrogen containing gas is usable if nitrogen, gaseous hydrocarbons, or oxides of carbon, and similar materials, are present in the hydrogen containing gas.
- hydrogen from synthesis gas hydrogen and carbon monoxide
- synthesis gas such synthesis gas potentially further including carbon dioxide, water, and various impurities.
- 1,3 -propanediol can be created from either 3-HP-CoA or 3-HP via the use of polypeptides having enzymatic activity. These polypeptides can be used either in vitro or in vivo.
- polypeptides having oxidoreductase activity or reductase activity e.g., enzymes from the 1.1.1. -class of enzymes
- oxidoreductase activity or reductase activity e.g., enzymes from the 1.1.1. -class of enzymes
- a combination of a polypeptide having aldyhyde dehydrogenase activity e.g., an enzyme from the 1.1.1.34 class
- a polypeptide having alcohol dehydrogenase activity e.g., an enzyme from the 1.1.1.32 class
- Another downstream production of 3-HP, acrylonitrile may be converted from acrylic acid by various organic syntheses, including by not limited to the Sohio acrylonitrile process, a single-step method of production known in the chemical manufacturing industry
- addition reactions may yield acrylic acid or acrylate derivatives having alkyl or aryl groups at the carbonyl hydroxyl group.
- Such additions may be catalyzed chemically, such as by hydrogen, hydrogen halides, hydrogen cyanide, or Michael additions under alkaline conditions optionally in the presence of basic catalysts.
- Alcohols, phenols, hydrogen sulfide, and thiols are known to add under basic conditions.
- Aromatic amines or amides, and aromatic hydrocarbons may be added under acidic conditions.
- Acrylic acid obtained from 3-HP made by the present invention may be further converted to various chemicals, including polymers, which are also considered downstream products in some embodiments.
- Acrylic acid esters may be formed from acrylic acid (or directly from 3-HP) such as by condensation esterification reactions with an alcohol, releasing water. This chemistry described in Monomeric Acrylic Esters, E. H.
- esters that are formed are methyl acrylate, ethyl acrylate, n-butyl acrylate, hydroxypropyl acrylate, hydroxyethyl acrylate, isobutyl acrylate, and 2-ethylhexyl acrylate, and these and/or other acrylic acid and/or other acrylate esters may be combined, including with other compounds, to form various known acrylic acid-based polymers.
- acrylamide is produced in chemical syntheses by hydration of acrylonitrile, herein a conversion may convert acrylic acid to acrylamide by amidation.
- Acrylic acid obtained from 3 -HP made by the present invention may be further converted to various chemicals, including polymers, which are also considered downstream products in some embodiments.
- Acrylic acid esters may be formed from acrylic acid (or directly from 3 -HP) such as by condensation esterification reactions with an alcohol, releasing water. This chemistry is described in Monomeric Acrylic Esters, E. H. Riddle, Reinhold, NY (1954), incorporated by reference for its esterification teachings.
- esters that are formed are methyl acrylate, ethyl acrylate, n-butyl acrylate, hydroxypropyl acrylate, hydroxyethyl acrylate, isobutyl acrylate, and 2-ethylhexyl acrylate, and these and/or other acrylic acid and/or other acrylate esters may be combined, including with other compounds, to form various known acrylic acid-based polymers.
- acrylamide is produced in chemical syntheses by hydration of acrylonitrile, herein a conversion may convert acrylic acid to acrylamide by amidation.
- Direct esterification of acrylic acid can take place by esterification methods known to the person skilled in the art, by contacting the acrylic acid obtained from 3 -HP dehydration with one or more alcohols, such as methanol, ethanol, 1-propanol, 2-propanol, n-butanol, tert-butanol or isobutanol, and heating to a temperature of at least 50, 75, 100, 125, or 150°C.
- the water formed during esterification may be removed from the reaction mixture, such as by azeotropic distillation through the addition of suitable separation aids, or by another means of separation. Conversions up to 95%, or more, may be realized, as is known in the art.
- esterification catalysts are commercially available, such as from Dow Chemical (Midland, Michigan US).
- AmberlystTM 131Wet Monodisperse gel catalyst confers enhanced hydraulic and reactivity properties and is suitable for fixed bed reactors.
- AmberlystTM 39Wet is a
- AmberlystTM 46 is a macroporous catalyst producing less ether byproducts than conventional catalyst (as described in U.S. Patent No. 5,426,199 to Rohm and Haas, which patent is incorporated by reference for its teachings of esterification catalyst compositions and selection considerations).
- Acrylic acid, and any of its esters, may be further converted into various polymers.
- Polymerization may proceed by any of heat, light, other radiation of sufficient energy, and free radical generating compounds, such as azo compounds or peroxides, to produce a desired polymer of acrylic acid or acrylic acid esters.
- free radical generating compounds such as azo compounds or peroxides
- Many other methods of polymerization are known in the art. Some are described in Ulmann's Encyclopedia of Industrial Chemistry, Polyacrylamides and Poly(Acrylic Acids), WileyVCH Verlag GmbH, Wienham (2005), incorporated by reference for its teachings of polymerization reactions.
- the free -radical polymerization of acrylic acid takes place by polymerization methods known to the skilled worker and can be carried out either in an emulsion or suspension in aqueous solution or another solvent.
- Initiators such as but not limited to organic peroxides, often are added to aid in the polymerization.
- organic peroxides that may be used as initiators are diacyls, peroxydicarbonates, monoperoxycarbonates, peroxyketals, peroxyesters, dialkyls, and hydroperoxides.
- Another class of initiators is azo initiators, which may be used for acrylate polyermization as well as co-polymerization with other monomers.
- 5,470,928; 5,510,307; 6,709,919; and 7,678,869 teach various approaches to polymerization using a number of initiators, including organic peroxides, azo compounds, and other chemical types, and are incorporated by reference for such teachings as applicable to the polymers described herein.
- co-monomers such as crosslinkers
- co-monomers such as crosslinkers
- the free -radical polymerization of the acrylic acid obtained from dehydration of 3 -HP, as produced herein, in at least partly neutralized form and in the presence of crosslinkers is practiced in certain embodiments.
- This polymerization may result in hydrogels which can then be comminuted, ground and, where appropriate, surface-modified, by known techniques.
- Superabsorbent polymers are primarily used as absorbents for water and aqueous solutions for diapers, adult incontinence products, feminine hygiene products, and similar consumer products. In such consumer products, superabsorbent materials can replace traditional absorbent materials such as cloth, cotton, paper wadding, and cellulose fiber. Superabsorbent polymers absorb, and retain under a slight mechanical pressure, up to 25 times or their weight in liquid.
- Superabsorbent polymer particles can be surface-modified to produce a shell structure with the shell being more highly crosslinked. This technique improves the balance of absorption, absorption under load, and resistance to gel-blocking. It is recognized that superabsorbent polymers have uses in fields other than consumer products, including agriculture, horticulture, and medicine.
- Superabsorbent polymers are prepared from acrylic acid (such as acrylic acid derived from 3-HP provided herein) and a crosslinker, by solution or suspension polymerization.
- acrylic acid such as acrylic acid derived from 3-HP provided herein
- a crosslinker by solution or suspension polymerization.
- Exemplary methods include U.S. Patent Nos. 5, 145,906; 5,350,799; 5,342,899; 4,857,610; 4,985,518; 4,708, 997; 5,180,798; 4,666,983;
- a diaper, a feminine hygiene product, and an adult incontinence product are made with superabsorbent polymer that itself is made substantially from acrylic acid converted from 3-HP made in accordance with the present invention.
- Diapers and other personal hygiene products may be produced that incorporate superabsorbent polymer made from acrylic acid made from 3-HP which is bio-produced by the teachings of the present application.
- the following provides general guidance for making a diaper that incorporates such superabsorbent polymer.
- the superabsorbent polymer first is prepared into an absorbent pad that may be vacuum formed, and in which other materials, such as a fibrous material (e.g., wood pulp) are added.
- the absorbent pad then is assembled with sheet(s) of fabric, generally a nonwoven fabric (e.g., made from one or more of nylon, polyester, polyethylene, and polypropylene plastics) to form diapers.
- a nonwoven fabric e.g., made from one or more of nylon, polyester, polyethylene, and polypropylene plastics
- a conveyer belt above a conveyer belt multiple pressurized nozzles spray superabsorbent polymer particles (such as about 400 micron size or larger), fibrous material, and/or a combination of these onto the conveyer belt at designated spaces/intervals.
- the conveyor belt is perforated and under vacuum from below, so that the sprayed on materials are pulled toward the belt surface to form a flat pad.
- fibrous material is applied first on the belt, followed by a mixture of fibrous material and the superabsorbent polymer particles, followed by fibrous material, so that the superabsorbent polymer is concentrated in the middle of the pad.
- a leveling roller may be used toward the end of the belt path to yield pads of uniform thickness.
- Each pad thereafter may be further processed, such as to cut it to a proper shape for the diaper, or the pad may be in the form of a long roll sufficient for multiple diapers. Thereafter, the pad is sandwiched between a top sheet and a bottom sheet of fabric (one generally being liquid pervious, the other liquid impervious), such as on a conveyor belt, and these are attached together such as by gluing, heating or ultrasonic welding, and cut into diaper-sized units (if not previously so cut). Additional features may be provided, such as elastic components, strips of tape, etc., for fit and ease of wearing by a person.
- the ratio of the fibrous material to polymer particles is known to effect performance characteristics. In some embodiments, this ratio is between 75:25 and 90: 10 (see U.S. Patent No. 4,685,915, incorporated by reference for its teachings of diaper manufacture).
- Other disposable absorbent articles may be constructed in a similar fashion, such as for adult incontinence, feminine hygiene (sanitary napkins), tampons, etc. (see, for example, U.S. Patent Nos. 5,009,653, 5,558,656, and 5,827,255 incorporated by reference for their teachings of sanitary napkin manufacture).
- Low molecular-weight polyacrylic acid has uses for water treatment, flocculants, and thickeners for various applications including cosmetics and pharmaceutical preparations.
- the polymer may be uncrosslinked or lightly crosslinked, depending on the specific application.
- the molecular weights are typically from about 200 to about 1,000,000 g/mol.
- Preparation of these low molecular-weight polyacrylic acid polymers is described in U.S. Patent Nos. 3,904,685; 4,301,266; 2,798,053; and 5,093,472, each of which is incorporated by reference for its teachings relating to methods to produce these polymers.
- Acrylic acid may be co-polymerized with one or more other monomers selected from acrylamide, 2- acrylamido-2-methylpropanesulfonic acid, ⁇ -dimethylacrylamide, AMsopropylacrylamide, methacrylic acid, and methacrylamide, to name a few.
- the relative reactivities of the monomers affect the microstructure and thus the physical properties of the polymer.
- Co-monomers may be derived from 3 -HP, or otherwise provided, to produce co-polymers. Ulmann's Encyclopedia of Industrial Chemistry, Polyacrylamides and Poly( Acrylic Acids), WileyVCH Verlag GmbH, Wienham (2005), is incorporated by reference herein for its teachings of polymer and co-polymer processing.
- Acrylic acid can in principle be copolymerized with almost any free -radically polymerizable monomers including styrene, butadiene, acrylonitrile, acrylic esters, maleic acid, maleic anhydride, vinyl chloride, acrylamide, itaconic acid, and so on. End-use applications typically dictate the co-polymer composition, which influences properties. Acrylic acid also may have a number of optional substitutions on it, and after such substitutions be used as a monomer for polymerization, or co-polymerization reactions.
- acrylic acid may be substituted by any substituent that does not interfere with the polymerization process, such as alkyl, alkoxy, aryl, heteroaryl, benzyl, vinyl, allyl, hydroxy, epoxy, amide, ethers, esters, ketones, maleimides, succinimides, sulfoxides, glycidyl and silyl (see U.S. Patent No. 7,678,869, incorporated by reference above, for further discussion).
- substituent such as alkyl, alkoxy, aryl, heteroaryl, benzyl, vinyl, allyl, hydroxy, epoxy, amide, ethers, esters, ketones, maleimides, succinimides, sulfoxides, glycidyl and silyl.
- Paints that comprise polymers and copolymers of acrylic acid and its esters are in wide use as industrial and consumer products. Aspects of the technology for making such paints can be found in U.S. Patent Nos. 3,687,885 and 3,891,591, incorporated by reference for its teachings of such paint manufacture.
- acrylic acid and its esters may form homopolymers or copolymers among themselves or with other monomers, such as amides, methacrylates, acrylonitrile, vinyl, styrene and butadiene.
- a desired mixture of homopolymers and/or copolymers referred to in the paint industry as 'vehicle' (or 'binder') are added to an aqueous solution and agitated sufficiently to form an aqueous dispersion that includes sub-micrometer sized polymer particles.
- the paint cures by coalescence of these 'vehicle' particles as the water and any other solvent evaporate.
- Other additives to the aqueous dispersion may include pigment, filler (e.g., calcium carbonate, aluminum silicate), solvent (e.g., acetone, benzol, alcohols, etc., although these are not found in certain no VOC paints), thickener, and additional additives depending on the conditions, applications, intended surfaces, etc.
- the weight percent of the vehicle portion may range from about nine to about 26 percent, but for other paints the weight percent may vary beyond this range.
- Acrylic -based polymers are used for many coatings in addition to paints.
- acrylic acid is used from 0.1-5.0%, along with styrene and butadiene, to enhance binding to the paper and modify rheology, freeze-thaw stability and shear stability.
- U.S. Patent Nos. 3,875,101 and 3,872,037 are incorporated by reference for their teachings regarding such latexes.
- Acrylate-based polymers also are used in many inks, particularly UV curable printing inks. For water treatment, acrylamide and/or hydroxy ethyl acrylate are commonly co-polymerized with acrylic acid to produce low molecular-weight linear polymers.
- 3- HP may be converted to 3-HP-CoA, which then may be converted into polymerized 3-HP with an enzyme having polyhydroxyacid synthase activity (EC 2.3.1.-).
- 1,3 -propanediol can be made using polypeptides having oxidoreductase activity or reductase activity (e.g. , enzymes in the EC 1.1.1.- class of enzymes).
- a combination of (1) a polypeptide having aldehyde dehydrogenase activity (e.g., an enzyme from the 1.1.1.34 class) and (2) a polypeptide having alcohol dehydrogenase activity (e.g., an enzyme from the 1.1.1.32 class) can be used.
- Polypeptides having lipase activity may be used to form esters. Enzymatic reactions such as these may be conducted in vitro, such as using cell-free extracts, or in vivo.
- various embodiments of the present invention include conversion steps to any such noted downstream products of microbially produced 3-HP, including but not limited to those chemicals described herein and in the incorporated references (the latter for jurisdictions allowing this).
- one embodiment is making 3-HP molecules by the teachings herein and further converting the 3-HP molecules to polymerized-3-HP (poly-3-HP) or acrylic acid, and such as from acrylic acid then producing from the 3-HP molecules any one of polyacrylic acid (polymerized acrylic acid, in various forms), methyl acrylate, acrylamide, acrylonitrile, propiolactone, ethyl 3 -HP, malonic acid, 1,3 -propanediol, ethyl acrylate, n-butyl acrylate, hydroxypropyl acrylate, hydroxyethyl acrylate, isobutyl acrylate, 2-ethylhexyl acrylate, and acrylic acid or an acrylic acid ester to which an alkyl or aryl addition is made, and/or to which halogens, aromatic amines or amides, and aromatic hydrocarbons are added.
- polyacrylic acid polymerized acrylic acid, in various forms
- methyl acrylate acrylamide
- 3- HP may be converted to 3-HP-CoA, which then may be converted into polymerized 3-HP with an enzyme having polyhydroxyacid synthase activity (EC 2.3.1.-).
- 1,3 -propanediol can be made using polypeptides having oxidoreductase activity or reductase activity (e.g. , enzymes in the EC 1.1.1.- class of enzymes).
- a combination of (1) a polypeptide having aldehyde dehydrogenase activity (e.g., an enzyme from the 1.1.1.34 class) and (2) a polypeptide having alcohol dehydrogenase activity (e.g., an enzyme from the 1.1.1.32 class) can be used.
- Polypeptides having lipase activity may be used to form esters. Enzymatic reactions such as these may be conducted in vitro, such as using cell-free extracts, or in vivo.
- various embodiments of the present invention include conversion steps to any such noted downstream products of microbially produced 3-HP, including but not limited to those chemicals described herein and in the incorporated references (the latter for jurisdictions allowing this).
- one embodiment is making 3-HP molecules by the teachings herein and further converting the 3-HP molecules to polymerized-3-HP (poly-3-HP) or acrylic acid, and such as from acrylic acid then producing from the 3-HP molecules any one of polyacrylic acid (polymerized acrylic acid, in various forms), methyl acrylate, acrylamide, acrylonitrile, propiolactone, ethyl 3-HP, malonic acid, 1,3 -propanediol, ethyl acrylate, n-butyl acrylate, hydroxypropyl acrylate, hydroxyethyl acrylate, isobutyl acrylate, 2-ethylhexyl acrylate, and acrylic acid or an acrylic acid ester to which an alkyl or aryl addition is made, and/or to which halogens, aromatic amines or amides, and aromatic hydrocarbons are added.
- polyacrylic acid polymerized acrylic acid, in various forms
- methyl acrylate acrylamide
- Stabilizing agents and/or inhibiting agents include, but are not limited to, e.g., phenolic compounds (e.g., dimethoxyphenol (DMP) or alkylated phenolic compounds such as di-tert-butyl phenol), quinones (e.g., t-butyl hydroquinone or the monomethyl ether of hydroquinone (MEHQ)), and/or metallic copper or copper salts (e.g., copper sulfate, copper chloride, or copper acetate).
- DMP dimethoxyphenol
- MEHQ monomethyl ether of hydroquinone
- metallic copper or copper salts e.g., copper sulfate, copper chloride, or copper acetate.
- Inhibitors and/or stabilizers can be used individually or in combinations as will be known by those of skill in the art.
- the one or more downstream compounds is/are recovered at a molar yield of up to about 100 percent, or a molar yield in the range from about 70 percent to about 90 percent, or a molar yield in the range from about 80 percent to about 100 percent, or a molar yield in the range from about 90 percent to about 100 percent.
- Such yields may be the result of single -pass (batch or continuous) or iterative separation and purification steps in a particular process.
- Acrylic acid and other downstream products are useful as commodities in manufacturing, such as in the manufacture of consumer goods, including diapers, textiles, carpets, paint, adhesives, and acrylic glass.
- a microorganism cell comprises a metabolic pathway from malonyl-CoA to a selected chemical product, such as 3 -HP as particularly described herein, and means for modulating conversion of malonyl-CoA to fatty acyl-ACP molecules (which thereafter may be converted to fatty acids) also are provided. Then, when the means for modulating modulate to decrease such conversion, a proportionally greater number of malonyl-CoA molecules are 1) produced and/or 2) converted via the metabolic pathway from malonyl-CoA to the selected chemical product.
- a metabolic pathway from malonyl-CoA to 3 -HP is disclosed herein and is not meant to be limiting.
- Other pathways to 3 -HP are known in the art and may be utilized to produce 3 -HP, including in combination with any combination of tolerance genetic modifications, as described herein.
- addition of such genetic modifications related to the 3HPTGC unexpectedly increase specific productivity at 3- HP levels below toxic levels.
- Any production pathway that produces 3 -HP may be combined with genetic modifications of the 3-HPTGC and achieve the specific and/or volumetric productivity metrics disclosed herein.
- genetic recombination techniques may be used to provide into a selected microorganism cell the polynucleotides that encode various polynucleotides that catalyze conversions along a respective metabolic pathway.
- Particular methods of genetic recombination are disclosed herein, and general references teaching such methods also are known to those skilled in the art and also referred to herein, so that one skilled in the art of genetic engineering reasonably may construct such microorganism cell based on these teachings.
- a wild-type microorganism cell comprising such metabolic pathway may be utilized as a starting cell for use in the present invention, such as for genetic modification and/or the methods and systems disclosed and claimed herein.
- temperature is in degrees Celsius and pressure is at or near atmospheric pressure at approximately 5,340 feet (1,628 meters) above sea level. It is noted that work done at external analytical and synthetic facilities is not conducted at or near atmospheric pressure at approximately 5,340 feet (1,628 meters) above sea level. Examples 11A and 11C were conducted at a contract laboratory, not at the indicated elevation. All reagents, unless otherwise indicated, are obtained commercially. Species and other phylogenic identifications are according to the classification known to a person skilled in the art of microbiology.
- the names and city addresses of major suppliers are provided herein.
- the DNeasy® Blood and Tissue Kit Cat. No. 69506, is used in the methods for genomic DNA preparation; the QIAprep® Spin ("mini prep"), Cat. No. 27106, is used for plasmid DNA purification, and the QIAquick® Gel Extraction Kit, Cat. No. 28706, is used for gel extractions as described herein.
- Example 1 Construction of plasmids expressing malonyl-CoA reductase (mcr)
- the nucleotide sequence for the malonyl-CoA reductase gene from Chloroflexus aurantiacus was codon-optimized for E. coli according to a service from DNA2.0 (Menlo Park, CA USA), a commercial DNA gene synthesis provider.
- This gene sequence (SEQ ID NO:803) incorporated an EcoRl restriction site before the start codon and was followed by a Hindlll restriction site. In addition, a ribosomal binding site was placed in front of the start codon.
- This gene construct was synthesized by DNA2.0 and provided in a pJ206 vector backbone (SEQ ID NO:804).
- Plasmid DNA pJ206 containing the synthesized mcr gene was subjected to enzymatic restriction digestion with the enzymes EcoRl and Hindlll obtained from New England BioLabs (Ipswich, MA USA) according to manufacturer's instructions. The digestion mixture was separated by agarose gel electrophoresis and the appropriate DNA fragment recovered as described in the Common Methods Section. An E. coli cloning strain bearing pKK223-aroH was obtained as a kind gift from the laboratory of Prof. Ryan T.
- Plasmid DNA was digested with the restriction endonucleases EcoRI and Hindlll obtained from New England Biolabs (Ipswich, MA USA) according to manufacturer's instructions. This digestion served to separate the aroH reading frame from the pKK223 backbone. The digestion mixture was separated by agarose gel electrophoresis, and he agarose gel slice containing the DNA piece corresponding to the backbone of the pKK223 plasmid was recovered as described in the Common Methods Section.
- pKK223-mcr confers resistance to ampicillin and contains the mcr gene of C. aurantiacus under control of a P tac promoter inducible in E. coli hosts by IPTG.
- the inducer-independent P ta i A promoter is based on sequences upstream of the E. coli talA gene.
- the nucleotide sequence of this promoter, placed immediately upstream of the initiator ATG codon of the synthetic mcr gene, is listed as SEQ ID NO: 805.
- the P ta i A :mcr construct was incorporated by PCR into a pSC-B vector (Stratagene Corporation ,La Jolla, CA, USA), which was propagated in an E. coli stock, the plasmid DNA purified according to methods described elsewhere herein.
- the P ⁇ mcr region in pSC-B-P ta iA:mcr was transferred to a plasmid vector, pSMART-HCamp (Lucigen Corporation, Middleton, WI, catalog number 40041-2, GenBank AF399742) by PCR using vector primers, M13F and M13R.
- the fragment generated by PCR was cloned into pSMART- HCamp according to the manufacturer's protocol resulting in plasmid pSMART(HC)Amp-P ta iA-mcr (SEQ ID NO: 806) in which mcr expression does not require induction with IPTG.
- Example 2 Construction of a plasmid expressing transhydrogenase (pntAB)
- a fusion of the inducer-independent E. coli promoter derived from the tpiA gene (PtpiA) an d the pyridine nucleotide transhydrogenase genes, pntAB, (SEQ ID NO:779 and SEQ ID NO:781) was created by amplifying the tpiA promoter region and pntAB region from genomic E. coli K12 DNA by polymerase chain reactions.
- the region was amplified using the pntAB forward primer
- GGGAACCATGGCAATTGGCATACCAAG (SEQ ID NO: 807, noting that all primers disclosed herein are artificial sequences) containing a Ncol site that incorporates the initiator Met for the protein sequence of pntA and the pntAB reverse primer GGGTTACAGAGCTTTCAGGATTGCATCC (SEQ ID NO: 808).
- the P tp iA region was amplified using the forward primer GGGAACGGCGGGGAAAAACAAACGTT (SEQ ID NO: 809) and the reverse primer GGTCCATGGTAATTCTCCACGCTTATAAGC (SEQ ID NO: 810) containing a Ncol restriction site.
- Polymerase chain reaction products were purified using a PCR purification kit from Qiagen Corporation (Valencia, CA, USA) using the manufacturer's instructions. Following purification, the products were subjected to enzymatic restriction digestion with the enzyme Ncol. Restriction enzymes were obtained from New England BioLabs (Ipswich, MA USA), and used according to manufacturer's instructions. The digestion mixtures were separated by agarose gel electrophoresis, and visualized under UV transillumination as described in the Common Methods Section. Agarose gel slices containing the DNA fragment corresponding to the amplified pntAB gene product and the P tpiA product were excised from the gel and the DNA recovered with a gel extraction kit from Qiagen used according to manufacturer's instructions. The recovered products were ligated together with T4 DNA ligase (New England BioLabs, Ipswich, MA USA) according to manufacturer's instructions.
- T4 DNA ligase New England BioLabs, Ipswich, MA USA
- the desired product corresponding to the Ppi A fragment ligated to the pntAB genes was amplified by polymerase chain reaction and isolated by a second gel purification.
- the forward primer was
- GGGTTACAGAGCTTTCAGGATTGCATCC (SEQ ID NO: 808), and the ligation mixture was used as template.
- the digestion mixtures were separated by agarose gel electrophoresis, and visualized under UV transillumination as described the Common Methods Section.
- Agarose gel slices containing the DNA piece corresponding to the amplified P tp i A -pntAB fusion was cut from the gel and the DNA recovered with a standard gel extraction protocol and components from Qiagen according to manufacturer's instructions. This extracted DNA was inserted into a pSC-B vector using the Blunt PCR Cloning kit obtained from Stratagene Corporation (La Jolla, CA, USA) using the manufacturer's instructions.
- Colonies were screened by colony polymerase chain reactions. Plasmid DNA from colonies showing inserts of correct size were cultured and miniprepped using a standard miniprep protocol and components from Qiagen according to the manufacturer's instruction. Isolated plasmids were checked by restriction digests and confirmed by sequencing. The sequenced-verified isolated plasmids produced with this procedure were designated pSC-B-P tp ⁇ pntAB.
- the P tp i A :pntAB region in pSC-B-P tp ⁇ pntAB was transferred to a pBT-3 vector (SEQ ID NO: 811) which provides a broad host range origin of replication and a chloramphenicol selection marker.
- a fragment from pBT-3 vector was produced by polymerase chain amplification using the forward primer AACGAATTCAAGCTTGATATC (SEQ ID NO: 812), and the reverse primer
- GAATTCGTTGACGAATTCTCT (SEQ ID NO:813), using pBT-3 as template.
- the amplified product was subjected to treatment with Dpnl to restrict the methylated template DNA, and the mixture was separated by agarose gel electrophoresis, and visualized under UV transillumination as described in the Common Methods Section.
- the agarose gel slice containing the DNA fragment corresponding to amplified pBT-3 vector product was cut from the gel and the DNA recovered with a standard gel extraction protocol and components from Qiagen according to manufacturer's instructions.
- the P tp iA:pntAB insert in pSC-B-P tp i ⁇ pntAB was amplified using a polymerase chain reaction with the forward primer GGAAACAGCTATGACCATGATTAC (SEQ ID NO:814) and the reverse primer TTGTAAAACGACGGCCAGTGAGCGCG (SEQ ID NO:815. Both primers were 5' phosphorylated.
- Plasmid DNA from colonies showing inserts of correct size were cultured and purified using a standard miniprep protocol and components from Qiagen according to the manufacturer's instruction. Isolated plasmids were checked by restriction digests and confirmed by sequencing. The sequenced-verified isolated plasmid produced with this procedure was designated pBT-S-P tp i A ipntAB (SEQ ID NO:816).
- Example 3 Construction of a plasmid expressing acetyl-CoA carboxylase (accABCD)
- a plasmid carrying two operons able to express the components the acetyl-CoA carboxyltransferase complex from E. coli was constructed by DNA2.0 (Menlo Park, CA USA), a commercial DNA gene synthesis provider. This construct incorporated the DNA sequences of the accA and accD genes under control of an inducer-independent promoter derived from the E. coli tpiA gene, and the DNA sequences of.the accB and accC genes under control of an inducer-independent promoter derived from the E. coli rpiA genes. Each coding sequence was preceded by a ribosome -binding sequence. The designed operons were provided in a pJ251 vector backbone and was designated pJ251 :26385 (SEQ ID NO:817).
- the tpiA promoter of the pJ251 :26385 plasmid was altered to provide better expression. This modification was incorporated by amplifying the pJ251 :26385 plasmid with the forward primer
- GCTTATAAGCGAATAAAGGAAGATGGCCGCCCCGCAGGGCAG SEQ ID NO:819.
- Each of these primers were synthesized with a 5' phosphorylation modification.
- the resulting PCR product was separated by agarose gel electrophoresis, and the appropriate DNA fragment recovered as described in the Common Methods Section.
- the recovered product was self-ligated with T4 DNA ligase obtained from New England BioLabs (Ipswich, MA USA) and digested with Dpnl according to manufacturer's instructions. Plasmid DNA from colonies showing inserts of correct size were cultured and purified using a standard miniprep protocol and components from Qiagen according to the manufacturer's instruction.
- Isolated plasmids were checked by restrictions digests and confirmed by sequencing.
- the sequenced-verified isolated plasmids produced with this procedure were designated pJ251(26385)-P tpiA :accAD-P rpiA :accBC (SEQ ID NO:820).
- Example 4 Construction of plasmids expressing genes related to the 3-HP toleragenic complex
- Example 5 Construction of specific strains that produce 3-hydroxypropionic acid
- the plasmids described herein were introduced into the respective base strains. All plasmids were introduced at the same time via electroporation using standard methods. Transformed cells were grown on the appropriate media with antibiotic supplementation and colonies were selected based on their appropriate growth on the selective media.
- the mcr expression plasmid pKK223-mcr was transformed into E. coli DF40 (Hfr, garBlO, fhuA22, ompF627, fadL701, relAl, pitAlO, spoTl, rrnB-2, pgi-2, mcrBl, creC527) or E.
- strains DF40 and JP1111 are generally available E. coli strains, available from sources including the Yale Coli Genetic Stock Collection (New Haven, CT USA). Strains carrying multiple compatible plasmids were constructed from these mcr transformants by preparing cells competent for transformation by electroporation as described in the Common Methods Section and transforming with the additional plasmids. Transformants were subsequently selected for on media containing the appropriate combination of antibiotics.
- Example 7 Effect on 3-HP production of increased malonyl-CoA precursor pools by inhibition of fatty acid synthesis
- Example 8 Effect on 3-HP production of increased malonyl-CoA precursor pools using temperature-sensitive fatty acid synthesis mutants
- a temperature-sensitive mutation in the fabl gene, encoding enoyl-ACP reductase, of strain JP1111 has relatively normal activity at reduced temperature, such as 30C, and becomes non-permissive, likely through denaturation and inactivation, at elevated temperature, such that when cultured at 37 to 42C a microorganism only comprising this temperature-sensitive mutant as its enoyl-ACP reductase will produce substantially less fatty acids and phospholipids. This leads to decreased or no growth.
- Table 13 shows the 3-HP production by strain JX3_0087 which carried a plasmid overexpressing the transhydrogenase gene in addition to a plasmid carrying the mcr gene.
- a specific productivity of 0.085 g 3-HP per gDCW in 24 h was attained. This is significantly higher than the specific productivity of JX3_0077 which does not carry the overexpressed transhydrogenase gene (Table 7).
- the specific productivity of the temperature-shifted culture of JX3_0087 was 1.68 g 3-HP per gDCW, a 20-fold increase over the specific productivity of the culture maintained constantly at 30°C in which the enoyl-ACP reductase was not inactivated.
- Table 14 shows the 3-HP production by strain JX3_0097 which carried a plasmid overexpressing genes encoding the acetyl-CoA carboxylase complex in addition to a plasmid carrying the mcr gene.
- a specific productivity of 0.0068 g 3-HP per gDCW in 24 h was attained. This specific productivity is similar to that attained by strain JX3_0077 in which acetyl-CoA carboxylase is not overexpressed.
- the specific productivity of the temperature-shifted culture of JX3 0097 was 0.29 g 3-HP per gDCW, a 42-fold increase over the specific productivity of the culture maintained constantly at 30°C in which the enoyl-ACP reductase was not inactivated
- Fed-batch medium a rich medium, may contain components that serve as fatty acid precursors and thus may reduce the demand for malonyl-CoA.
- 3-HP was produced by JX3_0077 in AM2 medium.
- a specific productivity of 0.024 g 3-HP per gDCW in 24 h was obtained by the culture maintained constantly at 30°C, approximately twice the value obtained in fed-batch medium.
- the temperature-shifted culture attained a specific productivity of 1.04 g 3-HP per gDCW over 24 h, a 44-fold increase compared to the specific productivity of the culture maintained constantly at 30°C, again indicating that conditional inactivation of the enoyl-ACP reductase increased the internal malonyl-CoA pool and hence increased the 3-HP production, as envisioned by the inventors.
- the specific productivity of the temperature -shifted culture of JX3_0087 was 0.50 g 3-HP per gDCW, a 27-fold increase over the specific productivity of the culture maintained constantly at 30°C in which the enoyl-ACP reductase was not inactivated.
- Table 17 shows the 3-HP production in AM2 medium by strain JX3_0097 which carried a plasmid overexpressing genes encoding the acetyl-CoA carboxylase complex in addition to a plasmid carrying the mcr gene.
- a specific productivity of 0.021 g 3-HP per gDCW in 24 h was attained. This specific productivity is similar to that attained by strain JX3_0077 in which acetyl-CoA carboxylase is not overexpressed.
- the specific productivity of the temperature-shifted culture of JX3_0097 was 0.94 g 3-HP per gDCW in 24 h, a 45-fold increase over the specific productivity of the culture maintained constantly at 30°C in which the enoyl-ACP reductase was not inactivated.
- Thermocyler conditions for the PCR were: 95°C, 10 min; 30 cycles of 95°C, 10s; 47°C increasing to
- the identification of the affected residue at codon 241 indicates that targeted mutagenesis at this codon, for example to amino acid residues such as Trp, Tyr, His, He, or other amino acids other than Ser or Phe, may result in fabl alleles with different properties than the fabI392 originally isolated in JP1111.
- Targeted mutagenesis at codons near to codon 241 may also be contemplated to obtain the desired fabl mutants with altered properties.
- Example 10 Effect on 3-HP production of overexpression of genes from the 3-HP toleragenic complex
- pSMART(HC)Amp-P ta iA-mcr alone or with compatible plasmids carrying representative genes from the 3-HP toleragenic complex (pJ61-aroG, pJ61-thrA, pACYC177-cynTS, pJ61-cynTS).
- Table 19 categorizes the strains and their characteristics.
- Table 21 Production of 3 -HP by strains carrying pSMART (HC)Amp-P ta i A -mcr and plasmids bearing genes from the 3 -HP toleragenic complex
- Example 11 Effect on volumetric 3 -HP production in 1L fermentations, of increased malonyl-coA precursor pools using temperature sensitive fatty acid synthesis mutants.
- the second vessel contained defined AM2 medium at 30°C, IPTG induction was added at 2mM at an OD 60 onm of 2, additional glucose feed was initiated when glucose was depleted to 0 g/L. The temperature was shifted 37°C over 1 hr at target OD of 10. The glucose feed rate was maintained less than or equal to 3g/L/hr.
- the third vessel contained rich medium at 30°C, IPTG induction was added at 2mM at an OD 60 onm of 2, additional glucose feed was initiated when glucose was depleted to 1-2 g/L. The temperature was shifted 37°C over 1 hr at target OD of 10.
- a high glucose feed rate was maintained at > 3g/L/hr until glucose began to accumulate at concentrations greater than lg/L at which time feed rate was varied to maintain residual glucose between 1 and lOg/L.
- the fourth vessel contained rich medium at 30°C, IPTG induction was added at 2mM at an OD 60 onm of 2, additional glucose feed was initiated when glucose was depleted to 0 g/L. The temperature was shifted 37°C over 1 hr at target OD of 10. The glucose feed rate was maintained less than or equal to 3g/L/hr.
- Example 11A Production of 3-HP in 250 liter fermentations
- Examples of two fed batch fermentations in a 250 liter volume stainless steel fermentor were carried out using the strain BX3_0240, the genotype of which is described elsewhere herein.
- a two stage seed process was used to generate inoculum for the 250 L fermentor. In the first stage, one ml of glycerol stock of the strain was inoculated into 100 ml of TB medium (Terrific Broth) in a shake flask and incubated at 30°C until the OD 6 oo was between 3 and 4.
- induction was effected by adding IPTG to a final concentration of 2 mM at an OD 6 oo of 20.
- Glucose feed (consisting of a 700 g/L glucose solution) was initiated when the residual glucose in the fermentor was 10-15 g/L.
- the feed rate was adjusted to maintain the residual glucose between 10 and 15 g/L until about the last 6 hours of the fermentation when the feed rate was reduced so that the residual glucose at harvest was ⁇ 1 g/L to facilitate 3-HP recovery.
- the temperature was shifted to 37°C over 1 hour.
- the dissolved oxygen (DO) set point was changed from 20% of air saturation to a point where the DO was maintained between 2-4 % of air saturation.
- the fermentation broth was harvested 48 hours after inoculation. The final broth volume was 169.5 liters.
- the second fermentation was run identically to the first example fermentation described above except for the following differences: induction with IPTG was effected at an OD 60 o of 15, the residual glucose (after the glucose feed was started) ranged between 3-30 g/L, and the fermentation broth was harvested at 38.5 hours after inoculation so that the final residual glucose concentration was 25 g/L. The final broth volume was 167 liters.
- Each fermentation broth was maintained at a pH of approximately 7.4 by the controlled addition of anhydrous ammonia gas. Dissolved oxygen was maintained at the desired levels by aeration with sparged, sterile -filtered air. Samples were taken for optical density measurements as well as HPLC analysis for 3-HP concentration.
- the maximum biomass concentration was 12.0 g dry cell weight/L and the biomass concentration at harvest was 11.4 g dry cell weight/L.
- the maximum 3 -HP titer in this fermentation was 20.7 g/L.
- the maximum biomass concentration was 10.2 g dry cell weight/L and the biomass concentration at harvest was 9.5 g dry cell weight/L.
- the maximum 3 -HP titer in this fermentation was 20.7 g/L.
- Example 1 IB Effect of growth medium on 3-HP production in 1 L fermentations
- Fermentors 1 and 2 contained defined FM3 medium. Fermentors 3-5 contained defined FM4 medium. Fermentors 6-8 contained defined FM5 medium. All media formulations are listed in the Common Methods Section. In each fermentor, the initial temperature was 30°C.
- Induction was effected by adding IPTG to a final concentration of 2 mM at OD 60 o values of 15-16.
- Glucose feed (consisting of a 500 g/L glucose solution for FM3 and FM5 media and 500 g/L glucose plus 75 mM MgSC>4 for FM4) was initiated when the residual glucose in the fermentor was about 10 g/L.
- the feed rate was adjusted to maintain the residual glucose >3 g/L (the exception was fermentor 8 in which the residual glucose temporarily reached 0.1 g/L before the feed rate was increased).
- Three hours after induction the temperature was shifted to 37°C over 1 hour. At the time the temperature shift was initiated, the dissolved oxygen (DO) set point was changed from 20% of air saturation to 1% of air saturation. The fermentations were stopped 48 hours after inoculation.
- DO dissolved oxygen
- the broth of each fermentor was maintained at a pH of approximately 7.4 by the controlled addition of a pH titrant.
- the pH titrant for FM3 medium was 5 M NaOH and for FM4 and FM5 it was a 50:50 mixture of concentrated ammonium hydroxide and water. Dissolved oxygen was maintained at the desired levels by sparging with sterile-filtered air. Samples were taken for optical density measurements as well as HPLC analysis for 3-HP concentration. The maximum biomass concentration and the biomass concentration at harvest as well as the maximum 3-HP titer in each fermentor are summarized in the Table 22 below.
- Example 11C Effect of batch phosphate concentration on 3-HP production in 1 L fermentations.
- the initial temperature was 30°C.
- Induction was effected by adding IPTG to a final concentration of 2 mM when the OD 60 o values were at the following values: fermentor 1, 15.3; fermentor 2, 16.0; fermentor 3, 18.1 ; fermentor 4, 18.4.
- Glucose feed (consisting of a 500 g/L glucose solution for FM3 and FM5 media and 500 g/L glucose plus 75 mM MgSC>4 for FM4) was initiated when the residual glucose in the fermentor was about 10 g/L.
- the feed rate was adjusted to maintain the residual glucose >6.5 g/L.
- Three hours after induction the temperature was shifted to 37°C over 1 hour. At the time the temperature shift was initiated, the dissolved oxygen (DO) set point was changed from 20% of air saturation to 1 % of air saturation.
- the fermentations were stopped 48 hours after inoculation.
- DO dissolved oxygen
- the broth of each fermentor was maintained at a pH of 7.4 by the controlled addition of a 50:50 mixture of concentrated ammonium hydroxide and water. Dissolved oxygen was maintained at the desired levels by sparging with sterile-filtered air. Samples were taken for optical density measurements as well as HPLC analysis for 3 -HP concentration. The maximum biomass concentration and the biomass concentration at harvest as well as the maximum 3 -HP titer in each fermentor are summarized in the Table 24 below.
- Example 1 ID 3 -HP production in 1 L fermentations
- Fermentors 1 and 2 contained defined FM5 medium, made as shown in the Common Methods Section except that Citric Acid was added at 2.0 g/L and MgSC>4 was added at 0.40 g/L. In each fermentor, the initial temperature was 30°C. Induction was effected by adding IPTG to a final concentration of 2 mM at OD 60 o values of 17-19, which corresponded to a time post-inoculation of 14.5 hr. Glucose feed (consisting of a 500 g/L glucose solution) was initiated when the residual glucose in the fermentor was about 1 g/L. The feed rate was adjusted to maintain the residual glucose >3 g/L. Three hours after induction, the temperature was shifted to 37°C over 1 hour.
- the OTR was set to 40mmol/L-hr by setting airflow and agitation to 1.08 vvm and 1000 rpm respectively. Compressed air at 2 bar was used as the air feed.
- the broth of each fermentor was maintained at a pH of approximately 7.4 by the controlled addition of a pH titrant. Two hours subsequent to IPTG induction, the pH titrant was changed from 50% NH 4 (OH) to 7.4 M NaOH . Samples were taken for optical density measurements as well as HPLC analysis for 3 -HP concentration. The maximum biomass concentration and the biomass concentration at harvest as well as the maximum 3 -HP titer in each fermentor are summarized in the Table 25 below.
- Example HE 3-HP production in 1 L fermentations
- the fermentation system included real-time monitoring and control of dissolved oxygen (%DO), pH, temperature, agitation, and feeding. All fermentors contained defined FM5 medium, made as shown in the Common Methods Section except that Citric Acid was added at 2.0 g/L and MgS0 4 was added at 0.40 g/L. In each fermentor, the initial temperature was 30°C. Induction was effected by adding IPTG to a final concentration of 2 mM at OD 60 o values of 15-19, which corresponded to a time post-inoculation of 15.75 hr. Glucose feed (consisting of a 500 g/L glucose solution) was initiated when the residual glucose in the fermentor was about 3 g/L.
- the feed rate was adjusted to maintain the residual glucose >3 g/L.
- the temperature was shifted to 37°C over 1 hour.
- the broth of each fermentor was maintained at a pH of approximately 7.4 by the controlled addition of a pH titrant 50% NH4(OH).
- the OTR was changed for each fermentor by varying the agitation and airflow according to Table 27. Compressed air at ( 2 bar was used as the air feed) Samples were taken for optical density measurements as well as HPLC analysis for 3 -HP concentration.
- the maximum biomass concentration and the biomass concentration at harvest as well as the maximum 3 -HP titer in each fermentor are summarized in the Table 27 below.
- Example 1 IF: 3-HP production in 1.8 L fermentation
- a 1.8 L fed batch fermentation experiment was carried out using the strain BX3_0240. Seed culture was started from 1 ml of glycerol stock of the strain inoculated into 105 ml of TB medium (Terrific Broth) in a shake flask and incubated at 30°C until the OD600 was between 5 and 7. 90 ml of the shake flask culture was used to aseptically inoculate 1.71 L of FM5 growth medium, except that the phosphate concentrations were 0.33 g/L K2HP04 and 0.17 g/L KH2P04 in batch medium. The other ingredients in the FM5 media formulation are as listed in the Common Methods Section. The initial temperature in the fermentor was 30°C.
- Induction was effected by adding IPTG to a final concentration of 2 mM when the OD600 value was at 15.46.
- Glucose feed (consisting of a 500 g/L glucose solution) was initiated when the residual glucose in the fermentor was about 10 g/L. The feed rate was adjusted to maintain the residual glucose >6.5 g/L.
- the temperature was shifted to 37°C over 1 hour. At the time the temperature shift was initiated, the dissolved oxygen (DO) set point was changed from 20% of air saturation to 1 % of air saturation.
- the broth of each fermentor was maintained at a pH of 7.4 by the controlled addition of a 50:50 mixture of concentrated ammonium hydroxide and water.
- the plasmids described herein were introduced into the respective strains. All plasmids were introduced at the same time via electroporation using standard methods. Transformed cells were grown on the appropriate media with antibiotic supplementation and colonies were selected based on their appropriate growth on the selective media. As summarized in Table 28, the mcr expression plasmids pTrc-ptrc-mcr or pACYC(kan)-ptalA-mcr were transformed into two strains derived from E.
- Strain BX_0590 comprises additional deletions of the ldhA,pflB, mgsA, and poxB genes. Strain BX_0591 comprises the additional deletions of Strain BX_0590 and an additional deletion of the ack _pta genes. Transformants were subsequently selected for on media containing the appropriate combination of antibiotics.
- Example 12A Construction of Additional Strains for Evaluation
- the host organism expressing ⁇ -red recombinase is transformed with a linear DNA product coding for a selectable marker flanked by the terminal regions (generally ⁇ 50 bp, and alternatively up to about -300 bp) homologous with the target gene or promoter sequence.
- the marker is thereafter removed by another recombination step performed by a plasmid vector carrying the FLP-recombinase, or another recombinase, such as Cre.
- Table 31 shows strains having genotypes that comprise deletions according to the methods of this Part.
- Part 2 Construction of strains BW_595 and BW_651 having a fabl mutation
- JPl 111 The fabf s mutation (Ser241 ⁇ Phe) in E. coli strain JPl 111 significantly increases the malonyl-CoA concentration when cells are grown at the nonpermissive temperature (37°C) and thus produces more 3 -HP at this temperature.
- JPl 111 is not an ideal strain for transitioning into pilot and commercial scale, since it is the product of NTG mutagenesis and thus may harbor unknown mutations, carries mutations in the stringency regulatory factors relA and spoT, and has enhanced conjugation propensity due to the presence of an Hfr factor.
- strain BX_591 a strain developed from the well- characterized BW23115 carrying the additional mutations AldhA, ApflB, AmgsA, ApoxB, Apta-ack. These mutations were generated by the sequential application of the gene deletion method described in Part 1 above.
- SEQ ID NO: 855 FW056: 5'-CCAGTGGGGAGCTACATTCTC;
- SEQ ID NO: 856 FW057: 5'-CGTCATTCAGATGCTGGCGCGATC.
- the FRT::kan::FRT cassette was then inserted at a Smal site downstream of the fabt to generate plasmid pS MART (HC) amp _ a3 ⁇ 4 s _FRT::kan::FRT. This plasmid was used as template DNA and the region between primers:
- SEQ ID NO: 857 FW043: 5'- ATGGGTTTTCTTTCCGG and
- Electrocompetent cells were made by standard methods. These cells were transformed with the amplification fragment bearing the ya3 ⁇ 4 s _FRT::kan::FRT cassette and transformant colonies isolated on LB plates containing 35 ⁇ kanamycin at 30°C. Individual colonies were purified by restreaking, and tested for temperature sensitivity by growth in liquid medium at 30°C and 42°C. Compared to wildtype parental strain, the strain bearing the fabf s allele grows poorly at 42°C but exhibited comparable growth at 30°C. Correct insertion of the FRT::kan::FRT marker was verified by colony PCR, and the fabf kan R strain was designated BX 594.
- the marker incorporated in the chromosome adjacent to fabf s was replaced with a DNA fragment encoding resistance to zeocin.
- the zeoR gene was amplified by PCR from plasmid pJ402 (DNA 2.0, Menlo Park, CA) using primers:
- Strain BX_651 was constructed by transferring the fabP-zeoR cassette from BX_595 to strain BW25113 which does not carry mutations in metabolic genes. A DNA fragment carrying this cassette was obtained by PCR using BX_595 chromosomal DNA and primers FW043 (see above) and
- the PCR product was purified and concentrated using the DNA Clean and Concentrator kit (Zymo Research, Orange, CA).
- Strain BW25113 was transformed with pRedD/ET (Gene Bridges GmBH, Heidelberg, Germany) and the lambda red genes carried on this plasmid were induced by the addition of L-arabinose to 5 mM for 2 hr.
- Electrocompetent cells were made by standard methods, and transformed with the fabf-zeoR DNA fragment. Transformants were plated as above on zeocin, and clones bearing the temperature-sensitive allele verified by growth at 30°C and 42°C as described above.
- the method involves replacement of the target gene (or, in this case, a promoter region) by a selectable marker via homologous recombination performed by the recombinase from ⁇ -phage.
- the host organism expressing ⁇ -red recombinase is transformed with a linear DNA product coding for a selectable marker flanked by the terminal regions (generally ⁇ 50 bp, and alternatively up to about -300 bp) homologous with the target gene or promoter sequence.
- the marker can then be removed by another recombination step performed by a plasmid vector carrying the FLP -recombinase, or another recombinase, such as Cre. This method was used according to manufacturer's instructions.
- T5-aceEF cassette (SEQ ID NO:863) also includes a zeocin resistance cassette flanked by loxP sites.
- the T5-pntAB (SEQ ID NO:864), T5-udhA (SEQ ID NO:865) and T5-cynTS (SEQ ID NO:866) cassettes each include a blasticidin resistance cassette flanked by loxP sites.
- T5-cynTS comprises modified loxP sites in accordance with Lambert et al., AEM 73(4) pi 126-1135.
- Each cassette first is used as a template for PCR amplification to generate a PCR product using the primers CAGTCCAGTTACGCTGGAGTC (SEQ ID NO: 861), and
- ACTGACCATTTAAATCATACCTGACC SEQ ID NO:862.
- This PCR product is used for electroporation (using standard methods such as described elsewhere herein) and recombination into the genome following the Red/ET recombination method of Gene Bridges described above. After transformation positive recombinants are selected on media containing zeocin or blasticidin antibiotics. Curing of the resistance marker is accomplished by expression of the Cre-recombinase according to standard methods. Table 31 shows strains having genotypes that comprise replaced promoters. These are shown as "T5" followed by the affected gene(s).
- plasmids those that comprise mono-functional malonyl-CoA reductase activity.
- truncated portions of malonyl-CoA reductase from C. aurantiacus were constructed by use of PCR primers adjacent, respectively, to nucleotide bases encoding amino acid residues 366 and 1220, and 496 and 1220, of the codon-optimized malonyl-CoA reductase from pTRC-ptrc-mcr-amp.
- a malonyl- CoA reductase from Erythrobacter sp. was incorporated into another plasmid. As for other plasmids, these were incorporated into strains and evaluated as described below.
- PACYC177 PACYC177- mcr/accABCD E4151S RE / (Swal, Xbal: 885 kan kan-ptrc- * B pACYC 177 kan mcr-PtpiA- ptrc-mcr), (Pmel, accAD-
- Part 5 Cloning of pACYC-cat-accABCD-P T5 -udhA.
- Vector pACYC-cat- accABCD-P tal -udhA was similarly digested with Swal and Ndel (New England BioLabs). The two digested DNA fragments were ligated and transformed to create pACYC-cat-accABCD-P T5 -udhA (SEQ ID NO: 887). Plasmid digests were used to confirm the correct sequence. This plasmid is incorporated into strains shown in Table 31.
- strains shown in Table 31, given the indicated Strain Names were produced providing the genotypes. This is not meant to be limiting, and other strains may be made using these methods and following the teachings provided in this application, including providing different genes and gene regions for tolerance, and/or 3-HP production and modifications to modulate the fatty acid synthase system. Further to the latter, such strains may be produced by chromosomal modifications and/or introduction of non-chromosomal introductions, such as plasmids.
- the plasmids described above were introduced into the respective strains. All plasmids were introduced at the same time via electroporation using standard methods. Transformed cells were grown on the appropriate media with antibiotic supplementation and colonies were selected based on their appropriate growth on the selective media.
- T5-aceEF T5-udhA-BSD
- Example 12B Preparing a Genetically Modi ied E. coli Host Cell Comprising malonyl-CoA -reductase
- mmsB such as from Pseudomonas auruginos, which further is codon-optimized for E. coli.
- Vectors comprising galP and a native or mutated ppc also may be introduced by methods known to those skilled in the art (see, e.g., Sambrook and Russell, Molecular Cloning: A Laboratory Manual, Third Edition 2001 (volumes 1-3), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., "Sambrook and Russell, 2001”), additionally recognizing that mutations may be made by a method using the XL 1 -Red mutator strain, using appropriate materials following a manufacturer's instructions (Stratagene QuikChange Mutagenesis Kit, Stratagene, La Jolla, CA USA) and selected for or screened under standard protocols.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Sustainable Development (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Polymers & Plastics (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Enzymes And Modification Thereof (AREA)
- Paints Or Removers (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010800536926A CN102695799A (en) | 2009-09-27 | 2010-09-27 | Method for producing 3-hydroxypropionic acid and other products |
GB1207409.2A GB2487866A (en) | 2009-09-27 | 2010-09-27 | Method for producing 3-Hydroxypropionic acid and other products |
CA2775390A CA2775390C (en) | 2009-09-27 | 2010-09-27 | Method for producing 3-hydroxypropionic acid and other products |
EP10819620.5A EP2480673B1 (en) | 2009-09-27 | 2010-09-27 | Method for producing 3-hydroxypropionic acid and other products |
AU2010298004A AU2010298004B2 (en) | 2009-09-27 | 2010-09-27 | Method for producing 3-hydroxypropionic acid and other products |
US13/498,468 US8883464B2 (en) | 2009-09-27 | 2010-09-27 | Methods for producing 3-hydroxypropionic acid and other products |
JP2012531103A JP2013505727A (en) | 2009-09-27 | 2010-09-27 | Process for producing 3-hydroxypropionic acid and other products |
KR1020127010712A KR20140015136A (en) | 2009-09-27 | 2010-09-27 | Method for producing 3-hydroxypropionic acid and other products |
MX2012003604A MX2012003604A (en) | 2009-09-27 | 2010-09-27 | Method for producing 3-hydroxypropionic acid and other products. |
BR112012006801A BR112012006801A2 (en) | 2009-09-27 | 2010-09-27 | method for production of 3-hydroxypropionic acid and other products |
US13/916,534 US9388419B2 (en) | 2009-09-27 | 2013-06-12 | Methods for producing 3-hydroxypropionic acid and other products |
US14/575,927 US9428778B2 (en) | 2009-09-27 | 2014-12-18 | Method for producing 3-hydroxypropionic acid and other products |
US15/167,439 US10100342B2 (en) | 2009-09-27 | 2016-05-27 | Method for producing 3-hydroxypropionic acid and other products |
US16/159,135 US20190119708A1 (en) | 2009-09-27 | 2018-10-12 | Method for producing 3-hydroxypropionic acid and other products |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24614109P | 2009-09-27 | 2009-09-27 | |
US61/246,141 | 2009-09-27 | ||
US29884410P | 2010-01-27 | 2010-01-27 | |
US61/298,844 | 2010-01-27 | ||
US32148010P | 2010-04-06 | 2010-04-06 | |
US61/321,480 | 2010-04-06 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/498,468 A-371-Of-International US8883464B2 (en) | 2009-09-27 | 2010-09-27 | Methods for producing 3-hydroxypropionic acid and other products |
US13/916,534 Continuation US9388419B2 (en) | 2009-09-27 | 2013-06-12 | Methods for producing 3-hydroxypropionic acid and other products |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011038364A1 true WO2011038364A1 (en) | 2011-03-31 |
Family
ID=43127955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/050436 WO2011038364A1 (en) | 2009-09-27 | 2010-09-27 | Method for producing 3-hydroxypropionic acid and other products |
Country Status (11)
Country | Link |
---|---|
US (5) | US8883464B2 (en) |
EP (1) | EP2480673B1 (en) |
JP (4) | JP2013505727A (en) |
KR (1) | KR20140015136A (en) |
CN (1) | CN102695799A (en) |
AU (1) | AU2010298004B2 (en) |
BR (1) | BR112012006801A2 (en) |
CA (1) | CA2775390C (en) |
GB (2) | GB2487866A (en) |
MX (1) | MX2012003604A (en) |
WO (1) | WO2011038364A1 (en) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013036764A1 (en) * | 2011-09-08 | 2013-03-14 | Genomatica, Inc | Eukaryotic organisms and methods for producing 1,3-butanediol |
WO2013131798A1 (en) * | 2012-03-06 | 2013-09-12 | Gea Mechanical Equipment Gmbh | Method and installation for processing raw liquid manure and/or fermentation residues from biogas production |
WO2013137277A1 (en) * | 2012-03-14 | 2013-09-19 | 株式会社日本触媒 | Method for producing 3-hydroxypropionic acid, genetically modified microorganism, and methods for producing acrylic acid, water-absorbable resin, acrylic acid ester and acrylic acid ester resin each utilizing said method |
WO2013192453A1 (en) * | 2012-06-20 | 2013-12-27 | Opx Biotechnologies, Inc. | Purification of 3-hydroxypropionic acid from crude cell broth and dehydration to acrylic acid |
WO2013192450A1 (en) * | 2012-06-20 | 2013-12-27 | Opx Biotechnologies, Inc. | Purification of 3-hydroxypropionic acid from crude cell broth and production of acrylamide |
US8652816B2 (en) | 2007-12-04 | 2014-02-18 | Opx Biotechnologies, Inc. | Compositions and methods for 3-hydroxypropionate bio-production from biomass |
US20140051136A1 (en) * | 2012-08-10 | 2014-02-20 | Opx Biotechnologies, Inc. | Micoorganisms and Methods for the Production of Fatty Acids and Fatty Acid Derived Products |
CN103857791A (en) * | 2011-09-30 | 2014-06-11 | 诺维信股份有限公司 | Dehydrogenase variants and polynucleotides encoding same |
US8809027B1 (en) | 2009-09-27 | 2014-08-19 | Opx Biotechnologies, Inc. | Genetically modified organisms for increased microbial production of 3-hydroxypropionic acid involving an oxaloacetate alpha-decarboxylase |
WO2014146026A1 (en) * | 2013-03-15 | 2014-09-18 | Opx Biotechnologies, Inc. | Bioproduction of chemicals |
WO2014145344A2 (en) * | 2013-03-15 | 2014-09-18 | Opx Biotechnologies, Inc. | Control of growth-induction-production phases |
WO2014145297A1 (en) * | 2013-03-15 | 2014-09-18 | Opx Biotechnologies, Inc. | Method of enhanced bioproduction |
WO2014144367A1 (en) * | 2013-03-15 | 2014-09-18 | Cargill, Incorporated | Recovery of 3-hydroxypropionic acid |
US20140330032A1 (en) * | 2011-03-22 | 2014-11-06 | Michael D. Lynch | Microbial production of chemical products and related compositions, methods and systems |
US8883464B2 (en) | 2009-09-27 | 2014-11-11 | Opx Biotechnologies, Inc. | Methods for producing 3-hydroxypropionic acid and other products |
WO2014210535A2 (en) * | 2013-06-28 | 2014-12-31 | Metabolix, Inc. | Genetically engineered methylotrophs for the production of pha biopolymers and c3, c4, and c5 biochemicals from methanol or methane as sole carbon feedstock |
US20150057455A1 (en) * | 2013-03-15 | 2015-02-26 | Cindy Hoppe | Flash evaporation for product purification and recovery |
WO2015057644A1 (en) | 2013-10-17 | 2015-04-23 | Dow Global Technologies Llc | Ammonium bisulfate catalyzed dehydration of beta-hydroxy acids |
US9090918B2 (en) | 2010-11-22 | 2015-07-28 | Novozymes A/A | Compositions and methods for 3-hydroxypropionic acid production |
US9365875B2 (en) | 2012-11-30 | 2016-06-14 | Novozymes, Inc. | 3-hydroxypropionic acid production by recombinant yeasts |
JP2016526919A (en) * | 2013-08-05 | 2016-09-08 | グリーンライト バイオサイエンシーズ インコーポレーテッドGreenlight Biosciences,Inc. | Engineered proteins with protease cleavage sites |
US9850192B2 (en) | 2012-06-08 | 2017-12-26 | Cj Cheiljedang Corporation | Renewable acrylic acid production and products made therefrom |
US10077455B2 (en) | 2013-06-14 | 2018-09-18 | Technical University Of Denmark | 3HP tolerance |
CN108728469A (en) * | 2017-04-14 | 2018-11-02 | 中国科学院微生物研究所 | The structure of recombination bacillus coli engineering bacteria and its application in producing Beta-alanine |
CN109593697A (en) * | 2018-12-18 | 2019-04-09 | 江苏师范大学 | It is a kind of produce 3- hydracrylic acid recombination pseudomonad and its construction method |
US10337038B2 (en) | 2013-07-19 | 2019-07-02 | Cargill, Incorporated | Microorganisms and methods for the production of fatty acids and fatty acid derived products |
US10494654B2 (en) | 2014-09-02 | 2019-12-03 | Cargill, Incorporated | Production of fatty acids esters |
KR20200005552A (en) * | 2017-04-14 | 2020-01-15 | 인스티튜트 오브 마이크로바이올로지, 차이니즈 아카데미 오브 사이언스즈 | Recombinant bacteria for producing 3-hydroxypropionic acid, methods of preparation thereof, and applications thereof |
WO2020128618A3 (en) * | 2018-12-18 | 2020-08-06 | Braskem S.A. | Co-production pathway for 3-hp and acetyl-coa derivatives from malonate semialdehyde |
US10786064B2 (en) | 2010-02-11 | 2020-09-29 | Cj Cheiljedang Corporation | Process for producing a monomer component from a genetically modified polyhydroxyalkanoate biomass |
US11345938B2 (en) | 2017-02-02 | 2022-05-31 | Cargill, Incorporated | Genetically modified cells that produce C6-C10 fatty acid derivatives |
US11408013B2 (en) | 2013-07-19 | 2022-08-09 | Cargill, Incorporated | Microorganisms and methods for the production of fatty acids and fatty acid derived products |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8647642B2 (en) | 2008-09-18 | 2014-02-11 | Aviex Technologies, Llc | Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment |
EP2495233B1 (en) * | 2009-10-29 | 2019-05-08 | Kabushiki Kaisha Sangi | Method for synthesizing unsaturated carboxylic acid and/or derivative of same |
US20110125118A1 (en) * | 2009-11-20 | 2011-05-26 | Opx Biotechnologies, Inc. | Production of an Organic Acid and/or Related Chemicals |
CN104364358A (en) * | 2012-04-09 | 2015-02-18 | Bp生物燃料英国有限公司 | Low polysaccharide microorganisms for production of biofuels and other renewable materials |
DE102012207921A1 (en) | 2012-05-11 | 2013-11-14 | Evonik Industries Ag | Multi-stage synthesis process with synthesis gas |
EP3385375B1 (en) * | 2013-01-16 | 2021-06-16 | Genomatica, Inc. | Acyl-acp reductase with improved properties |
WO2014144843A1 (en) | 2013-03-15 | 2014-09-18 | Board Of Trustees Of Michigan State University | Synthesis of biobased terephthalic acids and isophthalic acids |
KR20150018227A (en) * | 2013-08-09 | 2015-02-23 | 삼성전자주식회사 | Corynebacterium comprising heterologous fumarase gene and a method for producing C4 dicarboxylic acid using the same |
CN105802984B (en) * | 2014-01-24 | 2019-12-10 | 武汉大学 | Method for producing propionic acid by microorganisms |
DK3155102T3 (en) | 2014-06-11 | 2023-01-30 | Univ Duke | COMPOSITIONS AND METHODS FOR RAPID AND DYNAMIC FLOW REGULATION USING SYNTHETIC METABOLIC VALVES |
DE112015003962T5 (en) | 2014-08-29 | 2017-08-03 | Sk Innovation Co., Ltd. | 3-hydroxypropionic acid-producing recombinant yeast and method of producing 3-hydroxypropionic acid using the same |
WO2016036872A1 (en) * | 2014-09-03 | 2016-03-10 | Ciris Energy, Inc. | Production of 3-hydroxypropionic acid from carbonaceous material |
EP3227450B1 (en) * | 2014-12-02 | 2019-04-10 | Archer Daniels Midland Company | Process for making acrylic acid from dextrose |
CN104946576B (en) * | 2015-04-27 | 2018-03-23 | 中国科学院过程工程研究所 | Recombinant organism and its construction method and the application in pyruvic acid is produced |
EP3297666B1 (en) * | 2015-05-22 | 2019-07-03 | Consejo Superior De Investigaciones Científicas | Molecular adjuvant and vaccine |
KR20180043242A (en) * | 2015-06-04 | 2018-04-27 | 바이오엠버 인코퍼레이티드 | The bio-based generation of functionalized alpha-substituted acrylates and C4-dicarboxylic acids |
WO2016200239A1 (en) * | 2015-06-11 | 2016-12-15 | 부산대학교 산학협력단 | Promoter system inducing expression by 3-hydroxypropionic acid and method for biological production of 3-hydroxypropionic acid using same |
US10808255B2 (en) | 2015-06-11 | 2020-10-20 | Noroo Ic Co., Ltd. | Promoter system inducing expression by 3-hydroxypropionic acid and method for biological production of 3-hydroxypropionic acid using same |
DE102016212497B4 (en) * | 2015-07-13 | 2024-04-25 | Sk Innovation Co., Ltd. | Mutant microorganism comprising a gene encoding methylmalonyl-CoA reductase and its use |
US9988624B2 (en) | 2015-12-07 | 2018-06-05 | Zymergen Inc. | Microbial strain improvement by a HTP genomic engineering platform |
US11208649B2 (en) | 2015-12-07 | 2021-12-28 | Zymergen Inc. | HTP genomic engineering platform |
BR112018011503A2 (en) | 2015-12-07 | 2018-12-04 | Zymergen Inc | corynebacterium glutamicum promoters |
KR102547252B1 (en) * | 2016-01-08 | 2023-06-23 | 에스케이이노베이션 주식회사 | Method for Manufacturing Vapor Dehydration Reaction Feed of Organic Material |
KR101828551B1 (en) * | 2016-01-11 | 2018-02-13 | 한국과학기술원 | Recombinant Variant Microorganism Having a Producing Ability of Malonic Acid and Method for Preparing Malonic Acid Using the Same |
WO2017134661A1 (en) * | 2016-02-04 | 2017-08-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods for disrupting biofilms |
US11046642B2 (en) | 2016-02-19 | 2021-06-29 | Alliance For Sustainable Energy, Llc | Systems and methods for producing nitriles |
KR20190020121A (en) * | 2016-06-24 | 2019-02-27 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Host cells and methods for producing hydrocortisol |
KR102345898B1 (en) | 2016-06-30 | 2022-01-03 | 지머젠 인코포레이티드 | Methods for generating glucose permeabilization enzyme libraries and uses thereof |
US10544390B2 (en) | 2016-06-30 | 2020-01-28 | Zymergen Inc. | Methods for generating a bacterial hemoglobin library and uses thereof |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US20190323019A1 (en) * | 2016-12-21 | 2019-10-24 | Yi-Hua Hsu | Composition for editing a nucleic acid sequence and method using the same |
KR102418589B1 (en) * | 2018-01-10 | 2022-07-06 | 주식회사 엘지화학 | Method for recovering 3-hydroxypropionic acid |
US20190233853A1 (en) * | 2018-02-01 | 2019-08-01 | Invista North America S.A.R.L. | Methods and materials for the biosynthesis of beta hydroxy acids and/or derivatives thereof and/or compounds related thereto |
WO2019152754A1 (en) * | 2018-02-01 | 2019-08-08 | Invista North America S.A.R.L. | Methods and materials for the biosynthesis of beta hydroxy acids and derivatives and compounds related thereto |
KR102419608B1 (en) * | 2018-02-08 | 2022-07-08 | 주식회사 엘지화학 | Method for preparation of high concentration 3-hydroxypropionic acid aqueous solution |
KR102519456B1 (en) * | 2018-03-15 | 2023-04-06 | 주식회사 엘지화학 | Method for preparing poly(3-hydroxypropionate-b-lactate) block copolymer by using microorganisms |
KR102140596B1 (en) | 2018-04-17 | 2020-08-04 | 에스케이이노베이션 주식회사 | Novel Promotor from Organic Acid Resistant Yeast and Method for Expressing Target Gene Using The Same |
RU2687135C1 (en) * | 2018-10-02 | 2019-05-07 | Общество с ограниченной ответственностью "ГИПРОБИОСИНТЕЗ" | Strain of heterotrophic bacteria cupriavidus gilardii - associate for producing microbial protein mass |
US20220049279A1 (en) * | 2018-12-18 | 2022-02-17 | Alderys | Malonic semi-aldehyde-producing yeasts |
CA3139124C (en) * | 2019-06-21 | 2023-01-31 | Inscripta, Inc. | Genome-wide rationally-designed mutations leading to enhanced lysine production in e. coli |
KR20210041903A (en) | 2019-10-08 | 2021-04-16 | 에스케이이노베이션 주식회사 | Recombinant Acid Resistant Yeast Inhibited Lactate Metabolism and Alcohol Production and Method for Preparing Lactic Acid Using The Same |
KR20210158676A (en) | 2020-06-24 | 2021-12-31 | 에스케이이노베이션 주식회사 | Recombinant Acid Resistant Yeast Having Improbed Lactic Acid Productivity |
CN113278537A (en) * | 2021-06-15 | 2021-08-20 | 天津科技大学 | Series of low-yield higher alcohol saccharomyces cerevisiae and construction method and application thereof |
EP4324816A1 (en) * | 2021-11-29 | 2024-02-21 | Lg Chem, Ltd. | Process for recovery of 3-hydroxypropionic acid and 3-hydroxypropionic acid-containing slurry composition |
US20240141394A1 (en) * | 2021-11-29 | 2024-05-02 | Lg Chem, Ltd. | Process of recovering 3-hydroxypropionic acid and slurry composition comprising 3-hydroxypropionic acid |
EP4328215A1 (en) * | 2021-11-29 | 2024-02-28 | Lg Chem, Ltd. | Method for collecting alkali metal salt hydrate and 3-hydroxypropionic acid |
WO2023096456A1 (en) * | 2021-11-29 | 2023-06-01 | 주식회사 엘지화학 | Crystal of 3-hydroxypropionic acid salt, method for producing same, and process for recovering 3-hydroxypropionic acid |
CN115216194B (en) * | 2022-08-24 | 2022-12-27 | 中国科学院兰州化学物理研究所 | Self-polishing antifouling coating for embedding crushed Chinese prickly ash and preparation method and application thereof |
WO2024155699A1 (en) * | 2023-01-17 | 2024-07-25 | Bluestem Biosciences, Inc. | Anaerobic bioproduction of compounds |
CN116732081B (en) * | 2023-08-07 | 2023-12-29 | 中国科学院天津工业生物技术研究所 | Method for improving bacillus subtilis to synthesize menatetrenone, obtained recombinant strain and application thereof |
CN118165906A (en) * | 2024-05-14 | 2024-06-11 | 北京大学深圳研究生院 | Recombinant bacterium for producing 3-hydroxy propionic acid by directly utilizing waste carbon dioxide, and construction method and application thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087140A (en) * | 1997-02-19 | 2000-07-11 | Wisconsin Alumni Research Foundation | Microbial production of 1,2-propanediol from sugar |
US20050196758A1 (en) * | 2000-02-04 | 2005-09-08 | Rock Charles O. | Novel enoyl reductases and methods of use thereof |
US20050283029A1 (en) * | 2002-11-01 | 2005-12-22 | Xiangsheng Meng | Process for preparation of 1,3-propanediol |
US20070245431A1 (en) * | 2006-03-15 | 2007-10-18 | Martek Biosciences Corporation | Polyunsaturated fatty acid production in heterologous organisms using pufa polyketide synthase systems |
US20080076167A1 (en) * | 2000-11-20 | 2008-03-27 | Cargill, Incorporated | 3-hydroxypropionic acid and other organic compounds |
WO2008089102A2 (en) * | 2007-01-12 | 2008-07-24 | Regents Of The University Of Colorado | Compositions and methods for enhancing tolerance for the production of organic chemicals produced by microorganisms |
US20080199926A1 (en) * | 2007-01-22 | 2008-08-21 | Burgard Anthony P | Methods and Organisms for Growth-Coupled Production of 3-Hydroxypropionic Acid |
Family Cites Families (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2408889A (en) | 1946-10-08 | Production of organic compounds | ||
US2469701A (en) | 1946-02-13 | 1949-05-10 | American Cyanamid Co | Preparation of acrylic acid |
US2464768A (en) | 1946-02-13 | 1949-03-15 | American Cyanamid Co | Preparation of esters of acrylic acid |
US2798053A (en) | 1952-09-03 | 1957-07-02 | Goodrich Co B F | Carboxylic polymers |
US3904685A (en) | 1973-07-20 | 1975-09-09 | Celanese Corp | Polyacrylic acid having high chelation value and its production |
CH606154A5 (en) | 1974-07-02 | 1978-11-15 | Goodrich Co B F | |
US4029577A (en) | 1975-11-17 | 1977-06-14 | Betz Laboratories, Inc. | Polymers for use in water treatment |
DE2757329C2 (en) | 1977-12-22 | 1980-02-07 | Basf Ag, 6700 Ludwigshafen | Process for the production of polymers of acrylic acid or methacrylic acid |
US4268641A (en) | 1979-04-24 | 1981-05-19 | Union Carbide Corporation | Acrylic acid-acrylate copolymer thickening agents |
US4431547A (en) | 1981-08-24 | 1984-02-14 | Nalco Chemical Company | Use of acrylamide/acrylic acid copolymers for prevention of fouling by Ca3 (PO4)2 |
US4985518A (en) | 1981-10-26 | 1991-01-15 | American Colloid Company | Process for preparing water-absorbing resins |
JPS58180233A (en) | 1982-04-19 | 1983-10-21 | Nippon Shokubai Kagaku Kogyo Co Ltd | Absorbing agent |
US4685915A (en) | 1984-04-06 | 1987-08-11 | The Procter & Gamble Company | Disposable diaper having density and basis weight profiled absorbent core |
US4734478A (en) | 1984-07-02 | 1988-03-29 | Nippon Shokubai Kagaku Kogyo Co., Ltd. | Water absorbing agent |
US4708997A (en) | 1985-07-22 | 1987-11-24 | The Dow Chemical Company | Suspending agent for the suspension polymerization of water-soluble monomers |
DE3544770A1 (en) | 1985-12-18 | 1987-06-19 | Stockhausen Chem Fab Gmbh | METHOD AND DEVICE FOR THE CONTINUOUS PRODUCTION OF POLYMERISATES AND COPOLYMERISATES OF ACRYLIC ACID AND / OR METHACRYLIC ACID |
US5009653A (en) | 1988-03-31 | 1991-04-23 | The Procter & Gamble Company | Thin, flexible sanitary napkin |
US5135677A (en) | 1988-04-11 | 1992-08-04 | Nippon Shokubai Co., Ltd. | Process for producing acid-type maleic acid polymer and water-treating agent and detergent additive containing said polymer |
US4952505A (en) | 1988-08-08 | 1990-08-28 | Florida State University | Fermentation of trichoderma reesei and apparatus therefor |
IT1229506B (en) | 1989-01-26 | 1991-09-03 | Sigma Prodotti Chimici Srl | POLYMER OF ACRYLIC ACID FREE FROM RESIDUAL SOLVENTS AND PROCEDURE FOR ITS PREPARATION. |
US5252474A (en) | 1989-03-31 | 1993-10-12 | Merck & Co., Inc. | Cloning genes from Streptomyces avermitilis for avermectin biosynthesis and the methods for their use |
US5145906A (en) | 1989-09-28 | 1992-09-08 | Hoechst Celanese Corporation | Super-absorbent polymer having improved absorbency properties |
JP2938920B2 (en) | 1990-01-31 | 1999-08-25 | 住友精化株式会社 | Method for producing water absorbent resin |
US5350799A (en) | 1990-05-31 | 1994-09-27 | Hoechst Celanese Corporation | Process for the conversion of fine superabsorbent polymer particles into larger particles |
US5342899A (en) | 1991-05-16 | 1994-08-30 | The Dow Chemical Company | Process for recycling aqueous fluid absorbents fines to a polymerizer |
DE4138408A1 (en) | 1991-11-22 | 1993-05-27 | Cassella Ag | HYDROPHILES, HIGHLY SOURCE HYDROGELS |
CA2083346A1 (en) | 1991-12-13 | 1993-06-14 | Eric G. Lundquist | A catalyzed esterification process |
US5142023A (en) | 1992-01-24 | 1992-08-25 | Cargill, Incorporated | Continuous process for manufacture of lactide polymers with controlled optical purity |
US5827255A (en) | 1992-07-27 | 1998-10-27 | The Procter & Gamble Company | Sanitary napkin comprising an absorbent core having a density gradient |
US5405913A (en) | 1993-03-22 | 1995-04-11 | The University Of Akron | Free radical copper(II)-enolate polymerization initiators |
US5510307A (en) | 1993-04-08 | 1996-04-23 | Isp Investments Inc. | Free radical initiator delivery system |
US5510526A (en) | 1993-06-29 | 1996-04-23 | Cargill, Incorporated | Lactic acid production, separation and/or recovery process |
WO1995006114A1 (en) | 1993-08-24 | 1995-03-02 | Ajinomoto Co., Inc. | Variant phosphoenolpyruvate carboxylase, gene thereof, and process for producing amino acid |
US5487987A (en) | 1993-09-16 | 1996-01-30 | Purdue Research Foundation | Synthesis of adipic acid from biomass-derived carbon sources |
US5558656A (en) | 1993-12-20 | 1996-09-24 | The Procter & Gamble Company | Sanitary napkin having an internal shaping component |
US5723639A (en) | 1995-10-16 | 1998-03-03 | University Of Chicago | Esterification of fermentation-derived acids via pervaporation |
DE19629372A1 (en) | 1996-07-20 | 1998-01-22 | Degussa | Malonic acid or salt preparation |
CN1236063C (en) | 1996-11-13 | 2006-01-11 | 纳幕尔杜邦公司 | Method for the production of 1,3-propanediol by recombinant organisms |
SK285201B6 (en) | 1996-12-05 | 2006-08-03 | Ajinomoto Co., Inc. | Recombinant DNA autonomously replicable in cells of coryneform bacteria, coryneform bacterium and method for producing L-lysine, vector pVK7 |
US7125938B2 (en) | 1997-03-11 | 2006-10-24 | Carnegie Mellon University | Atom or group transfer radical polymerization |
US6566583B1 (en) | 1997-06-04 | 2003-05-20 | Daniel Facciotti | Schizochytrium PKS genes |
BE1011197A3 (en) | 1997-06-06 | 1999-06-01 | Brussels Biotech En Abrege Bb | Process for purification lactic acid. |
US6229046B1 (en) | 1997-10-14 | 2001-05-08 | Cargill, Incorported | Lactic acid processing methods arrangements and products |
KR100250830B1 (en) | 1997-12-09 | 2000-04-01 | 성재갑 | Method for producing optically active hydroxycarboxylic acids by autodegradation of polyhydroxyalkanoates |
JP4913929B2 (en) | 1998-06-12 | 2012-04-11 | 味の素株式会社 | Method for producing nucleic acid substances |
EP1105514B1 (en) | 1998-08-04 | 2008-02-06 | Metabolix, Inc. | Polyhydroxyalkanoate production from polyols |
JP4354118B2 (en) | 1998-10-30 | 2009-10-28 | キャタリティック・ディスティレイション・テクノロジーズ | Production of amides and / or acids from nitriles |
DE69939048D1 (en) | 1998-11-05 | 2008-08-21 | Nippon Catalytic Chem Ind | Water-absorbent resin and process for its preparation |
US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
DE60014047T2 (en) | 1999-03-22 | 2006-02-23 | Purac Biochem B.V. | PROCESS FOR PURIFYING MILKYLIC ACID ON INDUSTRIAL BASIS |
JP2002539798A (en) | 1999-03-23 | 2002-11-26 | ボード オブ トラスティーズ,オパレイティング ミシガン ステイト ユニバーシティ | Synthesis of 1,2,3,4-tetrahydroxybenzene from carbon derived from biomass |
EP1124979B1 (en) | 1999-08-30 | 2006-08-30 | Wisconsin Alumni Research Foundation | Production of 3-hydroxypropionic acid in recombinant organisms |
US6852517B1 (en) | 1999-08-30 | 2005-02-08 | Wisconsin Alumni Research Foundation | Production of 3-hydroxypropionic acid in recombinant organisms |
DE60026563D1 (en) | 1999-10-25 | 2006-05-04 | Kosan Biosciences Inc | PREPARATION OF POLYCETIDES |
US6531291B1 (en) | 1999-11-10 | 2003-03-11 | The Trustees Of Columbia University In The City Of New York | Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof |
AU1661901A (en) | 1999-11-24 | 2001-06-04 | Cargill Dow Llc | Improved lactic acid processing; methods; arrangements; and, products |
NL1013682C2 (en) | 1999-11-26 | 2001-05-30 | Purac Biochem Bv | Method and device for purifying an aqueous solution of lactic acid. |
RU2212447C2 (en) | 2000-04-26 | 2003-09-20 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" | Strain escherichia coli as producer of amino acid (variants) and method for preparing amino acid (variants) |
KR20040014389A (en) | 2000-07-21 | 2004-02-14 | 메타볼릭스 인코포레이티드 | Production of polyhydroxyalkanoates from polyols |
CA2322105A1 (en) | 2000-10-23 | 2002-04-23 | Plant Bioscience Limited | Antibiotic production (ii) |
US6623944B2 (en) | 2001-03-14 | 2003-09-23 | Degussa Ag | Process for preparation of D-pantothenic acid and/or salts thereof |
WO2002090312A1 (en) | 2001-05-07 | 2002-11-14 | Cargill, Incorporated | Process for preparing carboxylic acids and derivatives thereof |
US6723799B2 (en) | 2001-08-24 | 2004-04-20 | E I. Du Pont De Nemours And Company | Acid-dyeable polymer compositions |
AU2002353970A1 (en) | 2001-11-02 | 2003-05-19 | Rice University | Recycling system for manipulation of intracellular nadh availability |
US6933404B2 (en) | 2001-12-18 | 2005-08-23 | Metabolix Inc. | Methods of making intermediates from polyhydroxyalkanoates |
ATE432338T1 (en) | 2002-01-18 | 2009-06-15 | Novozymes As | ALANINE 2,3-AMINOMUTASE |
US6709919B2 (en) | 2002-05-15 | 2004-03-23 | Taiwan Semiconductor Manufacturing Company | Method for making auto-self-aligned top electrodes for DRAM capacitors with improved capacitor-to-bit-line-contact overlay margin |
US7314974B2 (en) | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
EP1487775A2 (en) | 2002-03-25 | 2004-12-22 | Cargill, Incorporated | Methods of manufacturing derivatives of beta-hydroxycarboxylic acids |
AU2003301617A1 (en) | 2002-05-10 | 2004-05-13 | Metabolix, Inc. | Bioabsorbable polymer containing 2-hdroxyacid monomers |
EP1532516A4 (en) * | 2002-07-10 | 2007-05-23 | Penn State Res Found | Method for determining gene knockout strategies |
US7826975B2 (en) | 2002-07-10 | 2010-11-02 | The Penn State Research Foundation | Method for redesign of microbial production systems |
AU2003205041A1 (en) | 2002-07-12 | 2004-01-29 | Ajinomoto Co., Inc. | Method for producing target substance by fermentation |
GB0218019D0 (en) | 2002-08-05 | 2002-09-11 | Ciba Spec Chem Water Treat Ltd | Production of a fermentation product |
ES2356526T3 (en) | 2002-10-04 | 2011-04-08 | E.I. Du Pont De Nemours And Company | PROCEDURE FOR THE BIOLOGICAL PRODUCTION OF 1,3-PROPANODIOL WITH HIGH PERFORMANCE. |
WO2004044210A2 (en) | 2002-11-06 | 2004-05-27 | University Of Florida | Materials and methods for the efficient production of acetate and other products |
BRPI0407600A (en) | 2003-02-18 | 2006-02-14 | Metabolic Explorer Sa | processes for the preparation of evolved microorganisms and an evolved protein and biotransformation, an evolved gene, an evolved protein, and the use of an evolved microorganism or an evolved protein |
US7141154B2 (en) | 2003-03-06 | 2006-11-28 | Uchicago Argonne Llc | Single-stage separation and esterification of cation salt carboxylates using electrodeionization |
DE10314618A1 (en) | 2003-04-01 | 2004-10-14 | Degussa Ag | Process for the preparation of L-amino acids using strains of the family Enterobacteriaceae |
US20040225116A1 (en) | 2003-05-08 | 2004-11-11 | Payne Mark S. | Nucleic acid fragments encoding nitrile hydratase and amidase enzymes from comamonas testosteroni 5-MGAM-4D and recombinant organisms expressing those enzymes useful for the production of amides and acids |
US7090008B2 (en) | 2003-05-29 | 2006-08-15 | Sensor Highway Limited | System to connect conduit sections in a subterranean well |
CN100422131C (en) | 2003-06-26 | 2008-10-01 | 嘉吉有限公司 | Process for separating and recovering 3-hydroxypropionic acid and acrylic acid |
FR2862068B1 (en) | 2003-11-06 | 2007-10-12 | Metabolic Explorer Sa | OPTIMIZED MICROORGANISM STRAINS FOR NADPH CONSUMPTION BIOSYNTHESIS PATHWAYS |
US7326557B2 (en) | 2003-11-14 | 2008-02-05 | Rice University | Increasing intracellular NADPH availability in E. coli |
EP1706457B1 (en) | 2003-12-04 | 2012-02-01 | Novozymes A/S | Production of 3-hydroxypropionic acid using beta-alanine/pyruvate aminotransferase |
US7186214B2 (en) | 2004-02-12 | 2007-03-06 | Medtronic, Inc. | Instruments and methods for accessing an anatomic space |
WO2005093060A1 (en) | 2004-03-26 | 2005-10-06 | Nippon Shokubai Co., Ltd. | Process for producing 1,3-propanediol and/or 3-hydroxypropionic acid |
WO2005095320A1 (en) | 2004-04-02 | 2005-10-13 | Ciba Specialty Chemicals Water Treatments Limited | Preparation of acrylic acid derivatives from alpha or beta-hydroxy carboxylic acids |
AU2005238534A1 (en) | 2004-04-28 | 2005-11-10 | Biogen Idec Ma Inc. | Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives |
US20050272135A1 (en) | 2004-06-02 | 2005-12-08 | The University Of Chicago | Processs for production and purification of fermentation derived organic acids |
US7652167B2 (en) | 2004-07-19 | 2010-01-26 | Board Of Trustees Of Michigan State University | Process for production of organic acid esters |
EP1786831A4 (en) | 2004-07-30 | 2008-01-23 | Cargill Inc | Alanine 2, 3 aminomutases |
US7148051B2 (en) | 2004-08-16 | 2006-12-12 | E. I. Du Pont De Nemours And Company | Production of 3-hydroxycarboxylic acid using nitrilase |
EP3130676A1 (en) | 2004-08-27 | 2017-02-15 | Rice University | Mutant e. coli strain with increased succinic acid production |
US7987056B2 (en) | 2004-09-20 | 2011-07-26 | The Regents Of The University Of Colorado, A Body Corporate | Mixed-library parallel gene mapping quantitative micro-array technique for genome-wide identification of trait conferring genes |
BRPI0515994A (en) | 2004-10-12 | 2008-08-19 | Univ Michigan State | floroglucinol biosynthesis and preparation of 1,3-dihydroxybenzene from it |
TWI529181B (en) | 2005-02-28 | 2016-04-11 | 贏創德固賽有限責任公司 | Water-absorbing polymer structures based upon renewable raw materials and process for their production |
US7524660B2 (en) | 2005-05-05 | 2009-04-28 | E.I. Du Pont De Nemours And Company | Utilization of fructose in microbial production strains |
US7772444B2 (en) | 2005-05-19 | 2010-08-10 | E. I. Du Pont De Nemours And Company | Method for the production of resveratrol in a recombinant oleaginous microorganism |
WO2007012078A1 (en) | 2005-07-18 | 2007-01-25 | Basf Ag | Methionine producing recombinant microorganisms |
US20070111294A1 (en) | 2005-09-09 | 2007-05-17 | Genomatica, Inc. | Methods and organisms for the growth-coupled production of succinate |
DE102005048818A1 (en) | 2005-10-10 | 2007-04-12 | Degussa Ag | Microbiological production of 3-hydroxypropionic acid |
WO2007047680A2 (en) | 2005-10-14 | 2007-04-26 | Cargill, Incorporated | Increasing the activity of radical s-adenosyl methionine (sam) enzymes |
US8535916B2 (en) | 2006-02-13 | 2013-09-17 | Ls9, Inc. | Modified microorganisms and uses therefor |
US20070219390A1 (en) | 2006-03-15 | 2007-09-20 | Battelle Memorial Institute | Method and apparatus for conversion of beta-hydroxy carbonyl compounds |
US7687661B2 (en) | 2006-03-15 | 2010-03-30 | Battelle Memorial Institute | Method for conversion of β-hydroxy carbonyl compounds |
CN101473038B (en) | 2006-03-15 | 2014-05-28 | Dsmip资产公司 | Plant seed oils containing polyunsaturated fatty acids |
US8110670B2 (en) | 2006-05-19 | 2012-02-07 | Ls9, Inc. | Enhanced production of fatty acid derivatives |
US20100274033A1 (en) | 2009-04-27 | 2010-10-28 | Ls9, Inc. | Production of fatty acid esters |
WO2007136762A2 (en) | 2006-05-19 | 2007-11-29 | Ls9, Inc. | Production of fatty acids and derivatives thereof |
DE102006025821A1 (en) * | 2006-06-02 | 2007-12-06 | Degussa Gmbh | An enzyme for the production of Mehylmalonatsemialdehyd or Malonatsemialdehyd |
DE102006039203B4 (en) * | 2006-08-22 | 2014-06-18 | Evonik Degussa Gmbh | Process for the preparation of crystallization-purified acrylic acid from hydroxypropionic acid and apparatus therefor |
WO2008028002A1 (en) | 2006-08-29 | 2008-03-06 | Rice University | Increasing nadph-dependent products |
US8030045B2 (en) | 2006-08-30 | 2011-10-04 | Cargill, Incorporated | Beta-alanine/alpha-ketoglutarate aminotransferase for 3-hydroxypropionic acid production |
BRPI0719792A2 (en) | 2006-10-04 | 2015-04-07 | Cargill Inc | Carboxylic acids prepared using a salt molecule division process |
NZ578813A (en) | 2007-02-09 | 2012-04-27 | Zeachem Inc | Energy efficient methods to produce alcohols and carboxylic acids |
WO2008113041A2 (en) | 2007-03-14 | 2008-09-18 | Ls9, Inc. | Process for producing low molecular weight hydrocarbons from renewable resources |
JPWO2008133131A1 (en) | 2007-04-16 | 2010-07-22 | 味の素株式会社 | Method for producing organic acid |
CN101679187B (en) | 2007-06-01 | 2013-06-05 | 赢创罗姆有限责任公司 | A process for preparing methacrylic acid or methacrylic esters |
US8198055B2 (en) | 2007-06-08 | 2012-06-12 | Coskata, Inc. | Process for converting syngas to liquid products with microorganisms on two-layer membrane |
JP2010263790A (en) | 2007-09-04 | 2010-11-25 | Ajinomoto Co Inc | Amino acid-producing microorganism and method for producing amino acid |
KR20090026230A (en) * | 2007-09-09 | 2009-03-12 | 김건 | Universal high-speed real-time monitoring device for embedded systems |
US20090191599A1 (en) | 2007-09-10 | 2009-07-30 | Joule Biotechnologies, Inc. | Engineered light-harvesting organisms |
JP2009067775A (en) | 2007-09-17 | 2009-04-02 | Rohm & Haas Co | Method for converting hydroxycarboxylic acid or salt thereof into unsaturated carboxylic acid and/or ester thereof |
AU2008304180B2 (en) | 2007-09-27 | 2014-02-27 | Genomatica, Inc. | Reduction of the toxic effect of impurities from raw materials by extractive fermentation |
US7785861B2 (en) | 2007-11-10 | 2010-08-31 | Joule Unlimited, Inc. | Hyperphotosynthetic organisms |
US8048624B1 (en) | 2007-12-04 | 2011-11-01 | Opx Biotechnologies, Inc. | Compositions and methods for 3-hydroxypropionate bio-production from biomass |
WO2009085278A1 (en) | 2007-12-21 | 2009-07-09 | Ls9, Inc. | Methods and compositions for producing olefins |
US8518678B2 (en) | 2007-12-21 | 2013-08-27 | Butamax(Tm) Advanced Biofuels Llc | Strain comprising increased expression of a CFA coding region for butanol production |
WO2009089457A1 (en) * | 2008-01-11 | 2009-07-16 | Novozymes A/S | Methods for producing 3-hydroxypropionic acid and compounds thereof |
JP2011509691A (en) | 2008-01-22 | 2011-03-31 | ジェノマティカ, インコーポレイテッド | Methods and organisms for utilizing synthesis gas or other gaseous carbon sources and methanol |
CA2728285A1 (en) | 2008-03-03 | 2009-09-11 | Joule Unlimited, Inc. | Engineered co2 fixing microorganisms producing carbon-based products of interest |
US8598378B2 (en) | 2008-03-14 | 2013-12-03 | University Of Hawaii | Methods and compositions for extraction and transesterification of biomass components |
CN105112454B (en) | 2008-05-16 | 2017-01-18 | Reg生命科学有限责任公司 | Methods and compositions for producing hydrocarbons |
PL2288710T3 (en) | 2008-05-23 | 2014-11-28 | Du Pont | DGAT genes from oleaginous organisms for increased seed storage lipid production and altered fatty acid profiles in in oilseed plants |
EP2283135A1 (en) | 2008-06-04 | 2011-02-16 | ButamaxTM Advanced Biofuels LLC | Deletion mutants for the production of isobutanol |
CN102317463B (en) | 2008-06-09 | 2014-12-03 | 蓝瑟科技纽西兰有限公司 | Production of butanediol by anaerobic microbial fermentation |
DE102008002309A1 (en) | 2008-06-09 | 2009-12-10 | Evonik Degussa Gmbh | Process for the preparation of L-amino acids using improved strains of the family Enterobacteriaceae |
AU2009273953B2 (en) * | 2008-07-23 | 2013-08-29 | Opx Biotechnologies, Inc | Methods, systems and compositions for increased microorganism tolerance to and production of 3-hydroxypropionic acid (3-HP) |
US20100021978A1 (en) | 2008-07-23 | 2010-01-28 | Genomatica, Inc. | Methods and organisms for production of 3-hydroxypropionic acid |
US20160362710A9 (en) | 2008-08-18 | 2016-12-15 | REG Life Sciences, LLC | Systems and methods for production of mixed fatty esters |
US20130189787A1 (en) | 2008-09-15 | 2013-07-25 | Opx Biotechnologies ,Inc. | Methods, Systems And Compositions Related To Reduction Of Conversions Of Microbially Produced 3-Hydroxyproplonic Acid (3-HP) To Aldehyde Metabolites |
MX2011003597A (en) | 2008-10-07 | 2011-06-20 | Ls9 Inc | Method and compositions for producing fatty aldehydes. |
BRPI0922944A2 (en) | 2008-12-12 | 2015-08-25 | Celexion Llc | Metabolically engineered host cell for the production of an alkane, containing one or more exogenous nucleic acid sequences and method for producing an alkane |
MX2011006785A (en) | 2008-12-23 | 2011-09-27 | Ls9 Inc | Methods and compositions related to thioesterase enzymes. |
CN102459569B (en) | 2009-04-10 | 2018-02-23 | Reg生命科学有限责任公司 | The generation of derivative of fatty acid |
US20110144377A1 (en) | 2009-06-16 | 2011-06-16 | E. I. Du Pont Nemours And Company | Process for the biological production of 3-hydroxypropionic acid with high yield |
US8809027B1 (en) | 2009-09-27 | 2014-08-19 | Opx Biotechnologies, Inc. | Genetically modified organisms for increased microbial production of 3-hydroxypropionic acid involving an oxaloacetate alpha-decarboxylase |
GB2487866A (en) * | 2009-09-27 | 2012-08-08 | Opx Biotechnologies Inc | Method for producing 3-Hydroxypropionic acid and other products |
WO2011063304A1 (en) | 2009-11-20 | 2011-05-26 | Opx Biotechnologies, Inc. | Methods, systems, and compositions for microbial bio-production of biomolecules using syngas components, or sugars, as feedstocks |
US20110125118A1 (en) | 2009-11-20 | 2011-05-26 | Opx Biotechnologies, Inc. | Production of an Organic Acid and/or Related Chemicals |
BR112012013158A2 (en) | 2009-12-02 | 2016-03-01 | Univ Michigan State | method of producing an alkyl ester of a carboxylic acid and method for isolating diethyl succinate |
US8530221B2 (en) | 2010-01-14 | 2013-09-10 | Ls9, Inc. | Production of branched chain fatty acids and derivatives thereof in recombinant microbial cells |
KR20120136349A (en) | 2010-01-27 | 2012-12-18 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | Microorganism production of high-value chemical products, and related compositions, methods and systems |
US8859259B2 (en) | 2010-02-14 | 2014-10-14 | Ls9, Inc. | Surfactant and cleaning compositions comprising microbially produced branched fatty alcohols |
WO2012019175A2 (en) | 2010-08-06 | 2012-02-09 | Mascoma Corporation | Production of malonyl-coa drived products via anaerobic pathways |
US8372610B2 (en) | 2010-09-15 | 2013-02-12 | Ls9, Inc. | Production of odd chain fatty acid derivatives in recombinant microbial cells |
WO2012054400A1 (en) | 2010-10-18 | 2012-04-26 | Zeachem, Inc. | Recovery of organic acid using a complex extraction solvent |
US20120264902A1 (en) | 2011-04-18 | 2012-10-18 | The Regents Of The University Of Colorado, A Body Corporate | Methods, Systems and Compositions for Increased Microorganism Tolerance to and Production of 3-Hydroxypropionic Acid (3-HP) |
US20130345470A1 (en) | 2012-06-20 | 2013-12-26 | Opx Biotechnologies, Inc. | Purification of 3-Hydroxypropionic Acid from Crude Cell Broth and Production of Acrylamide |
EP3385375B1 (en) | 2013-01-16 | 2021-06-16 | Genomatica, Inc. | Acyl-acp reductase with improved properties |
EP2976141A4 (en) | 2013-03-15 | 2016-10-05 | Cargill Inc | Flash evaporation for production purification and recovery |
US9447438B2 (en) * | 2013-03-15 | 2016-09-20 | Cargill, Incorporated | Acetyl-coA carboxylases |
-
2010
- 2010-09-27 GB GB1207409.2A patent/GB2487866A/en not_active Withdrawn
- 2010-09-27 WO PCT/US2010/050436 patent/WO2011038364A1/en active Application Filing
- 2010-09-27 BR BR112012006801A patent/BR112012006801A2/en not_active Application Discontinuation
- 2010-09-27 AU AU2010298004A patent/AU2010298004B2/en not_active Ceased
- 2010-09-27 CN CN2010800536926A patent/CN102695799A/en active Pending
- 2010-09-27 JP JP2012531103A patent/JP2013505727A/en not_active Ceased
- 2010-09-27 GB GB1016137A patent/GB2473755B/en active Active
- 2010-09-27 EP EP10819620.5A patent/EP2480673B1/en active Active
- 2010-09-27 CA CA2775390A patent/CA2775390C/en active Active
- 2010-09-27 US US13/498,468 patent/US8883464B2/en active Active
- 2010-09-27 MX MX2012003604A patent/MX2012003604A/en not_active Application Discontinuation
- 2010-09-27 KR KR1020127010712A patent/KR20140015136A/en not_active Application Discontinuation
-
2013
- 2013-03-19 JP JP2013056264A patent/JP2013128494A/en not_active Withdrawn
- 2013-06-12 US US13/916,534 patent/US9388419B2/en active Active
-
2014
- 2014-12-18 US US14/575,927 patent/US9428778B2/en active Active
-
2015
- 2015-12-10 JP JP2015241185A patent/JP6271494B2/en active Active
- 2015-12-10 JP JP2015241186A patent/JP2016039825A/en active Pending
-
2016
- 2016-05-27 US US15/167,439 patent/US10100342B2/en active Active
-
2018
- 2018-10-12 US US16/159,135 patent/US20190119708A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087140A (en) * | 1997-02-19 | 2000-07-11 | Wisconsin Alumni Research Foundation | Microbial production of 1,2-propanediol from sugar |
US20050196758A1 (en) * | 2000-02-04 | 2005-09-08 | Rock Charles O. | Novel enoyl reductases and methods of use thereof |
US20080076167A1 (en) * | 2000-11-20 | 2008-03-27 | Cargill, Incorporated | 3-hydroxypropionic acid and other organic compounds |
US20050283029A1 (en) * | 2002-11-01 | 2005-12-22 | Xiangsheng Meng | Process for preparation of 1,3-propanediol |
US20070245431A1 (en) * | 2006-03-15 | 2007-10-18 | Martek Biosciences Corporation | Polyunsaturated fatty acid production in heterologous organisms using pufa polyketide synthase systems |
WO2008089102A2 (en) * | 2007-01-12 | 2008-07-24 | Regents Of The University Of Colorado | Compositions and methods for enhancing tolerance for the production of organic chemicals produced by microorganisms |
US20080199926A1 (en) * | 2007-01-22 | 2008-08-21 | Burgard Anthony P | Methods and Organisms for Growth-Coupled Production of 3-Hydroxypropionic Acid |
Non-Patent Citations (2)
Title |
---|
ALBER ET AL.: "Malonyl-coenryme A reductase in the modified 3-hydroxypropionate cycle for autotrophic carbon fixation in archaeal Metallosphaera and Sulfolobus spp.", J BACTERIOLOGY, vol. 188, pages 8551 - 8559, XP008154562 * |
See also references of EP2480673A4 * |
Cited By (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8652816B2 (en) | 2007-12-04 | 2014-02-18 | Opx Biotechnologies, Inc. | Compositions and methods for 3-hydroxypropionate bio-production from biomass |
US10100342B2 (en) | 2009-09-27 | 2018-10-16 | Cargill, Incorporated | Method for producing 3-hydroxypropionic acid and other products |
US8809027B1 (en) | 2009-09-27 | 2014-08-19 | Opx Biotechnologies, Inc. | Genetically modified organisms for increased microbial production of 3-hydroxypropionic acid involving an oxaloacetate alpha-decarboxylase |
US9388419B2 (en) | 2009-09-27 | 2016-07-12 | Cargill, Incorporated | Methods for producing 3-hydroxypropionic acid and other products |
US8883464B2 (en) | 2009-09-27 | 2014-11-11 | Opx Biotechnologies, Inc. | Methods for producing 3-hydroxypropionic acid and other products |
US9428778B2 (en) | 2009-09-27 | 2016-08-30 | Cargill, Incorporated | Method for producing 3-hydroxypropionic acid and other products |
US10786064B2 (en) | 2010-02-11 | 2020-09-29 | Cj Cheiljedang Corporation | Process for producing a monomer component from a genetically modified polyhydroxyalkanoate biomass |
US11118187B2 (en) | 2010-11-22 | 2021-09-14 | Cargill, Incorporated | Compositions and methods for 3-hydroxypropionic acid production |
US10633664B2 (en) | 2010-11-22 | 2020-04-28 | Cargill, Incorporated | Compositions and methods for 3-hydroxypropionic acid production |
US12054721B2 (en) | 2010-11-22 | 2024-08-06 | Cargill, Incorporated | Compositions and methods for 3-hydroxypropionic acid production |
US9090918B2 (en) | 2010-11-22 | 2015-07-28 | Novozymes A/A | Compositions and methods for 3-hydroxypropionic acid production |
US10260072B2 (en) | 2010-11-22 | 2019-04-16 | Cargill, Incorporated | Compositions and methods for 3-hydroxypropionic acid production |
US20140330032A1 (en) * | 2011-03-22 | 2014-11-06 | Michael D. Lynch | Microbial production of chemical products and related compositions, methods and systems |
WO2013036764A1 (en) * | 2011-09-08 | 2013-03-14 | Genomatica, Inc | Eukaryotic organisms and methods for producing 1,3-butanediol |
CN103857791A (en) * | 2011-09-30 | 2014-06-11 | 诺维信股份有限公司 | Dehydrogenase variants and polynucleotides encoding same |
CN103857791B (en) * | 2011-09-30 | 2016-11-23 | 诺维信股份有限公司 | Dehydrogenase modification and their polynucleotide of coding |
US9650274B2 (en) | 2012-03-06 | 2017-05-16 | Gea Mechanical Equipment Gmbh | Method and installation for processing raw liquid manure and/or fermentation residues from biogas production |
WO2013131798A1 (en) * | 2012-03-06 | 2013-09-12 | Gea Mechanical Equipment Gmbh | Method and installation for processing raw liquid manure and/or fermentation residues from biogas production |
WO2013137277A1 (en) * | 2012-03-14 | 2013-09-19 | 株式会社日本触媒 | Method for producing 3-hydroxypropionic acid, genetically modified microorganism, and methods for producing acrylic acid, water-absorbable resin, acrylic acid ester and acrylic acid ester resin each utilizing said method |
JPWO2013137277A1 (en) * | 2012-03-14 | 2015-08-03 | 株式会社日本触媒 | Method for producing 3-hydroxypropionic acid, genetically modified microorganism, and method for producing acrylic acid, water-absorbing resin, acrylic ester, and acrylic ester resin using said method |
US9850192B2 (en) | 2012-06-08 | 2017-12-26 | Cj Cheiljedang Corporation | Renewable acrylic acid production and products made therefrom |
WO2013192450A1 (en) * | 2012-06-20 | 2013-12-27 | Opx Biotechnologies, Inc. | Purification of 3-hydroxypropionic acid from crude cell broth and production of acrylamide |
WO2013192453A1 (en) * | 2012-06-20 | 2013-12-27 | Opx Biotechnologies, Inc. | Purification of 3-hydroxypropionic acid from crude cell broth and dehydration to acrylic acid |
US20160340700A1 (en) * | 2012-08-10 | 2016-11-24 | Cargill, Incorporated | Microorganisms and methods for the production of fatty acids and fatty acid derived products |
US10465213B2 (en) * | 2012-08-10 | 2019-11-05 | Cargill, Incorporated | Microorganisms and methods for the production of fatty acids and fatty acid derived products |
US20140051136A1 (en) * | 2012-08-10 | 2014-02-20 | Opx Biotechnologies, Inc. | Micoorganisms and Methods for the Production of Fatty Acids and Fatty Acid Derived Products |
US9365875B2 (en) | 2012-11-30 | 2016-06-14 | Novozymes, Inc. | 3-hydroxypropionic acid production by recombinant yeasts |
US9512057B2 (en) * | 2013-03-15 | 2016-12-06 | Cargill, Incorporated | 3-hydroxypropionic acid compositions |
US11236036B2 (en) | 2013-03-15 | 2022-02-01 | Cargill, Incorporated | Recovery of 3-hydroxypropionic acid |
WO2014146026A1 (en) * | 2013-03-15 | 2014-09-18 | Opx Biotechnologies, Inc. | Bioproduction of chemicals |
US11834403B2 (en) | 2013-03-15 | 2023-12-05 | Cargill, Incorporated | Recovery of 3-hydroxypropionic acid |
US11834402B2 (en) | 2013-03-15 | 2023-12-05 | Cargill, Incorporated | Recovery of 3-hydroxypropionic acid |
US20150057455A1 (en) * | 2013-03-15 | 2015-02-26 | Cindy Hoppe | Flash evaporation for product purification and recovery |
US9447438B2 (en) | 2013-03-15 | 2016-09-20 | Cargill, Incorporated | Acetyl-coA carboxylases |
US11236037B2 (en) | 2013-03-15 | 2022-02-01 | Cargill, Incorporated | Recovery of 3-hydroxpropionic acid |
US10047383B2 (en) | 2013-03-15 | 2018-08-14 | Cargill, Incorporated | Bioproduction of chemicals |
WO2014145344A2 (en) * | 2013-03-15 | 2014-09-18 | Opx Biotechnologies, Inc. | Control of growth-induction-production phases |
WO2014145344A3 (en) * | 2013-03-15 | 2014-11-06 | Opx Biotechnologies, Inc. | Control of growth-induction-production phases |
US10815473B2 (en) | 2013-03-15 | 2020-10-27 | Cargill, Incorporated | Acetyl-CoA carboxylases |
US10155937B2 (en) | 2013-03-15 | 2018-12-18 | Cargill, Incorporated | Acetyl-CoA carboxylases |
WO2014145297A1 (en) * | 2013-03-15 | 2014-09-18 | Opx Biotechnologies, Inc. | Method of enhanced bioproduction |
WO2014144400A1 (en) * | 2013-03-15 | 2014-09-18 | Cargill, Incorporated | Recovery of 3-hydroxypropionic acid |
WO2014144367A1 (en) * | 2013-03-15 | 2014-09-18 | Cargill, Incorporated | Recovery of 3-hydroxypropionic acid |
US10442748B2 (en) | 2013-03-15 | 2019-10-15 | Cargill, Incorporated | Recovery of 3-hydroxypropionic acid |
US10442749B2 (en) | 2013-03-15 | 2019-10-15 | Cargill, Incorporated | Recovery of 3-hydroxypropionic acid |
WO2014145334A1 (en) | 2013-03-15 | 2014-09-18 | Opx Biotechnologies, Inc. | Acetyl-coa carboxylase mutations |
US10077455B2 (en) | 2013-06-14 | 2018-09-18 | Technical University Of Denmark | 3HP tolerance |
WO2014210535A3 (en) * | 2013-06-28 | 2015-04-09 | Metabolix, Inc. | Genetically engineered methylotrophs for the production of pha biopolymers and c3, c4, and c5 biochemicals from methanol or methane as sole carbon feedstock |
WO2014210535A2 (en) * | 2013-06-28 | 2014-12-31 | Metabolix, Inc. | Genetically engineered methylotrophs for the production of pha biopolymers and c3, c4, and c5 biochemicals from methanol or methane as sole carbon feedstock |
US11408013B2 (en) | 2013-07-19 | 2022-08-09 | Cargill, Incorporated | Microorganisms and methods for the production of fatty acids and fatty acid derived products |
US10337038B2 (en) | 2013-07-19 | 2019-07-02 | Cargill, Incorporated | Microorganisms and methods for the production of fatty acids and fatty acid derived products |
JP2016526919A (en) * | 2013-08-05 | 2016-09-08 | グリーンライト バイオサイエンシーズ インコーポレーテッドGreenlight Biosciences,Inc. | Engineered proteins with protease cleavage sites |
US9701610B2 (en) | 2013-10-17 | 2017-07-11 | Dow Global Technologies Llc | Ammonium bisulfate catalyzed dehydration of beta-hydroxy acids |
WO2015057644A1 (en) | 2013-10-17 | 2015-04-23 | Dow Global Technologies Llc | Ammonium bisulfate catalyzed dehydration of beta-hydroxy acids |
US10494654B2 (en) | 2014-09-02 | 2019-12-03 | Cargill, Incorporated | Production of fatty acids esters |
US11345938B2 (en) | 2017-02-02 | 2022-05-31 | Cargill, Incorporated | Genetically modified cells that produce C6-C10 fatty acid derivatives |
EP3613844A4 (en) * | 2017-04-14 | 2021-07-07 | Institute of Microbiology, Chinese Academy of Sciences | Recombinant bacteria for producing 3-hydroxy propionic acid, preparation method therefor, and applications thereof |
CN108728469A (en) * | 2017-04-14 | 2018-11-02 | 中国科学院微生物研究所 | The structure of recombination bacillus coli engineering bacteria and its application in producing Beta-alanine |
CN108728469B (en) * | 2017-04-14 | 2022-03-01 | 中国科学院微生物研究所 | Construction of recombinant escherichia coli engineering bacteria and application thereof in production of beta-alanine |
KR102646320B1 (en) * | 2017-04-14 | 2024-03-11 | 인스티튜트 오브 마이크로바이올로지, 차이니즈 아카데미 오브 사이언스즈 | Recombinant bacteria for producing 3-hydroxypropionic acid, method for producing the same, and application thereof |
KR20200005552A (en) * | 2017-04-14 | 2020-01-15 | 인스티튜트 오브 마이크로바이올로지, 차이니즈 아카데미 오브 사이언스즈 | Recombinant bacteria for producing 3-hydroxypropionic acid, methods of preparation thereof, and applications thereof |
CN109593697A (en) * | 2018-12-18 | 2019-04-09 | 江苏师范大学 | It is a kind of produce 3- hydracrylic acid recombination pseudomonad and its construction method |
CN109593697B (en) * | 2018-12-18 | 2022-07-12 | 江苏师范大学 | Recombinant pseudomonas for producing 3-hydroxypropionic acid and construction method thereof |
US11377671B2 (en) | 2018-12-18 | 2022-07-05 | Braskem S.A. | Co-production pathway for 3-HPA and acetyl-CoA derivatives from malonate semialdehyde |
WO2020128618A3 (en) * | 2018-12-18 | 2020-08-06 | Braskem S.A. | Co-production pathway for 3-hp and acetyl-coa derivatives from malonate semialdehyde |
Also Published As
Publication number | Publication date |
---|---|
EP2480673A1 (en) | 2012-08-01 |
KR20140015136A (en) | 2014-02-06 |
US8883464B2 (en) | 2014-11-11 |
GB2473755A (en) | 2011-03-23 |
GB2473755B (en) | 2011-09-07 |
EP2480673B1 (en) | 2018-05-23 |
BR112012006801A2 (en) | 2018-04-10 |
AU2010298004B2 (en) | 2016-02-25 |
CA2775390C (en) | 2021-06-29 |
US20150344916A1 (en) | 2015-12-03 |
US20130071893A1 (en) | 2013-03-21 |
GB201016137D0 (en) | 2010-11-10 |
MX2012003604A (en) | 2012-09-12 |
CN102695799A (en) | 2012-09-26 |
US20190119708A1 (en) | 2019-04-25 |
GB201207409D0 (en) | 2012-06-13 |
US20170114377A1 (en) | 2017-04-27 |
US9428778B2 (en) | 2016-08-30 |
JP6271494B2 (en) | 2018-01-31 |
US10100342B2 (en) | 2018-10-16 |
US9388419B2 (en) | 2016-07-12 |
AU2010298004A1 (en) | 2012-04-26 |
EP2480673A4 (en) | 2014-10-08 |
JP2016036346A (en) | 2016-03-22 |
US20140045231A1 (en) | 2014-02-13 |
JP2013128494A (en) | 2013-07-04 |
CA2775390A1 (en) | 2011-03-31 |
JP2013505727A (en) | 2013-02-21 |
JP2016039825A (en) | 2016-03-24 |
GB2487866A (en) | 2012-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10100342B2 (en) | Method for producing 3-hydroxypropionic acid and other products | |
AU2011210852B2 (en) | Microorganism production of high-value chemical products, and related compositions, methods and systems | |
EP2689020B1 (en) | Microbial production of chemical products and related compositions, methods and systems | |
US20150056684A1 (en) | Methods, systems, and compositions for increased microorganism tolerance to and production of 3-hydroxypropionic acid (3-hp) | |
US8809027B1 (en) | Genetically modified organisms for increased microbial production of 3-hydroxypropionic acid involving an oxaloacetate alpha-decarboxylase | |
US20120264902A1 (en) | Methods, Systems and Compositions for Increased Microorganism Tolerance to and Production of 3-Hydroxypropionic Acid (3-HP) | |
US20180312886A1 (en) | Microbial production of chemical products and related compositions, methods and systems | |
WO2013043758A2 (en) | Compositions and methods regarding direct nadh utilization to produce 3-hydroxypropionic acid, derived chemicals and further derived products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10819620 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2775390 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012531103 Country of ref document: JP Ref document number: MX/A/2012/003604 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1201001371 Country of ref document: TH Ref document number: 2010819620 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010298004 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2010298004 Country of ref document: AU Date of ref document: 20100927 Kind code of ref document: A Ref document number: 20127010712 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 1207409 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20100927 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1207409.2 Country of ref document: GB |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13498468 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012006801 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012006801 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120327 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112012006801 Country of ref document: BR Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 112012006801 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120327 |